

CITATION REPORT

List of articles citing

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

DOI: 10.1053/jhep.2003.50047
Hepatology, 2003, 37, 429-42.

Source: <https://exaly.com/paper-pdf/34900755/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2331	HCC surveillance: who is the target population?. <i>Hepatology</i> , 2003 , 37, 507-9	11.2	40
2330	Future perspectives for hepatocellular carcinoma. 2003 , 5, 206-13		9
2329	Treatment of Hepatocellular Carcinoma. 2003 , 6, 465-472		11
2328	Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma (Br J Surg 2003; 90: 325-331). 2003 , 90, 1022		4
2327	Scientific surgery. 2003 , 90, 1454-1454		
2326	Meta-analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma. 2003 , 17, 1247-61		86
2325	Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD), in predicting outcome after treatment. 2003 , 17, 1563-9		44
2324	Hepatocellular carcinoma: present status and future prospects. 2003 , 38 Suppl 1, S136-49		176
2323	Spiral computed tomography versus ultrasound in the follow-up of cirrhotic patients previously treated for hepatocellular carcinoma: a prospective study. 2003 , 39, 93-8		8
2322	Hepatocellular carcinoma. 2003 , 362, 1907-17		3580
2321	Non-Surgical Treatment Options in Hepatocellular Carcinoma. 2003 , 01, 245-279		1
2320	Sequential transarterial chemoembolization and percutaneous acetic acid injection therapy versus repeated percutaneous acetic acid injection for unresectable hepatocellular carcinoma: a prospective study. 2003 , 14, 1648-53		24
2319	Pharmacotherapy of hepatocellular carcinoma. 2003 , 4, 2175-85		3
2318	An independent evaluation of modern prognostic scores in a central European cohort of 120 patients with hepatocellular carcinoma. 2003 , 15, 1305-15		17
2317	Embolisation of cancer: what is the evidence?. 2004 , 4, 133-41		11
2316	Unresectable hepatocellular carcinoma: meta-analysis of arterial embolization. 2004 , 230, 300-1; author reply 301-2		18
2315	The potential role of hypoxia inducible factor 1alpha in tumor progression after hypoxia and chemotherapy in hepatocellular carcinoma. 2004 , 64, 5496-503		56

2314	Diagnostic biopsy for hepatocellular carcinoma in cirrhosis: useful, necessary, dangerous, or academic sport?. 2004 , 53, 1224-6	16
2313	Is transarterial chemoembolization an option for all patients with unresectable hepatocellular carcinoma?. 2004 , 1, 78-9	3
2312	pRb2/p130, vascular endothelial growth factor, p27(KIP1), and proliferating cell nuclear antigen expression in hepatocellular carcinoma: their clinical significance. 2004 , 10, 3509-17	43
2311	Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival. 2004 , 99, 1470-6	105
2310	Induction of complete tumor necrosis may reduce intrahepatic metastasis and prolong survival in patients with hepatocellular carcinoma undergoing locoregional therapy: a prospective study. 2004 , 15, 775-80	20
2309	Suppression of hepatocellular carcinoma growth via oral immune regulation towards tumor-associated antigens is associated with increased NKT and CD8+ lymphocytes. 2004 , 66, 323-30	22
2308	Regression of a hepatocellular carcinoma following treatment with octreotide and tamoxifen in a patient with advanced alcoholic cirrhosis. 2004 , 19, 719-20	1
2307	Management of inoperable hepatocellular carcinoma. 2004 , 19, S272-S278	4
2306	Long-term oral branched chain amino acids in patients undergoing chemoembolization for hepatocellular carcinoma: a randomized trial. 2004 , 19, 779-88	88
2305	Acute renal failure after transarterial chemoembolization for hepatocellular carcinoma: a retrospective study of the incidence, risk factors, clinical course and long-term outcome. 2004 , 19, 999-1007	40
2304	Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. 2004 , 19, 1159-72	119
2303	Comparison of transarterial chemoembolization and percutaneous acetic acid injection as the primary loco-regional therapy for unresectable hepatocellular carcinoma: a prospective survey. 2004 , 19, 1301-8	15
2302	Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study. 2004 , 24, 210-5	54
2301	The role of transcatheter arterial embolization in patients with resectable hepatocellular carcinoma: a nation-wide, multicenter study. 2004 , 24, 419-24	24
2300	Hepatic artery chemoembolization for hepatocellular carcinoma in patients listed for liver transplantation. 2004 , 4, 782-7	67
2299	[Treatment of hepatocellular carcinoma in the cirrhotic liver]. 2004 , 141, 71-83	
2298	Improvement of survival by surgery in the treatment of hepatocellular carcinoma: evidence or non-evidenced-based?. 2004 , 11, 460-1	
2297	[Surgical requirements for radiological diagnostics of liver pathologies]. 2004 , 44, 1154-9	

2296	Treatment of hepatocarcinoma. 2004 , 6, 184-91		13
2295	Treatment of Hepatocellular Carcinoma. 2004 , 7, 431-441		40
2294	Liver transplant for hepatocellular cancer: a treatment for the select few. 2004 , 18, 205-10		13
2293	Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. <i>Hepatology</i> , 2004 , 40, 1352-60	11.2	340
2292	Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen. <i>Hepatology</i> , 2004 , 40, 1361-9	11.2	74
2291	AASLD single-topic research conference on hepatocellular carcinoma: Conference proceedings. <i>Hepatology</i> , 2004 , 40, 1465-73	11.2	40
2290	The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. 2004 , 10, S115-20		513
2289	Liver transplantation in patients with hepatocellular carcinoma. 2004 , 10, S81-5		32
2288	Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. 2004 , 10, 449-55		169
2287	Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. 2004 , 10, 1301-11		207
2286	The chance of further chemoembolization and intrahepatic disease control after radiotherapy to portal vein thrombus. 2004 , 58, 1316		
2285	Systemic therapies for hepatocellular carcinoma. 2004 , 13, 1555-68		41
2284	Screening and treatment for hepatocellular carcinoma. 2004 , 33, 671-91, xi		7
2283	Tratamiento del hepatocarcinoma. 2004 , 204, 218-220		
2282	Diagnosis and staging of hepatocellular carcinoma. 2004 , 127, S126-32		98
2281	Chemoembolization for hepatocellular carcinoma. 2004 , 127, S179-88		434
2280	Hepatocellular carcinoma: current management and future trends. 2004 , 127, S218-24		196
2279	Liver transplantation for hepatocellular carcinoma. 2004 , 127, S268-76		123

2278	Hepatocellular carcinoma: summary and recommendations. 2004 , 127, S319-23	39
2277	Outcomes of patients with hepatocellular carcinoma presenting with variceal bleeding. 2004 , 99, 2158-65	42
2276	Palliative techniques for hepatic cancer. 2004 , 13, 505-16, ix	2
2275	Hepatocellular carcinoma. 2004 , 50, 556-73	24
2274	Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives. 2004 , 7, 125-38	62
2273	Systemic therapy for advanced hepatocellular carcinoma: a review. 2004 , 40, 1474-84	150
2272	Angiogenesis and hepatocellular carcinoma. 2004 , 41, 864-80	286
2271	Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. 2004 , 5, 409-18	136
2270	Role of additional angiography and chemoembolization in patients with hepatocellular carcinoma who achieved complete necrosis following transarterial chemoembolization. 2004 , 19, 1074-80	13
2269	Hepatitis C virus infection with hepatocellular carcinoma: not a controversial indication for liver transplantation. 2004 , 78, 580-3	7
2268	Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-I: hepatic arterial embolization and embolization-based therapies in unresectable hepatocellular carcinoma. 2004 , 15, 427-37	27
2267	Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-II: systemic and local non-embolization-based therapies in unresectable and advanced hepatocellular carcinoma. 2004 , 15, 439-52	51
2266	Transcatheter arterial embolisation and chemoembolisation for hepatocellular carcinoma. 2004 ,	
2265	Tamoxifen for hepatocellular carcinoma. 2004 , CD001024	11
2264	Radiofrequency thermal ablation versus other interventions for hepatocellular carcinoma. 2004 , CD003046	21
2263	Transarterial chemoembolization in a patient with recurrent hepatocellular carcinoma and portal vein thrombosis: a case report and review of the literature. 2005 , 28, 638-9	4
2262	Hepatocellular carcinoma: interventional bridging to liver transplantation. 2005 , 80, S113-9	36
2261	Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. 2005 , 28, 496-504	153

2260	131I-Labelled-iodized oil for palliative treatment of hepatocellular carcinoma. 2005 , 17, 905-10	15
2259	Hepatitis status, child-pugh classification, and serum AFP levels predict survival in patients treated with transarterial embolization for unresectable hepatocellular carcinoma. 2005 , 9, 638-45	13
2258	Clinical trial design in hepatocellular carcinoma. 2005 , 19, 119-27	2
2257	Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. 2005 , 12, 364-73	203
2256	Staging systems in hepatocellular carcinoma. 2005 , 7, 35-41	183
2255	Non-surgical treatment of hepatocellular carcinoma. 2005 , 7, 50-5	28
2254	Chinese herbal medicine and chemotherapy in the treatment of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. 2005 , 4, 219-29	60
2253	The role of transcatheter arterial embolization for patients with unresectable hepatocellular carcinoma: a nationwide, multicentre study evaluated by cancer stage. 2005 , 21, 687-94	31
2252	Selective arterial chemoembolization for hepatic metastases from medullary thyroid carcinoma. 2005 , 138, 986-93; discussion 993	56
2251	Reply. <i>Hepatology</i> , 2005 , 41, 942-943	11.2 0
2250	AASLD practice guidelines: Evaluation of the patient for liver transplantation. <i>Hepatology</i> , 2005 , 41, 1407-32	575
2249	Management of hepatocellular carcinoma. <i>Hepatology</i> , 2005 , 42, 1208-36	11.2 4778
2248	Thalidomide for advanced hepatocellular carcinoma: is this a real alternative?. 2005 , 103, 1-4	9
2247	Use of tamoxifen in advanced-stage hepatocellular carcinoma. A systematic review. 2005 , 103, 1408-14	49
2246	Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. 2005 , 11, 767-775	181
2245	Treatment of hepatocellular carcinoma by means of radiopharmaceuticals. 2005 , 32, 980-9	40
2244	A critical evaluation of hepatic resection in cirrhosis: optimizing patient selection and outcomes. 2005 , 29, 124-30	16
2243	Interventional radiology in liver transplantation. 2005 , 28, 271-83	12

2242	Treatment of hepatocellular carcinoma. 2005 , 19, 129-45	33
2241	Early liver cancer: concepts, diagnosis, and management. 2005 , 10, 384-90	5
2240	Hepatocellular carcinoma: current treatment strategies. 2005 , 8, 457-66	9
2239	Hepatocellular carcinoma: therapy and prevention. 2005 , 11, 7391-400	186
2238	p53 gene (Gendicine) and embolisation overcame recurrent hepatocellular carcinoma. 2005 , 54, 1318-9	16
2237	Hepatocellular carcinoma in cirrhosis: enhancement patterns at dynamic gadolinium- and superparamagnetic iron oxide-enhanced T1-weighted MR imaging. 2005 , 237, 520-8	54
2236	Finding evidence-based answers to practical questions in radiology: which patients with inoperable hepatocellular carcinoma will survive longer after transarterial chemoembolization?. 2005 , 237, 404-13	13
2235	Functional CT quantification of tumor perfusion after transhepatic arterial embolization in a rat model. 2005 , 237, 144-50	61
2234	Large infiltrative hepatocellular carcinomas: treatment with percutaneous intraarterial ethanol injection alone or in combination with conventional percutaneous ethanol injection. 2005 , 234, 299-309	24
2233	Natural history of untreated nonsurgical hepatocellular carcinoma. 2005 , 100, 1995-2004	111
2232	Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study. 2005 , 92, 628-30	19
2231	Hepatocellular carcinoma: the need for progress. 2005 , 23, 2892-9	339
2230	Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. 2005 , 23, 4338-46	107
2229	An intensive surveillance program detected a high incidence of hepatocellular carcinoma among hepatitis B virus carriers with abnormal alpha-fetoprotein levels or abdominal ultrasonography results. 2005 , 23, 8041-7	34
2228	Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. 2005 , 65, 6321-9	305
2227	Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression. 2005 , 10, 718-27	32
2226	Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand by elimination of Mcl-1. 2005 , 65, 7393-402	58
2225	Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma. 2005 , 69, 363-71	46

2224	Recognizing extrahepatic collateral vessels that supply hepatocellular carcinoma to avoid complications of transcatheter arterial chemoembolization. 2005 , 25 Suppl 1, S25-39	178
2223	The progression of hepatitis B- and C-infections to chronic liver disease and hepatocellular carcinoma: presentation, diagnosis, screening, prevention, and treatment of hepatocellular carcinoma. 2005 , 89, 345-69	9
2222	Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. 2005 , 16, 1653-9	177
2221	Case-controlled comparison of a percutaneous collagen arteriotomy closure device versus manual compression after liver chemoembolization. 2005 , 16, 339-45	18
2220	Influence of recent advances in medical management on clinical outcomes of cirrhosis. 2005 , 80, 1501-8	39
2219	Chemoembolization and bland embolization: a critical appraisal. 2005 , 9, 287-300, vii	9
2218	Liver transplantation for hepatocellular carcinoma: is expansion of criteria justified?. 2005 , 9, 315-28	19
2217	Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. 2005 , 42, 210-7	84
2216	Hypermethylation of NAD(P)H: quinone oxidoreductase 1 (NQO1) gene in human hepatocellular carcinoma. 2005 , 42, 511-9	39
2215	Refined tools for the treatment of hepatocellular carcinoma. 2005 , 42, 629-31	9
2214	Should we expand the criteria for hepatocellular carcinoma with living-donor liver transplantation?--no, never. 2005 , 43, 573-7	35
2213	How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated?. 2005 , 43, 584-9	58
2212	Hepatocellular carcinoma supplied by the ileocolic branch of the superior mesenteric artery. 2005 , 60, 723-6	4
2211	Double phase CT during hepatic arteriography for diagnosis of hepatocellular carcinoma. 2005 , 54, 246-52	18
2210	Outcome of regional and local ablative therapies for hepatocellular carcinoma: a collective review. 2005 , 31, 331-47	110
2209	Outcomes of emergency treatment in ruptured hepatocellular carcinoma in the ED. 2005 , 23, 730-6	28
2208	[Early diagnosis of liver cancer]. 2005 , 28, 292-7	4
2207	Altered expression of TGF-beta receptors in hepatocellular carcinoma--effects of a constitutively active TGF-beta type I receptor mutant. 2005 , 71, 78-91	21

2206	The continuing challenge of hepatic cancer in Asia. 2005 , 3, 210-5	118
2205	Liver transplantation for hepatocellular carcinoma. 2005 , 128, 1752-64	111
2204	Case records of the Massachusetts General Hospital. Case 23-2005. A 57-year-old man with a mass in the liver. 2005 , 353, 401-10	2
2203	The progression of hepatitis B- and C-infections to chronic liver disease and hepatocellular carcinoma: presentation, diagnosis, screening, prevention, and treatment of hepatocellular carcinoma. 2006 , 20, 1-25	6
2202	Multidisciplinary treatment of patients with hepatocellular carcinoma. 2006 , 6, 1377-84	8
2201	Carcinome h�pato-cellulaire. 2006 , 195-217	
2200	Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 2: special topics. 2006 , 17, 1425-39	173
2199	Hepatocellular carcinoma. 2006 , 10, 339-51, ix	26
2198	Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization. 2006 , 17, 1335-43	156
2197	Chemoembolization in patients at high risk: results and complications. 2006 , 17, 47-53	42
2196	Palliative care for patients with end-stage liver disease ineligible for liver transplantation. 2006 , 35, 201-19	42
2195	Hepatocellular carcinoma: transcatheter arterial chemoembolization of the gonadal artery. 2006 , 17, 703-9	9
2194	Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. 2006 , 17, 217-23	90
2193	[Clivus metastasis from hepatocarcinoma associated with transarterial hepatic chemoembolization]. 2006 , 29, 401-4	7
2192	Hepatocarcinoma y VHC. 2006 , 29, 196-199	0
2191	Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. 2006 , 32, 594-606	74
2190	Study of severe and rare complications of transarterial chemoembolization (TACE) for liver cancer. 2006 , 59, 407-12	123
2189	Chemoocclusion vs chemoperfusion for treatment of advanced hepatocellular carcinoma: a randomised trial. 2006 , 32, 201-7	31

2188	Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. 2006 , 44, 158-66	198
2187	Analysis of factors predicting survival in patients with hepatocellular carcinoma treated with percutaneous laser ablation. 2006 , 44, 902-9	37
2186	Transcatheter arterial chemoembolization of hepatocellular carcinoma: prevalence and causative factors of extrahepatic collateral arteries in 479 patients. 2006 , 7, 257-66	74
2185	Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable. 2006 , 29, 568-75	87
2184	Treatment and prognostic factors in patients with hepatocellular carcinoma. 2006 , 26, 680-7	42
2183	Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter. 2006 , 23, 129-35	52
2182	Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials. 2006 , 23, 1535-47	293
2181	New aspects of diagnosis and therapy of hepatocellular carcinoma. 2006 , 25, 3848-56	125
2180	Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. 2006 , 66, 792-800	181
2179	Hepatocellular carcinoma--rising incidence, changing therapeutic strategies. 2006 , 156, 404-9	20
2178	(188)Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study. 2006 , 33, 344-52	23
2177	Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. 2006 , 29, 522-9	186
2176	Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma. 2006 , 57, 436-42	17
2175	Treatment of hepatocellular carcinoma. 2006 , 60, 89-98	123
2174	Management of hepatocellular carcinoma. 2006 , 10, 761-80	65
2173	Liver-directed therapies for patients with primary liver cancer and hepatic metastases. 2006 , 7, 399-409	19
2172	Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. 2006 , 6, 2644-50	136
2171	Waiting list treatment of hepatocellular carcinoma: when do we need level 1 evidence?. 2006 , 6, 2531-2	5

2170	Transarterial chemoembolization for hepatocellular carcinoma. 2006 , 202, 155-68	71
2169	[Palliative treatment of hepatocellular carcinoma]. 2006 , 30, 887-90	4
2168	Hepatocellular carcinoma (primary cancer of the liver). 2006 , 30, 57-61	1
2167	Radiation therapy for hepatocellular carcinoma: from palliation to cure. 2006 , 106, 1653-63	196
2166	Expanding HCC criteria for liver transplant: the urgent need for prospective, robust data. 2006 , 12, 1741-3	14
2165	Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: a critical appraisal. 2006 , 12, 1747-54	15
2164	Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. 2006 , 94, 572-86	257
2163	Effects of patupilone (epothilone B; EPO906), a novel chemotherapeutic agent, in hepatocellular carcinoma: an in vitro study. 2006 , 71, 292-6	19
2162	Technology insight: Image-guided therapies for hepatocellular carcinoma--intra-arterial and ablative techniques. 2006 , 3, 315-24	48
2161	Medical treatments for hepatocellular carcinoma (HCC): what's next?. 2006 , 17 Suppl 10, x308-14	23
2160	Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma. 2006 , 17, 304-12	73
2159	High doses of tyrosine kinase inhibitor PTK787 enhance the efficacy of ischemic hypoxia for the treatment of hepatocellular carcinoma: dual effects on cancer cell and angiogenesis. 2006 , 5, 2261-70	24
2158	Promoter Hypermethylation of a Novel Gene,ZHX2,in Hepatocellular Carcinoma. 2006 , 125, 740-746	35
2157	Radiofrequency ablation for small hepatocellular carcinoma: prospective comparison of internally cooled electrode and expandable electrode. 2006 , 238, 346-53	111
2156	Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization. 2007 , 178, 1914-22	109
2155	Strategies for the management of hepatocellular carcinoma. 2007 , 4, 424-32	222
2154	Survival impact of delayed treatment in patients with hepatocellular carcinoma undergoing locoregional therapy: is there a lead-time bias?. 2007 , 42, 485-92	20
2153	Future of molecular profiling of human hepatocellular carcinoma. 2007 , 3, 429-39	17

2152	Current concepts in the evaluation of patients for liver transplantation. 2007 , 1, 307-20	1
2151	Management of hepatocellular carcinoma. 2007 , 25, 279-81	15
2150	Inoperable hepatocellular carcinoma: transarterial 188Re HDD-labeled iodized oil for treatment--prospective multicenter clinical trial. 2007 , 243, 509-19	54
2149	Potential prognostic benefits of radiotherapy as an initial treatment for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels. 2007 , 73, 90-7	38
2148	Superselective transcatheter arterial chemoembolisation of an unresectable hepatocellular carcinoma using three-dimensional rotational angiography. 2007 , 80, e85-7	2
2147	Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy. 2007 , 12, 1425-32	43
2146	Liver resection or combined chemoembolization and radiofrequency ablation improve survival in patients with hepatocellular carcinoma. 2007 , 75, 104-12	44
2145	Repeated courses of transarterial embolization with polyvinyl alcohol particles: 'long life elixir' in a cirrhotic patient with unresectable hepatocellular carcinoma. 2007 , 19, 329-32	4
2144	LONG-ACTING OCTREOTIDE FOR ADVANCED LIVER CANCER: A WELL-DESIGNED NEGATIVE TRIAL. 2007 , 8, 43-44	
2143	Hepatocellular cancer: a guide for the internist. 2007 , 120, 194-202	130
2142	A primer on transarterial, chemical, and thermal ablative therapies for hepatic tumors. 2007 , 194, 79-88	35
2141	Factors predicting survival in advanced T-staged hepatocellular carcinoma patients treated with reduction hepatectomy followed by transcatheter arterial chemoembolization. 2007 , 33, 1019-24	4
2140	Random-effects model for meta-analysis of clinical trials: an update. 2007 , 28, 105-14	1402
2139	Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. 2007 , 46, 474-81	734
2138	Interventional radiology as a fine art. 2007 , 46, 362-4	2
2137	Intra-arterial injection of iodine-131-labeled lipiodol for treatment of hepatocellular carcinoma. 2007 , 82, 76-82	36
2136	Internal mammary arteries supplying hepatocellular carcinoma: vascular anatomy at digital subtraction angiography in 97 patients. 2007 , 242, 925-32	30
2135	Current management of liver cancer. 2007 , 5, 444-446	4

2134	Management of hepatocellular carcinoma. 2007 , 11, 305-21	17
2133	Treatment options for hepatobiliary and pancreatic cancer. 2007 , 82, 628-37	51
2132	Transarterial chemoembolization for primary hepatocellular carcinoma in patients at high risk. 2007 , 18, 1517-26; quiz 1527	83
2131	Hepatocellular carcinoma with internal mammary artery supply: feasibility and efficacy of transarterial chemoembolization and factors affecting patient prognosis. 2007 , 18, 611-9; quiz 620	27
2130	A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. 2007 , 5, 1100-8	234
2129	Recurrence of nonviral diseases. 2007 , 11, 377-95	3
2128	[Updated guide for diagnosis, staging and treatment of hepatocellular carcinoma]. 2007 , 128, 741-8	3
2127	[Cell biology and genetics in liver cancer]. 2007 , 30, 360-9	4
2126	[Prognostic factors in patients with non-active treatment of hepatocellular carcinoma]. 2007 , 30, 441-8	1
2125	Dramatic reduction in tumour size in hepatocellular carcinoma patients on thalidomide therapy. 2007 , 21, 517-8	2
2124	Treatment Approaches for Hepatocellular Carcinoma. 2007 , 1, 117955490700100	
2123	Tumor response to transcatheter arterial chemoembolization in recurrent hepatocellular carcinoma after living donor liver transplantation. 2007 , 8, 320-7	33
2122	Efficacy of transcatheter embolization/chemoembolization (TAE/TACE) for the treatment of single hepatocellular carcinoma. 2007 , 13, 2952-5	55
2121	WITHDRAWN: Resection versus no intervention or other surgical interventions for colorectal cancer liver metastases. 2007 , CD006039	2
2120	Multidisciplinary Team Management of Upper Gastrointestinal, Hepatic, Pancreatic, and Biliary Cancers. 2007 ,	
2119	Role of transplantation in the management of hepatic malignancy. 2007 , 94, 1319-30	6
2118	Antiangiogenic therapy enhances the efficacy of transcatheter arterial embolization for hepatocellular carcinomas. 2007 , 121, 416-24	46
2117	Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. <i>Hepatology</i> , 2008 , 47, 71-81	11.2 448

2116	Locoregional treatment for hepatocellular carcinoma: From clinical exploration to robust clinical data, changing standards of care. <i>Hepatology</i> , 2008 , 47, 5-7	11.2	15
2115	Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. 2007 , 109, 2132-41		85
2114	Clinical and molecular classification of hepatocellular carcinoma. 2007 , 13, S13-6		16
2113	Is hepatic transplantation justified for primary liver cancer?. 2007 , 95, 674-9		7
2112	CD117 (c-kit) expression in human hepatocellular carcinoma. 2007 , 19, 204-8		30
2111	Hepatic resection compared to percutaneous ethanol injection for small hepatocellular carcinoma using propensity score matching. 2007 , 22, 1643-9		17
2110	Predictors of outcome in patients with unresectable hepatocellular carcinoma receiving transcatheter arterial chemoembolization. 2007 , 26, 393-400		19
2109	Pre-operative transarterial chemoembolization for resectable hepatocellular carcinoma adversely affects post-operative patient outcome. 2008 , 27, 338-45		16
2108	Consensus and controversy in the management of hepatocellular carcinoma. 2007 , 205, 108-23		21
2107	Transarterial chemoembolization for patients with hepatocellular carcinoma. 2007 , 37 Suppl 2, S230-7		12
2106	Hepatocellular carcinoma (HCC): an update. 2007 , 34, S12-20		50
2105	Large-sized hepatocellular carcinoma (HCC): a neoadjuvant treatment protocol with repetitive transarterial chemoembolization (TACE) before percutaneous MR-guided laser-induced thermotherapy (LITT). 2007 , 17, 553-63		34
2104	The surgeon and palliative care. 2007 , 14, 1257-63		10
2103	Salvage surgery following downstaging of unresectable hepatocellular carcinoma--a strategy to increase resectability. 2007 , 14, 3301-9		73
2102	[Systemic treatment of liver and biliary tumors]. 2007 , 48, 46-9		1
2101	[Update on chemoinfusion and chemoembolization treatments]. 2007 , 47, 1097-106, 1108		6
2100	[Combined therapies including interventional radiology]. 2007 , 47, 1072, 1074-82		1
2099	Is preoperative transarterial chemoembolization needed for a resectable hepatocellular carcinoma?. 2007 , 31, 2370-7		34

2098	Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. 2007 , 30, 6-25	599
2097	Retrospective evaluation of tumor-mass-reduction therapy for the prognosis of recurrent hepatocellular carcinoma. 2007 , 1, 460-8	2
2096	Früherkennung des hepatozellulären Karzinoms. 2007 , 2, 356-364	1
2095	Molecular targeted therapy for advanced hepatocellular carcinoma. 2007 , 2, 199-210	6
2094	A decision analysis model identifies the interval of efficacy for transarterial chemoembolization (TACE) in cirrhotic patients with hepatocellular carcinoma awaiting liver transplantation. 2007 , 11, 1328-32	21
2093	Racial and geographic disparities in the utilization of surgical therapy for hepatocellular carcinoma. 2007 , 11, 1636-46; discussion 1646	54
2092	A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). 2008 , 26, 265-72	48
2091	Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC bead. 2008 , 33, 512-9	89
2090	Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. 2008 , 31, 269-80	163
2089	Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with inferior vena cava and right atrial tumors. 2008 , 31, 735-44	42
2088	Bland embolization of hepatocellular carcinoma using superabsorbent polymer microspheres. 2008 , 31, 1108-16	44
2087	Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres: preliminary results from an Italian multicentre study. 2008 , 31, 1141-9	91
2086	A phase II trial of transcatheter arterial infusion chemotherapy with an epirubicin-Lipiodol emulsion for advanced hepatocellular carcinoma refractory to transcatheter arterial embolization. 2008 , 61, 683-8	5
2085	Hepatozelluläres Karzinom. 2008 , 3, 147-157	1
2084	Angiographic evaluation of hepatic arterial damage after transarterial chemoembolization for hepatocellular carcinoma. 2008 , 26, 206-12	37
2083	Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience. 2008 , 12, 129-37	103
2082	Standards und neue Aspekte der Diagnostik und Therapie des hepatozellulären Karzinoms. 2008 , 1, 109-119	
2081	Application of meta-analysis in evidence-based oncology. 2008 , 5, 1-9	

2080	Early detection of liver cancer: diagnosis and management. 2008 , 10, 60-6		17
2079	Update on the treatment of hepatocellular carcinoma. 2008 , 1, 111-115		
2078	Systemic therapy of hepatocellular carcinoma: are we making progress?. 2008 , 25, 1089-104		61
2077	Leberzellkarzinom. 2008 , 3, 6-19		
2076	In search of liver cancer stem cells. 2008 , 4, 179-92		21
2075	Liver embolizations in oncology: a review. Part I. Arterial (chemo)embolizations. 2008 , 25, 1-11		10
2074	Hepatocarcinoma: from pathogenic mechanisms to target therapy. 2008 , 2, 214-222		2
2073	Treatment and prognosis of hepatocellular carcinoma: a population based study in France. 2008 , 98, 505-9		59
2072	Molecular targeted therapies in hepatocellular carcinoma. <i>Hepatology</i> , 2008 , 48, 1312-27	11.2	801
2071	Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats. <i>Hepatology</i> , 2008 , 48, 1864-73	11.2	33
2070	Systematic review and meta-analysis of the effect of portal triad clamping on outcome after hepatic resection. 2008 , 95, 424-32		326
2069	Conformal radiotherapy for hepatocellular carcinoma. 2008 , 67, 113-23		38
2068	Radiotherapy for hepatocellular carcinoma: an overview. 2008 , 15, 1015-24		70
2067	Treatment before liver transplantation for HCC. 2008 , 15, 993-1000		95
2066	Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation. 2008 , 15, 3169-77		116
2065	Surgical treatment of hepatocellular carcinoma beyond Milan criteria. Results of liver resection, salvage transplantation, and primary liver transplantation. 2008 , 15, 1383-91		246
2064	Laparoscopic radiofrequency ablation of unresectable hepatocellular carcinoma: long-term follow-up. 2008 , 10, 315-20		22
2063	Treatment response to transcatheter arterial embolization and chemoembolization in primary and metastatic tumors of the liver. 2008 , 10, 396-404		17

2062	[Liver transplant in patients with hepatocellular carcinoma]. 2008 , 84, 117-24	3
2061	Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. 2008 , 8, 349	73
2060	Thymostimulin in advanced hepatocellular carcinoma: a phase II trial. 2008 , 8, 72	6
2059	A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. 2008 , 8, 839-46	143
2058	Sorafenib in advanced hepatocellular carcinoma. 2008 , 359, 378-90	9089
2057	Diagnosis and treatment of hepatocellular carcinoma. 2008 , 134, 1752-63	842
2056	Drug-eluting particles in the treatment of HCC: chemoembolization with doxorubicin-loaded DC Bead. 2008 , 8, 1643-50	39
2055	Hepatocellular carcinoma: prediction of blood supply from an internal mammary artery with multi-detector row CT. 2008 , 19, 1419-25; quiz 1426	15
2054	Hepatocellular carcinoma: epidemiology and clinical aspects. 2008 , 29, 130-43	78
2053	Novel advancements in the management of hepatocellular carcinoma in 2008. 2008 , 48 Suppl 1, S20-37	635
2052	Selective transarterial chemoembolization of advanced hepatocellular carcinomas: a reasonable palliative option. 2008 , 40, 3179-81	6
2051	The evolving role of radiation therapy in hepatocellular carcinoma. 2008 , 12, 96-101	21
2050	Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402). 2008 , 44, 528-38	78
2049	The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - Survival analysis of 3892 patients. 2008 , 44, 1000-6	163
2048	Serious bile cast formation after transarterial chemoembolization for liver cancer. 2008 , 68, e121-e123	1
2047	Natural history of hepatocellular carcinoma and current treatment options. 2008 , 38, S13-8	54
2046	Carcinoma hepatocelular. 2008 , 10, 770-776	
2045	Hepatocellular carcinoma: detection of blood supply from the right inferior phrenic artery by the use of multi-detector row CT. 2008 , 19, 1551-7	13

2044	Evaluation of different calibrated spherical polyvinyl alcohol microspheres in transcatheter arterial chemoembolization: VX2 tumor model in rabbit liver. 2008 , 19, 1065-9	28
2043	Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma. 2008 , 19, 862-9	129
2042	Diffusion-weighted MR: therapeutic evaluation after chemoembolization of VX-2 carcinoma implanted in rabbit liver. 2008 , 15, 593-600	26
2041	Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada. 2008 , 24, 3559-69	25
2040	Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging. 2008 , 246, 812-22	451
2039	Optimal strategies for combining transcatheter arterial chemoembolization and radiofrequency ablation in rabbit VX2 hepatic tumors. 2008 , 19, 1740-8	42
2038	Comparison of hypoxia-inducible factor-1alpha expression before and after transcatheter arterial embolization in rabbit VX2 liver tumors. 2008 , 19, 1483-9	72
2037	Safety and effectiveness of repeat arterial closure using the AngioSeal device in patients with hepatic malignancy. 2008 , 19, 1704-8	12
2036	High-dimensional biology to comprehend hepatocellular carcinoma. 2008 , 5, 45-60	22
2035	MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. 2008 , 247, 311-30	303
2034	Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. 2008 , 103, 914-21	333
2033	Hepatitis B virus genotype and mutants: risk factors for hepatocellular carcinoma. 2008 , 100, 1121-3	13
2032	Molecular Targeting in Hepatocellular Carcinoma. 2008 , 165-210	1
2031	Interventional radiology in liver cancer. 2008 , 20, 185-193	
2030	Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma. 2008 , 14, 3520-8	71
2029	Three-dimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava invasion. 2008 , 38, 438-44	17
2028	Bendamustine--a new approach to the treatment of advanced hepatocellular carcinoma?. 2008 , 20, 112-8	1
2027	TACE versus TAE as therapy for hepatocellular carcinoma. 2008 , 8, 1623-41	65

2026	Evidence-based diagnosis and locoregional therapy for hepatocellular carcinoma. 2008 , 2, 761-84	11
2025	Fever after transcatheter arterial chemoembolization for hepatocellular carcinoma: incidence and risk factor analysis. 2008 , 43, 992-9	21
2024	Design and endpoints of clinical trials in hepatocellular carcinoma. 2008 , 100, 698-711	1360
2023	Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. 2008 , 8, 1743-9	64
2022	Can tumor growth be further inhibited by combining drugs such as bortezomib with image-guided interventional oncologic procedures?. 2008 , 248, 323-5	3
2021	Sequential arterial and portal vein embolization in patients with cirrhosis and hepatocellular carcinoma: the hospital beaumont experience. 2008 , 25, 155-61	11
2020	The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. 2008 , 16, 1637-42	156
2019	Visualization of hypervascular liver lesions During TACE: comparison of angiographic C-arm CT and MDCT. 2008 , 190, W263-9	67
2018	New Concepts in Targeting and Imaging Liver Cancer. 202-212	
2017	Benign and Malignant Tumors of the Liver. 195-214	
2016	Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. 2008 , 20, 444-53	51
2015	Radiofrequency ablation and chemoembolization for hepatocellular carcinoma. 2008 , 14, 117-22	49
2014	Wnt signaling in liver cancer. 2008 , 9, 1013-24	133
2013	Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. 2008 , 248, 617-25	231
2012	Hepatocellular carcinoma: management of an increasingly common problem. 2008 , 21, 266-80	128
2011	Regional therapies for treatment of intermediate-stage hepatocellular carcinoma. 66-96	
2010	Radiological identification of residual and recurrent hepatocellular carcinoma. 122-135	
2009	[Local therapy for hepatocellular carcinoma as a bridge to liver transplantation]. 2009 , 36, 487-92	

2008	Successful transcatheter chemoembolization for acute jaundice in a patient with advanced hepatocellular carcinoma and portal vein tumor thrombosis: a case report. 2009 , 76, 217-20	2
2007	The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma. 2009 , 10, 425-34	113
2006	Rupture and intra-peritoneal bleeding of a hepatocellular carcinoma after a transarterial chemoembolization procedure: a case report. 2009 , 2, 68	9
2005	Multimodal approaches to the treatment of hepatocellular carcinoma. 2009 , 6, 159-69	59
2004	Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine. 2009 , 50, 1441-7	46
2003	Current status of therapy for hepatocellular carcinoma. 2009 , 2, 45-57	11
2002	A case of biliopleural fistula in a patient with hepatocellular carcinoma. 2009 , 6, 248-51	4
2001	Antisense hypoxia-inducible factor-1alpha augments transcatheter arterial embolization in the treatment of hepatocellular carcinomas in rats. 2009 , 20, 314-24	24
2000	Identification of genes conferring resistance to 5-fluorouracil. 2009 , 106, 12938-43	128
1999	Triple-drug transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma: assessment of survival in 124 consecutive patients. 2009 , 193, 1665-71	11
1998	Vascular interventional radiology in oncology. 2009 , 21, 122-130	
1997	The effect of Scutellaria baicalensis on the signaling network in hepatocellular carcinoma cells. 2009 , 61, 530-7	57
1996	Long-term outcome of cirrhotic patients with early hepatocellular carcinoma treated with ultrasound-guided percutaneous laser ablation: a retrospective analysis. 2009 , 27, 2615-21	92
1995	Commentary: Sorafenib -- the end of a long journey in search of systemic therapy for hepatocellular carcinoma, or the beginning?. 2009 , 14, 92-4	10
1994	Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer. 2009 , 50, 871-7	32
1993	Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. 2009 , 7, 41	101
1992	A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. 2009 , 9, 1920-8	447
1991	[Hepatocellular carcinoma management in the era of sorafenib]. 2009 , 33, 327-33	

1990	[Hepatocellular carcinoma: increasing incidence and optimized management]. 2009 , 33, 830-9		9
1989	Safety of using iodized oil in chemoembolization for liver tumors in patients with previous adverse reactions to iodinated contrast media. 2009 , 33, 365-8		1
1988	[Sorafenib: effectiveness versus safety. Prevention of hand-foot syndrome]. 2009 , 33, 288-9		1
1987	Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. <i>Hepatology</i> , 2009 , 49, 453-9	11.2	328
1986	Sorafenib: A glimmer of hope for unresectable hepatocellular carcinoma?. <i>Hepatology</i> , 2009 , 49, 332-4	11.2	9
1985	The reduction of cell death and proliferation by p27(Kip1) minimizes DNA damage in an experimental model of genotoxicity. 2009 , 125, 2270-80		7
1984	Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?. 2009 , 115, 616-23		359
1983	The efficacy for unresectable hepatocellular carcinoma may be improved by transcatheter arterial chemoembolization in combination with a traditional Chinese herbal medicine formula: a retrospective study. 2009 , 115, 5132-8		37
1982	The outcomes of elderly patients with hepatocellular carcinoma treated with transarterial chemoembolization. 2009 , 115, 5507-15		37
1981	Meta-analysis of standard, restrictive and supplemental fluid administration in colorectal surgery. 2009 , 96, 331-41		243
1980	A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma. 2009 , 135, 1437-45		99
1979	Effects of kanglaite capsules combined with transcatheter arterial chemoembolization (TACE) on patients with mid or late-stage primary hepatocellular carcinoma (HCC). 2009 , 8, 65-68		8
1978	Brain metastases from hepatocellular carcinoma: prognostic factors and outcome: brain metastasis from HCC. 2009 , 91, 307-13		89
1977	A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma. 2009 , 3, 480-9		18
1976	Surgical treatment for hepatocellular carcinoma in cirrhotic patients. Guide to the selection and decision-making process in a context of multimodal strategy. 2009 , 11, 20-7		1
1975	Role of stereotactic body radiotherapy in the management of primary hepatocellular carcinoma. Rationale, technique and results. 2009 , 11, 276-83		14
1974	Das hepatozelluläre Karzinom. 2009 , 4, 33-41		
1973	Treating hepatocellular carcinoma without liver transplantation. 2009 , 11, 69-75		

1972	Transarterielle Chemoembolisation bei hepatozellulärem Karzinom [neue Entwicklungen]. 2009 , 4, 330-339	1
1971	Is liver resection justified in advanced hepatocellular carcinoma? Results of an observational study in 464 patients. 2009 , 13, 1313-20	58
1970	Radiologic findings following Y90 radioembolization for primary liver malignancies. 2009 , 34, 566-81	76
1969	The anterior branch of the left inferior phrenic artery arising from the right inferior phrenic artery: an angiographic and CT study. 2009 , 32, 250-4	14
1968	Hepatocellular carcinoma invading the main portal vein: treatment with transcatheter arterial chemoembolization and portal vein stenting. 2009 , 32, 52-61	17
1967	Experimental liver embolization with four different spherical embolic materials: impact on inflammatory tissue and foreign body reaction. 2009 , 32, 303-12	28
1966	A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma. 2009 , 18, 492-9	32
1965	Combination effect of oncolytic adenovirus therapy and herpes simplex virus thymidine kinase/ganciclovir in hepatic carcinoma animal models. 2009 , 30, 617-27	22
1964	Phase II study of irinotecan in combination with capecitabine as a first-line chemotherapy in Asian patients with inoperable hepatocellular carcinoma. 2009 , 5, 95-100	
1963	Targeted agents for the systemic treatment of advanced hepatocellular carcinoma. 2009 , 5, 76-86	1
1962	Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. 2009 , 24, 806-14	111
1961	Combination therapy with transarterial chemoembolization and interferon-alpha compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma. 2009 , 24, 1437-44	24
1960	Transarterial chemoembolization for hepatocellular carcinoma with portal vein invasion: a helpful palliative approach. 2009 , 24, 1317-9	1
1959	Hepatic resection for large hepatocellular carcinoma in the era of UCSF criteria. 2009 , 11, 551-8	10
1958	Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model. 2009 , 29, 284-90	32
1957	Potential and future strategies for radiotherapy in hepatocellular carcinoma. 2009 , 29, 145-6	6
1956	New drugs for the treatment of hepatocellular carcinoma. 2009 , 29 Suppl 1, 148-58	19
1955	Liver cancer stem cells: implications for a new therapeutic target. 2009 , 29, 955-65	64

1954	Magnetic nanoparticles encapsulated into biodegradable microparticles steered with an upgraded magnetic resonance imaging system for tumor chemoembolization. 2009 , 30, 6327-32	109
1953	The value of combined soft-tissue and vessel visualisation before transarterial chemoembolisation of the liver using C-arm computed tomography. 2009 , 19, 2302-9	22
1952	Meta-analysis of the clamp-crushing technique for transection of the parenchyma in elective hepatic resection: back to where we started?. 2009 , 16, 630-9	57
1951	Liver resection improves the survival of patients with multiple hepatocellular carcinomas. 2009 , 16, 848-55	89
1950	Image-guided thermochemical ablation: theoretical and practical considerations. 2009 , 2009, 4291-4	3
1949	Gestione del carcinoma epatocellulare: le linee guida internazionali. 2009 , 3, 136-147	
1948	Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. 2009 , 193, 1044-52	150
1947	Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. 2009 , 72, 505-16	108
1946	Empiric antibiotics for transarterial embolization in hepatocellular carcinoma: indicated?. 2009 , 151, 121-4	7
1945	[Diagnosis and treatment of hepatocellular carcinoma]. 2009 , 132, 272-87	37
1944	The burden of illness associated with hepatocellular carcinoma in the United States. 2009 , 50, 89-99	113
1943	Angiogenesis in liver disease. 2009 , 50, 604-20	438
1942	Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial. 2009 , 51, 1030-6	68
1941	Transarterial therapies in HCC: does embolization increase survival?. 2009 , 51, 981-3	5
1940	Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. 2009 , 104, 1802-29	182
1939	Transarterial embolization with microspheres in the treatment of monofocal HCC. 2009 , 41, 143-9	6
1938	Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. 2009 , 9, 503-9	81
1937	MicroRNA expression, survival, and response to interferon in liver cancer. 2009 , 361, 1437-47	675

1936	Preoperative combined with postoperative chemoembolization can improve survival in patients with hepatocellular carcinoma: a single-center study. 2009 , 20, 472-83	8
1935	Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. 2009 , 20, S317-23	28
1934	Safety and feasibility of outpatient transcatheter hepatic arterial embolization for hepatocellular carcinoma. 2009 , 20, 203-8	11
1933	Extrahepatic collateral artery supply to the tumor thrombi of hepatocellular carcinoma invading inferior vena cava: the prevalence and determinant factors. 2009 , 20, 22-9	50
1932	Identifying feeding arteries during TACE of hepatic tumors: comparison of C-arm CT and digital subtraction angiography. 2009 , 192, 1057-63	88
1931	Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. 2009 , 10, 1111-8	325
1930	Clinical application of an enzyme-linked immunosorbent assay detecting hepatoma-specific gamma-glutamyltransferase. 2009 , 39, 979-87	7
1929	Therapeutic results of computed-tomography-guided transcatheter arterial chemoembolization for local recurrence of hepatocellular carcinoma after initial transcatheter arterial chemoembolization: the results of 85 recurrent tumors in 35 patients. 2009 , 54, 661-9	12
1928	Transcatheter arterial chemoembolization for hepatocellular carcinoma: prospective assessment of the right inferior phrenic artery with C-arm CT. 2009 , 20, 888-95	28
1927	Does postembolization fever after chemoembolization have prognostic significance for survival in patients with unresectable hepatocellular carcinoma?. 2009 , 20, 209-16	25
1926	Current management of hepatocellular carcinoma. 2009 , 93, 885-900, viii	45
1925	Modern diagnosis and management of hepatocellular carcinoma. 2009 , 13, 233-47	34
1924	Radiologic monitoring of hepatocellular carcinoma tumor viability after transhepatic arterial chemoembolization: estimating the accuracy of contrast-enhanced cross-sectional imaging with histopathologic correlation. 2009 , 20, 30-8	50
1923	Arterial chemoembolization/embolization and early complications after hepatocellular carcinoma treatment: a safe standardized protocol in selected patients with Child class A and B cirrhosis. 2009 , 20, 896-902	31
1922	Pilot study of transarterial chemoembolization with pirarubicin and amiodarone for unresectable hepatocellular carcinoma. 2009 , 32, 238-44	8
1921	Efficacy and safety of transarterial chemoembolization in recurrent hepatocellular carcinoma after curative surgical resection. 2009 , 32, 564-9	28
1920	The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. 2009 , 249, 20-5	240
1919	Pathogenesis of hepatocellular carcinoma and molecular therapies. 2009 , 25, 186-94	109

1918 Traitements radiologiques des tumeurs hépatiques. **2009**, 4, 1-27

1917 Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. **2010**, 22, 391-8 56

1916 Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions. **2010**, 22, 205-11 12

1915 Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. **2010**, 22, 1106-10 60

1914 Sorafenib in hepatocellular carcinoma. **2010**, 71, 451-6 13

1913 Transarterial chemoembolization in patients with hepatocellular carcinoma and renal insufficiency. **2010**, 44, e171-7 29

1912 Interventional radiological treatment of hepatocellular carcinoma. **2010**, 17, 87-99 15

1911 Nonsurgical options for hepatocellular carcinoma: evolving role of external beam radiotherapy. **2010**, 17, 100-10 19

1910 Development and in vitro characterization of galactosylated low molecular weight chitosan nanoparticles bearing doxorubicin. **2010**, 11, 686-97 37

1909 Complete necrosis after transarterial chemoembolization could predict prolonged survival in patients with recurrent intrahepatic hepatocellular carcinoma after curative resection. **2010**, 17, 869-77 41

1908 Management of small hepatocellular carcinoma: a review of transplantation, resection, and ablation. **2010**, 17, 1226-33 65

1907 Comparing hepatic resection and transarterial chemoembolization for Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma: change for treatment of choice?. **2010**, 34, 2155-61 71

1906 Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. **2010**, 33, 41-52 1076

1905 MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma. **2010**, 33, 532-40 96

1904 Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. **2010**, 33, 541-51 271

1903 Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up. **2010**, 33, 552-9 76

1902 A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma. **2010**, 65, 373-82 44

1901 [Differentiated therapy of liver tumors]. **2010**, 51, 53-62

1900	[Multimodality treatment for hepatocellular carcinoma]. 2010 , 51, 1374-81	1
1899	Traitements du carcinome hpatocellulaire non accessible ^ un traitement curatif: actualit\$. 2010 , 12, 615-622	
1898	Capecitabine plus cisplatin treatment in patients with advanced hepatocellular carcinoma. 2010 , 9, 718-723	
1897	Transcatheter arterial infusion chemotherapy with cisplatin-lipiodol suspension in patients with hepatocellular carcinoma. 2010 , 45, 60-7	22
1896	Minimally invasive image-guided therapy for inoperable hepatocellular carcinoma: What is the evidence today?. 2010 , 1, 167-81	16
1895	Sequential therapy of transarterial chemoembolisation and sorafenib in intermediate stage hepatocellular carcinoma. 2010 , 41, 149-52	3
1894	Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. 2010 , 4, 439-74	825
1893	Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. 2010 , 12, 218-25	228
1892	A protocol to effectively create single cell suspensions of adherent cells for multiparameter high-throughput flow cytometry. 2010 , 46, 97-101	6
1891	Transarterial chemoembolization, transarterial chemotherapy, and intra-arterial chemotherapy for hepatocellular carcinoma treatment. 2010 , 37, 89-93	34
1890	[Percutaneous and intra-arterial treatment of hepatocellular carcinoma]. 2010 , 52, 399-413	0
1889	[Hepatocellular carcinoma: diagnosis, staging, and treatment strategy]. 2010 , 52, 385-98	7
1888	Markedly effective local control of hepatocellular carcinoma with a poor prognosis by combined multimodal therapy with sorafenib as a neoadjuvant approach. 2010 , 34, 314-8	5
1887	Harm and benefits of primary liver resection and salvage transplantation for hepatocellular carcinoma. 2010 , 10, 619-27	64
1886	Excellent outcomes with angiographic subsegmentectomy in the treatment of typical hepatocellular carcinoma: a retrospective study of local recurrence and long-term survival rates in 120 patients with hepatocellular carcinoma. 2010 , 116, 393-9	23
1885	Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. 2010 , 116, 1305-14	147
1884	Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. 2010 , 116, 4590-6	129
1883	Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis. <i>Hepatology</i> , 2010 , 51, 1284-90	11.2 184

1882	A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. <i>Hepatology</i> , 2010 , 51, 1274-83	11.2	292
1881	Loco-regional treatment of hepatocellular carcinoma. <i>Hepatology</i> , 2010 , 52, 762-73	11.2	383
1880	Hepatocellular carcinoma: assessment of response to transarterial chemoembolization with image subtraction. 2010 , 31, 348-55		66
1879	Morphological features of advanced hepatocellular carcinoma as a predictor of downstaging and liver transplantation: an intention-to-treat analysis. 2010 , 16, 289-99		69
1878	Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. 2010 , 16, 262-78		306
1877	Inherited hepatocellular carcinoma. 2010 , 24, 725-34		17
1876	Analysis of prognostic factors after yttrium-90 radioembolization of advanced hepatocellular carcinoma. 2010 , 77, 1441-8		46
1875	Is local radiotherapy still valuable for patients with multiple intrahepatic hepatocellular carcinomas?. 2010 , 77, 1433-40		16
1874	Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival. 2010 , 78, 172-9		84
1873	Angiogenic blockade and radiotherapy in hepatocellular carcinoma. 2010 , 78, 188-93		42
1872	Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study. 2010 , 5, 12		31
1871	Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study. 2010 , 12, 31-6		35
1870	Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference. 2010 , 12, 321-2		1
1869	Longterm follow-up after transarterial chemotherapy for hepatocellular carcinoma in a Scandinavian centre. 2010 , 12, 637-43		7
1868	Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma. 2010 , 30, 166-74		50
1867	TACE it or leave it: hard choices for intermediate-stage hepatocellular carcinoma patients beyond perfect health. 2010 , 30, 3-4		
1866	Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis. 2010 , 30, 741-9		79
1865	Remission of extensive intrahepatic metastasis by C-arm computed tomography guided chemoembolization in uveal melanoma. 2010 , 8, 525-8		

1864	Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study. 2010 , 64, 1034-41	59
1863	Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma. 2010 , 6, 80-8	23
1862	Impact of evidence-based medicine on the treatment of patients with unresectable hepatocellular carcinoma. 2010 , 31, 493-501	27
1861	Review article: the management of hepatocellular carcinoma. 2010 , 31, 461-76	158
1860	Intra-arterial therapy with cisplatin suspension in lipiodol and 5-fluorouracil for hepatocellular carcinoma with portal vein tumour thrombosis. 2010 , 32, 543-50	28
1859	Locoregional therapies for hepatocellular carcinoma: which patients are most likely to gain a survival advantage?. 2010 , 25, 1299-305	4
1858	Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening. 2010 , 25, 1426-34	27
1857	Optimal management of hepatocellular carcinoma: challenges and opportunities. 2010 , 25, 1336-8	9
1856	Economic evaluation of sorafenib in unresectable hepatocellular carcinoma. 2010 , 25, 1739-46	40
1855	Loco-regional interventional treatment of hepatocellular carcinoma: techniques, outcomes, and future prospects. 2010 , 23, 698-703	23
1854	Diagnosis and management of hepatocellular carcinoma: results of a consensus meeting of The Ottawa Hospital Cancer Centre. 2010 , 17, 6-12	6
1853	Does Surgical Resection Have a Role in the Treatment of Large or Multinodular Hepatocellular Carcinoma?. 2010 , 76, 1189-1197	13
1852	Management of biliopleural fistula after transarterial chemoembolization of a liver lesion. 2010 , 24, 281-3	5
1851	The role of perfusion CT as a follow-up modality after transcatheter arterial chemoembolization: an experimental study in a rabbit model. 2010 , 45, 427-36	51
1850	Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma. 2010 , 2, 147-55	3
1849	Refusal of cancer-directed surgery strongly impairs survival of patients with localized hepatocellular carcinoma. 2010 , 2010, 381795	11
1848	An evidence-based multidisciplinary approach to the management of hepatocellular carcinoma (HCC): the Alberta HCC algorithm. 2010 , 24, 643-50	28
1847	CT findings of completely regressed hepatocellular carcinoma with main portal vein tumor thrombosis after transcatheter arterial chemoembolization. 2010 , 11, 69-74	3

1846	Long-lasting Response with Metronomic Capecitabine in Advanced Hepatocellular Carcinoma. 2010 , 96, 768-770	9
1845	Relevance of Two Genes in the Multidrug Resistance of Hepatocellular Carcinoma: In Vivo and Clinical Studies. 2010 , 96, 90-96	38
1844	Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. 2010 , 15, 1198-204	73
1843	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. 2010 , 56, e1-48	160
1842	Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now?. 2010 , 16, 390-7	94
1841	Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. 2010 , 3, 55-66	60
1840	Hepatocellular carcinoma: the place of new medical therapies. 2010 , 3, 259-67	8
1839	Transarterial embolisation of hepatocellular carcinoma with doxorubicin-eluting beads: single centre early experience. 2010 , 6, e7	15
1838	Chemoembolization of the left inferior phrenic artery in patients with hepatocellular carcinoma: 9-year single-center experience. 2010 , 194, 1124-30	11
1837	Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides. 2010 , 7, 41-9	41
1836	Molecular mechanism of chemoresistance by astrocyte elevated gene-1. 2010 , 70, 3249-58	174
1835	Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?. 2010 , 15 Suppl 4, 42-52	121
1834	Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation. 2010 , 31, 1643-8	37
1833	Combination percutaneous and intraarterial therapy for the treatment of hepatocellular carcinoma: a review. 2010 , 27, 296-301	9
1832	Hepatic artery pseudoaneurysms arising from within a hepatocellular carcinoma. 2010 , 83, e252-4	3
1831	Developing better treatments in hepatocellular carcinoma. 2010 , 4, 551-60	20
1830	Targeted sonography for small hepatocellular carcinoma discovered by CT or MRI: factors affecting sonographic detection. 2010 , 194, W396-400	78
1829	Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. 2010 , 194, 830-7	83

1828	Semiautomated segmentation for volumetric analysis of intratumoral ethiodol uptake and subsequent tumor necrosis after chemoembolization. 2010 , 195, 1220-30	45
1827	A 30-year, population-based study shows improved management and prognosis of hepatocellular carcinoma. 2010 , 8, 986-91	20
1826	In vitro characterization of cisplatin-loaded superabsorbent polymer microspheres designed for chemoembolization. 2010 , 21, 877-81	14
1825	Radiofrequency ablation of the liver: extended effect of transcatheter arterial embolization with iodized oil and gelatin sponge on histopathologic changes during follow-up in a pig model. 2010 , 21, 1716-24	14
1824	Drug-eluting beads for liver embolization: concentration of doxorubicin in tissue and in beads in a pig model. 2010 , 21, 259-67	89
1823	Transcatheter arterial chemoembolization for liver metastases in patients with adrenocortical carcinoma. 2010 , 21, 1527-32	47
1822	Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. 2010 , 21, 327-32	111
1821	Chronic hepatitis B and hepatocellular carcinoma. 2010 , 14, 461-76	56
1820	Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib. 2010 , 11, 2187-98	11
1819	Cancer epigenome. 2010 , 70, 247-76	32
1818	Chemoembolization with lobaplatin mixed with iodized oil for unresectable recurrent hepatocellular carcinoma after orthotopic liver transplantation. 2010 , 21, 333-8	40
1817	Transcatheter arterial chemoembolisation for hepatocellular carcinoma in cirrhosis: survival rate and prognostic factors. 2010 , 42, 515-9	16
1816	Role of surgical resection for pulmonary metastasis of hepatocellular carcinoma. 2010 , 70, 295-300	24
1815	Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents. 2010 , 9, 127	20
1814	The intermediate hepatocellular carcinoma stage: Should treatment be expanded?. 2010 , 42 Suppl 3, S258-63	46
1813	Molecular approaches to treatment of hepatocellular carcinoma. 2010 , 42 Suppl 3, S264-72	65
1812	Future perspectives in hepatocellular carcinoma. 2010 , 42 Suppl 3, S302-9	55
1811	Clinical Development and Future Direction for the Treatment of Hepatocellular Carcinoma. 2010 , 2, 93-103	18

1810	Hepatocellular Carcinoma: Diagnosis, staging, and treatment strategy. 2010 , 52, 385-398	5
1809	Nonresectable combined hepatocellular carcinoma and cholangiocarcinoma: analysis of the response and prognostic factors after transcatheter arterial chemoembolization. 2010 , 255, 270-7	68
1808	Liver cancer: from molecular pathogenesis to new therapies: summary of the EASL single topic conference. 2010 , 52, 296-304	36
1807	[Treatment of advanced hepatocellular carcinoma]. 2010 , 33, 461-8	2
1806	[Imaging techniques in hepatocellular carcinoma: diagnosis, extension and evaluation of therapeutic response]. 2010 , 33, 721-6	0
1805	[Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma]. 2010 , 33, 741-52	8
1804	[Nonsurgical management of hepatocellular carcinoma]. 2010 , 14, 469-73	
1803	Approach to radiation therapy in hepatocellular carcinoma. 2010 , 36, 157-63	38
1802	Heated lipiodol as an embolization agent for transhepatic arterial embolization in VX2 rabbit liver cancer model. 2010 , 73, 412-9	22
1801	Characterization of small (10 mm) focal liver lesions: value of respiratory-triggered echo-planar diffusion-weighted MR imaging. 2010 , 76, 89-95	79
1800	A case-control study comparing percutaneous radiofrequency ablation alone or combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. 2010 , 36, 257-63	49
1799	Geographic difference in survival outcome for advanced hepatocellular carcinoma: implications on future clinical trial design. 2010 , 31, 55-61	41
1798	Patients with unresectable hepatocellular carcinoma beyond Milan criteria: should we perform transarterial chemoembolization or liver transplantation?. 2010 , 42, 821-4	12
1797	Effect of necrosis modulator necrox-7 on hepatic ischemia-reperfusion injury in beagle dogs. 2010 , 42, 3414-21	29
1796	Megestrol and embryonic extracts in the treatment of advanced hepatocellular carcinoma: A prospective randomized trial in the pre-sorafenib era. 2010 , 40, 153-60	6
1795	Phase I/II study of a fine-powder formulation of cisplatin for transcatheter arterial chemoembolization in hepatocellular carcinoma. 2010 , 40, 369-75	9
1794	Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). 2010 , 40, 667-85	144
1793	Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: A meta-analysis. 2010 , 40, 943-53	79

1792	Transcatheter chemoembolization for unresectable hepatocellular carcinoma and comparison of five staging systems. 2010 , 40, 1082-91	7
1791	Vascular complications of hepatic artery after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. 2010 , 195, 245-51	74
1790	Neuroradiologie et radiologie digestive interventionnelles. 2010 , 6, 47-50	
1789	Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. 2010 , 21, 224-30	153
1788	Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis. 2010 , 29, 164	30
1787	Tumor doubling time after initial response to transarterial chemoembolization in patients with hepatocellular carcinoma. 2010 , 45, 332-9	17
1786	Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. 2011 , 197, W562-70	136
1785	Advances in regional chemotherapy of the liver. 2011 , 8, 1057-69	15
1784	Venous thrombosis after radiofrequency ablation for hepatocellular carcinoma. 2011 , 197, 1474-80	20
1783	The use of transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: a response to the Cochrane Collaboration review of 2011. 2011 , 22, 1693-6	24
1782	Hepatocellular carcinoma: locoregional and targeted therapies. 2011 , 40, 599-610	6
1781	Locoregional therapy for hepatocellular carcinoma. 2011 , 15, 395-421, vii-x	14
1780	Transarterial chemoembolization of a colic branch of the superior mesenteric artery in patients with unresectable hepatocellular carcinoma. 2011 , 22, 47-54	11
1779	Hepatocellular carcinoma: prediction of blood supply from an intercostal artery with multidetector row computed tomography. 2011 , 22, 1403-1408.e1	10
1778	Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. 2011 , 22, 1545-52	156
1777	Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort. 2011 , 22, 917-23	75
1776	Hepatocellular necrosis, apoptosis, and proliferation after transcatheter arterial embolization or chemoembolization in a standardized rabbit model. 2011 , 22, 1606-12	13
1775	HBV-related HCC, clinical issues and therapy. 2011 , 43 Suppl 1, S32-9	13

1774	Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma. 2011 , 53, 246-253	27
1773	Nuclear receptors as new perspective for the management of liver diseases. 2011 , 140, 1120-1125.e1-12	80
1772	Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. 2011 , 141, 526-35, 535.e1-2	133
1771	Randomised controlled trial of lipiodol transarterial chemoembolisation with or without amiodarone for unresectable hepatocellular carcinoma. 2011 , 43, 905-11	7
1770	A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. 2011 , 43, 1015-21	8
1769	Induction Chemotherapy for Hepatocellular Carcinoma. 2011 , 237-250	
1768	Radiotherapeutic strategies in the management of hepatocellular carcinoma. 2011 , 81 Suppl 1, 123-33	22
1767	Targeted therapies for hepatocellular carcinoma. 2011 , 140, 1410-26	360
1766	Prise en charge des tumeurs primitives du foie et des voies biliaires. 2011 , 401-413	
1765	Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. 2011 , 22, 1697-705	81
1764	Tumor Growth After Portal Vein Embolization. 2011 , 271-278	1
1763	Randomized controlled trial of a collaborative care intervention to manage cancer-related symptoms: lessons learned. 2011 , 8, 298-310	19
1762	Polyol profile as an early diagnostic and prognostic marker in natural product chemoprevention of hepatocellular carcinoma in diabetic rats. 2011 , 92, 228-37	13
1761	MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. 2011 , 310, 160-9	149
1760	[Transarterial chemoembolization and conformal radiotherapy for hepatocellular carcinoma]. 2011 , 15, 69-71	4
1759	Successful resection of huge hepatocellular carcinoma with inferior vena cava thrombus after downsizing by three-dimensional conformal radiation therapy and transarterial chemoembolization. 2011 , 44, 156-159	1
1758	Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. 2011 , 47, 2117-27	390
1757	Noncontrast chest computed tomography immediately after transarterial chemoembolization in patients with hepatocellular carcinoma: clinical benefits and effect of radiation reduction on image quality in low-dose scanning. 2011 , 80, e188-94	1

1756	Clinical study of transarterial chemoembolization combined with 3-dimensional conformal radiotherapy for hepatocellular carcinoma. 2011 , 37, 245-51	16
1755	Signaling pathways in hepatocellular carcinoma. 2011 , 81 Suppl 1, 18-23	31
1754	Transcatheter arterial infusion chemotherapy with a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. 2011 , 41, 770-5	20
1753	Gene-expression signature of vascular invasion in hepatocellular carcinoma. 2011 , 55, 1325-31	108
1752	EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. 2011 , 55, 1309-16	253
1751	Embolization of hepatocellular carcinoma with drug-eluting beads: new insight into the biologic effects of tumor ablation. 2011 , 55, 1169-70	4
1750	CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. 2011 , 9, 50-63	463
1749	19-Nor-2[3-hydroxypropyl]-1[5-dihydroxyvitamin D3 (MART-10) is a potent cell growth regulator with enhanced chemotherapeutic potency in liver cancer cells. 2011 , 76, 1513-9	31
1748	Outcomes of loco-regional therapy for down-staging of hepatocellular carcinoma prior to liver transplantation. 2011 , 10, 143-50	9
1747	Comparative study of cisplatin and epirubicin in transcatheter arterial chemoembolization for hepatocellular carcinoma. 2011 , 41, 303-9	14
1746	Combining sorafenib with chemoembolization for hepatocellular cancer. 2011 , 8, 216-219	
1745	Carcinoma hepatocellular. 2011 , 15, 1-9	
1744	Thermal tumor ablation in clinical use. 2011 , 2, 28-38	103
1743	Portal vein thrombosis and arteriportal shunts: effects on tumor response after chemoembolization of hepatocellular carcinoma. 2011 , 17, 1267-75	23
1742	Transarterial Chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs. TACE with cisplatin/lipiodol (cTACE). 2011 , 17, CR189-95	51
1741	Hepatic Arterial Therapy as a Bridge to Ablation or Transplant in the Treatment of Hepatocellular Carcinoma. 2011 , 77, 868-873	1
1740	Advanced hepatocellular carcinoma. Review of targeted molecular drugs. 2011 , 10, 21-27	86
1739	Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. 2011 , 18, 228-40	44

1738	Hepatocellular carcinomas smaller than 4 cm supplied by the intercostal artery: can we predict which intercostal artery supplies the tumor?. 2011 , 12, 693-9	8
1737	Hepatic regeneration after sublethal partial liver irradiation in cirrhotic rats. 2011 , 52, 582-91	11
1736	The Analysis of the Causes of Prolonged Hospitalization after Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma. 2011 , 64, 33	2
1735	Could HBx protein expression affect signal pathway inhibition by gefitinib or selumetinib, a MEK inhibitor, in hepatocellular carcinoma cell lines?. 2011 , 26, 214-21	2
1734	Transarterial chemoembolization in patients with hepatocellular carcinoma: predictors of survival. 2011 , 25, 426-32	8
1733	[Economic impact of transarterial chemoembolization with drug eluting beads in the treatment of hepatocellular carcinoma]. 2011 , 98, 671-8	11
1732	Arterial embolization hyperthermia using As ₂ O ₃ nanoparticles in VX2 carcinoma-induced liver tumors. 2011 , 6, e17926	22
1731	Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma. 2011 , 6, e23621	123
1730	Who could Benefit from Chemoembolisation?. 2011 , 125-135	
1729	Hepatocellular carcinoma: current management and perspectives for the future. 2011 , 253, 453-69	333
1728	Phase I/II study of hepatic arterial infusion chemotherapy with gemcitabine in patients with unresectable intrahepatic cholangiocarcinoma (JIVROSG-0301). 2011 , 34, 58-62	35
1727	Transcatheter arterial chemoembolization for hepatocellular carcinoma in cirrhosis: influence on portal hypertension. 2011 , 23, 573-7	9
1726	Selective targeting of genetically engineered mesenchymal stem cells to tumor stroma microenvironments using tissue-specific suicide gene expression suppresses growth of hepatocellular carcinoma. 2011 , 254, 767-74; discussion 774-5	88
1725	Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. 2011 , CD004787	146
1724	Carcinome h�patocellulaire. 2011 , 6, 1-9	
1723	Growth inhibition and apoptosis induced by lupeol, a dietary triterpene, in human hepatocellular carcinoma cells. 2011 , 34, 517-22	29
1722	Electro-coagulation for liver metastases. 2011 ,	1
1721	Clinical outcomes of liver transplantation for HBV-related hepatocellular carcinoma: data from the NIH HBV OLT study. 2011 , 25, E152-62	12

1720	Risk factors of survival after liver transplantation for HCC: a multivariate single-center analysis. 2011 , 25, E541-51	17
1719	Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. 2011 , 26, 340-7	64
1718	Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients?. 2011 , 26, 145-54	86
1717	Clinical significance and implication of neoangiogenesis in hepatocellular carcinoma. 2011 , 26, 792-3	3
1716	Hepatocellular carcinoma and vitamin D: a review. 2011 , 26, 1597-603	48
1715	Comparison between observed survival after resection of transplantable hepatocellular carcinoma and predicted survival after listing through a Markov model simulation. 2011 , 24, 787-96	12
1714	Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. 2011 , 34, 196-204	46
1713	The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. 2011 , 34, 205-13	81
1712	Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. 2011 , 34, 949-59	63
1711	Presentation and outcomes of hepatocellular carcinoma patients at a western centre. 2011 , 13, 712-22	22
1710	Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies. 2011 , 65, 182-8	19
1709	Lutetium-177 and iodine-131 loaded chelating polymer microparticles intended for radioembolization of liver malignancies. 2011 , 71, 1155-1159	8
1708	[Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma]. 2011 , 53, 246-53	35
1707	Radiosensitizers in hepatocellular carcinoma. 2011 , 21, 303-11	15
1706	Hepatic arterial infusion of doxorubicin-loaded microsphere for treatment of hepatocellular cancer: a multi-institutional registry. 2011 , 213, 493-500	15
1705	Chemoembolization agents for cancer treatment. 2011 , 44, 1-10	47
1704	Transarterial chemoembolisation: effect of selectivity on tolerance, tumour response and survival. 2011 , 21, 1719-26	43
1703	Surgical treatment of huge hepatocellular carcinoma in the caudate lobe. 2011 , 41, 520-5	9

1702	Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled. 2011 , 44, 183-9	23
1701	Improved diagnostic imaging and interventional therapies prolong survival after resection for hepatocellular carcinoma in cirrhosis: the university of bologna experience over 10 years. 2011 , 18, 1630-7	39
1700	Significance of tumor necrosis for outcome of patients with hepatocellular carcinoma receiving locoregional therapy prior to liver transplantation. 2011 , 18, 2638-46	34
1699	The management of hospitalized patients with cirrhosis: the Mount Sinai experience and a guide for hospitalists. 2011 , 56, 1266-81	11
1698	Clinical characteristics of patients with hepatocellular carcinoma in Austria - is there a need for a structured screening program?. 2011 , 123, 542-51	43
1697	A novel transcatheter arterial infusion chemotherapy using iodized oil and degradable starch microspheres for hepatocellular carcinoma: a prospective randomized trial. 2011 , 46, 359-66	27
1696	Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies. 2011 , 44, 117-24	17
1695	Incidence and risk factors for radiocontrast-induced nephropathy in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization. 2011 , 15, 714-719	10
1694	Chemoembolization decreases drop-off risk of hepatocellular carcinoma patients on the liver transplant list. 2011 , 34, 1254-61	20
1693	Transcatheter arterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres for 135 hepatocellular carcinoma patients: single-center experience. 2011 , 34, 557-65	47
1692	Hepatic arterial embolization with doxorubicin-loaded superabsorbent polymer microspheres in a rabbit liver tumor model. 2011 , 34, 1021-30	42
1691	Enhanced antitumor effect of tirapazamine delivered intraperitoneally to VX2 liver tumor-bearing rabbits subjected to transarterial hepatic embolization. 2011 , 34, 1272-7	7
1690	Early identification of poor responders to transarterial chemoembolization for hepatocellular carcinoma. 2011 , 5, 975-84	12
1689	Hepatocellular carcinoma: prevention and therapy. 2011 , 13, 186-94	7
1688	Relevance of circulating nucleosomes and oncological biomarkers for predicting response to transarterial chemoembolization therapy in liver cancer patients. 2011 , 11, 202	20
1687	Protein induced by vitamin K absence or antagonist-II production is a strong predictive marker for extrahepatic metastases in early hepatocellular carcinoma: a prospective evaluation. 2011 , 11, 435	17
1686	Phase i study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: the PROMETHEUS-01 trial. 2011 , 11, 67	29
1685	Permanent and Peripheral Embolization: Temperature-Sensitive p(N-Isopropylacrylamide-co-butyl Methylacrylate) Nanogel as a Novel Blood-Vessel-Emboloc Material in the Interventional Therapy of Liver Tumors. 2011 , 21, 2035-2042	61

1684	Lupeol targets liver tumor-initiating cells through phosphatase and tensin homolog modulation. <i>Hepatology</i> , 2011 , 53, 160-70	11.2	80
1683	Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (. <i>Hepatology</i> , 2011 , 53, 1580-9	11.2	187
1682	Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. <i>Hepatology</i> , 2011 , 54, 868-78	11.2	458
1681	Hepatic and biliary damage after transarterial chemoembolization for malignant hepatic tumors: incidence, diagnosis, treatment, outcome and mechanism. 2011 , 79, 164-74		47
1680	Transcatheter arterial chemoembolization in combination with high-intensity focused ultrasound for unresectable hepatocellular carcinoma: a systematic review and meta-analysis of the chinese literature. 2011 , 37, 1009-16		10
1679	Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. 2011 , 258, 627-34		206
1678	Science to practice: Which approaches to combination interventional oncologic therapy hold the greatest promise of obtaining maximal clinical benefit?. 2011 , 261, 667-9		4
1677	Arterially directed therapies for hepatocellular carcinoma. 2011 , 197, W590-602		16
1676	Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. 2011 , 2, e150		70
1675	A human model of epithelial to mesenchymal transition to monitor drug efficacy in hepatocellular carcinoma progression. 2011 , 10, 850-60		52
1674	Next generation radiologic-pathologic correlation in oncology: Rad-Path 2.0. 2011 , 197, 990-7		23
1673	Diagnosis and management of chronic liver disease in older people. 2011 , 21, 1-15		7
1672	Histone deacetylase inhibitors (epigenetic alterations). 2011 , 62-72		
1671	Superselective transarterial chemoembolization for hepatocellular carcinoma: recent progression and perspective. 2011 , 81 Suppl 1, 105-10		7
1670	C-arm CT for assessing initial failure of iodized oil accumulation in chemoembolization of hepatocellular carcinoma. 2011 , 197, W337-42		24
1669	TACE and sorafenib: a good marriage?. 2011 , 29, 3949-52		50
1668	Randomised double-blind trial of megestrol acetate vs placebo in treatment-naive advanced hepatocellular carcinoma. 2011 , 105, 945-52		29
1667	Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib. 2011 , 11, 1807-16		19

1666	Herbal medicine and hepatocellular carcinoma: applications and challenges. 2011 , 2011, 541209	38
1665	Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in Japan. 2012 , 4, 165-83	20
1664	Hepatitis B- and hepatitis C-related hepatocellular carcinomas in the United States: similarities and differences. 2012 , 12, e7635	41
1663	Resistance to paclitaxel in hepatoma cells is related to static JNK activation and prohibition into entry of mitosis. 2012 , 302, G1016-24	15
1662	Approach of the patient with a liver mass. 2012 , 3, 252-262	3
1661	Transarterial chemoembolization for hepatocellular carcinoma over three decades: current progress and perspective. 2012 , 42, 247-55	37
1660	Local-regional treatment of hepatocellular carcinoma. 2012 , 262, 43-58	264
1659	Therapeutic effect of high-intensity focused ultrasound combined with transarterial chemoembolisation for hepatocellular carcinoma . 2012 , 85, e940-6	23
1658	Hepatocellular carcinoma. 2012 , 366, 92; author reply 92-3	49
1657	Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2012 , 23 Suppl 7, vii41-8	270
1656	Transarterial chemoembolization for HCC in patients with extensive liver transplantation waiting times. 2012 , 63, 206-12	6
1655	In reply. 2012 , 17, e24-5	
1654	Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. 2012 , 4, 19-37	151
1653	Contemporary strategies in the management of hepatocellular carcinoma. 2012 , 2012, 154056	4
1652	Chemoembolization in patients with hepatocellular carcinoma. 2012 , 1, 41-50	70
1651	How to improve treatment outcomes for hepatocellular carcinoma of intermediate and advanced stage. 2012 , 30, 598-602	16
1650	Perspectives on the design of clinical trials combining transarterial chemoembolization and molecular targeted therapy. 2012 , 1, 168-76	13
1649	Application of Radiotherapeutic Strategies in the BCLC-Defined Stages of Hepatocellular Carcinoma. 2012 , 1, 216-25	26

1648	Ultrasensitive transcatheter infusion of epirubicin in water-in-oil-in-water emulsion for small hepatocellular carcinoma. 2012 , 85, e584-9	6
1647	Primary Liver Cancer. 2012 , 163-182	1
1646	The role of microRNAs in liver cancer. 2012 , 24, 223-8	28
1645	Microwave coagulation for liver metastases. 2012 ,	1
1644	A transcatheter arterial chemotherapy using a novel lipophilic platinum derivative (miriplatin) for patients with small and multiple hepatocellular carcinomas. 2012 , 24, 583-8	2
1643	Utilization and outcomes of palliative therapy for hepatocellular carcinoma: a population-based study in the United States. 2012 , 46, 71-7	66
1642	Transarterial (chemo)embolisation versus no intervention or placebo intervention for liver metastases. 2012 , CD009498	9
1641	Comparison of the efficacy of transcatheter arterial chemoembolization and sorafenib for advanced hepatocellular carcinoma. 2012 , 4, 381-386	11
1640	Chinese herbal medicines for adverse events of transarterial chemoembolization in patients with primary liver cancer. 2012 ,	
1639	Hepatocarcinoma. 2012 , 11, 693-703	
1638	Management of HCC. 2012 , 56 Suppl 1, S75-87	438
1637	Hepatocellular carcinoma. 2012 , 379, 1245-55	3423
1636	Hepatocellular carcinoma. 2012 , 380, 470; author reply 470-1	31
1635	Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria. 2012 , 99, 1622-9	138
1634	Outcomes of ultrasound-guided percutaneous argon-helium cryoablation of hepatocellular carcinoma. 2012 , 19, 674-84	46
1633	Mortality and morbidity of hepatectomy, radiofrequency ablation, and embolization for hepatocellular carcinoma: a national survey of 54,145 patients. 2012 , 47, 1125-33	86
1632	A high value of serum des- γ -carboxy prothrombin before hepatocellular carcinoma treatment can be associated with long-term liver dysfunction after treatment. 2012 , 47, 1134-42	8
1631	Acute ischemic cholecystitis after transarterial chemoembolization with drug-eluting beads. 2012 , 36, 861-4	6

1630	Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. 2012 , 84, 355-61	132
1629	An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma. 2012 , 160, 146-52	49
1628	Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy. 2012 , 33, 2401-9	42
1627	Ethiodized oil uptake does not predict doxorubicin drug delivery after chemoembolization in VX2 liver tumors. 2012 , 23, 265-73	38
1626	In vivo evaluation of cisplatin-loaded superabsorbent polymer microspheres for use in chemoembolization of VX2 liver tumors. 2012 , 23, 397-404.e1	5
1625	Ischaemia reperfusion may be a new approach in cancer interventional therapy. 2012 , 6, 50-52	0
1624	Improved time to progression for transarterial chemoembolization compared with transarterial embolization for patients with unresectable hepatocellular carcinoma. 2012 , 11, 185-90	15
1623	Multidisciplinary management of hepatocellular carcinoma. 2012 , 10, 354-62	41
1622	Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. 2012 , 57, 1244-50	173
1621	Chemoembolization for hepatocellular carcinoma. 2012 , 39, 503-9	85
1620	Reducible self-assembled micelles for enhanced intracellular delivery of doxorubicin. 2012 , 22, 7121	34
1619	[Current therapeutic strategies for hepatocellular carcinoma]. 2012 , 154, 63-7; quiz 68-9	
1618	Hepatocellular Carcinoma. 2012 , 1005-1031	1
1617	Care of the cirrhotic patient. 2012 , 26, 979-94	3
1616	Impact of restricting access to high-cost medications for hepatocellular carcinoma. 2012 , 12, 465-73	6
1615	Analysis of survival predictors in a prospective cohort of patients undergoing transarterial chemoembolization for hepatocellular carcinoma in a single Canadian centre. 2012 , 14, 162-70	10
1614	Quality of life and survival analysis of patients undergoing transarterial chemoembolization for primary hepatic malignancies: a prospective cohort study. 2012 , 14, 341-50	21
1613	Radioembolization for hepatocellular carcinoma. 2012 , 56, 464-73	228

1612	Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?. 2012 , 56, 686-95	142
1611	Chemoembolization for intermediate HCC: is there proof of survival benefit?. 2012 , 56, 984-6	89
1610	EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. 2012 , 56, 908-43	4465
1609	TACE treatment in hepatocellular carcinoma: what should we do now?. 2012 , 57, 221-2	20
1608	Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. 2012 , 56, 1330-5	354
1607	TACE with or without systemic therapy?. 2012 , 56, 1224-5	19
1606	Why men are at higher risk for hepatocellular carcinoma?. 2012 , 57, 453-4	23
1605	VCC-1 over-expression inhibits cisplatin-induced apoptosis in HepG2 cells. 2012 , 420, 336-42	8
1604	Value of subtraction MRI in assessing treatment response following image-guided loco-regional therapies for hepatocellular carcinoma. 2012 , 67, 649-55	23
1603	EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. 2012 , 48, 599-641	356
1602	Should a radiological diagnosis of hepatocellular carcinoma be routinely confirmed by a biopsy? Yes. 2012 , 23, 34-6	7
1601	Effect of transarterial pulsed perfusion with heated saline on tumor vascular permeability in a rabbit VX2 liver tumor model. 2012 , 81, e209-16	3
1600	Histopathologic correlation of hepatocellular carcinoma after transcatheter arterial chemoembolization with polyvinyl alcohol particle of various sizes. 2012 , 81, 1976-9	16
1599	Selective and sequential transarterial chemoembolization: survival in patients with hepatocellular carcinoma. 2012 , 81, 2290-7	11
1598	Phase I study of miriplatin combined with transarterial chemotherapy using CDDP powder in patients with hepatocellular carcinoma. 2012 , 12, 127	9
1597	The efficacy of TACE combined sorafenib in advanced stages hepatocellular carcinoma. 2012 , 12, 263	69
1596	Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study. 2012 , 10, 41	29
1595	Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial. 2012 , 13, 144	23

1594	Systematic review: the role of liver transplantation in the management of hepatocellular carcinoma. 2012 , 35, 1113-34	34
1593	Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. 2012 , 263, 590-9	154
1592	Comparison of surgical resection and transarterial chemoembolization for hepatocellular carcinoma beyond the Milan criteria: a propensity score analysis. 2012 , 19, 842-9	90
1591	First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI). 2012 , 41, 1213-20	51
1590	Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy. 2012 , 83, 216-24	37
1589	Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how?. 2012 , 38, 54-62	49
1588	Midterm follow-up after DC-BEAD ⁺ TACE of hepatocellular carcinoma (HCC). 2012 , 81, 3857-61	10
1587	Emerging signaling pathways in hepatocellular carcinoma. 2012 , 1, 83-93	144
1586	Integrated Treatment of Hepatic Cancer. 2012 , 399-431	
1585	Hepatocellular Carcinoma. 2012 , 141-157	
1584	Hepatocellular carcinoma with blood supply from parasitized omental artery: angiographic appearance and chemoembolization. 2012 , 24, 207-12	2
1583	Screening and Management of Hepatocellular Carcinoma: The Australian Perspective. 2012 , 11, 197-205	
1582	Transarterial chemoembolization can prolong survival for patients with metastatic hepatocellular carcinoma: a propensity score matching analysis. 2012 , 6, 753-62	17
1581	Medical care costs and survival associated with hepatocellular carcinoma among the elderly. 2012 , 10, 547-54	18
1580	Phase I/II multicenter study of transarterial chemoembolization with a cisplatin fine powder and porous gelatin particles for unresectable hepatocellular carcinoma: Japan Interventional Radiology in Oncology Study Group Study 0401. 2012 , 23, 1278-85	14
1579	Safety and feasibility of same-day discharge of patients with unresectable hepatocellular carcinoma treated with doxorubicin drug-eluting bead transcatheter chemoembolization. 2012 , 23, 1286-93.e1 ²²	
1578	Effects of some anti-neoplastic drugs on sheep liver sorbitol dehydrogenase. 2012 , 118, 244-52	23
1577	Systemtherapie des Leberzellkarzinoms. 2012 , 15, 26-30	

1576	Hepatocellular carcinoma supplied from the short gastric artery: treatment with chemoembolization. 2012 , 35, 1512-4	2
1575	Radioembolization after portal vein embolization in a patient with multifocal hepatocellular carcinoma. 2012 , 35, 1519-23	5
1574	Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): technical recommendations. 2012 , 35, 980-5	206
1573	Serum gamma-glutamyl-transferase independently predicts outcome after transarterial chemoembolization of hepatocellular carcinoma: external validation. 2012 , 35, 1102-8	23
1572	Quality-improvement guidelines for hepatic transarterial chemoembolization. 2012 , 35, 765-74	54
1571	Detection of focal hepatic lesions with 3-T MRI: comparison of two-dimensional and three-dimensional T2-weighted sequences. 2012 , 30, 721-8	3
1570	Hepatic arterial embolization for unresectable hepatocellular carcinomas: do technical factors affect prognosis?. 2012 , 30, 560-6	46
1569	Chimioembolisations et chimiothérapies intra-artérielles hépatiques. 2012 , 119-136	
1568	Embolisations artérielles hépatiques. 2012 , 99-117	
1567	Serum YKL-40 independently predicts outcome after transcatheter arterial chemoembolization of hepatocellular carcinoma. 2012 , 7, e44648	8
1566	Survival after locoregional treatments for hepatocellular carcinoma: a cohort study in real-world patients. 2012 , 2012, 564706	19
1565	Embolization of liver tumors: Past, present and future. 2012 , 4, 405-12	54
1564	Cytokines as important playmakers of experimental hepatocarcinogenesis confounded by diabetes. 2012 , 11, 118-127	5
1563	Radiofrequency ablation for viable hepatocellular carcinoma around retained iodized oil after transcatheter arterial chemoembolization: usefulness of biplane fluoroscopy plus ultrasound guidance. 2012 , 13, 784-94	7
1562	Comparison of epirubicin-iodized oil suspension and emulsion for transcatheter arterial chemoembolization in VX2 tumor. 2012 , 2012, 961986	8
1561	Hepatic tumors. 2012 , 352-362	
1560	Antibiotic prophylaxis in transarterial therapy of hepatocellular carcinoma: a meta-analysis. 2012 , 26, 85-91	7
1559	Effective therapeutic management of hepatocellular carcinoma - on the basis of a clinical case. 2012 , 16, 60-3	8

1558	Liver and Biliary Tract Tumors. 2012 , 1297-1303	0
1557	Transarterial chemoembolization with/without cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma. 2012 , 4, 188-196	5
1556	Interventional therapies for hepatocellular carcinoma. 2012 , 12, 79-88	23
1555	Local tumor progression following lipiodol-based targeted chemoembolization of hepatocellular carcinoma: a retrospective comparison of miriplatin and epirubicin. 2012 , 4, 113-9	17
1554	Beneficial effects of preoperative lipiodolization for resectable large hepatocellular carcinoma (≥ 5 cm in diameter). 2012 , 106, 498-503	12
1553	Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma. 2012 , 118, 3191-8	92
1552	Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus. 2012 , 118, 4725-36	118
1551	Management of hepatocellular carcinoma: beyond sorafenib. 2012 , 14, 257-66	22
1550	Hepatocellular carcinoma. 2012 , 1283-1289.e2	6
1549	A prospective randomized controlled trial of preoperative whole-liver chemolipiodolization for hepatocellular carcinoma. 2012 , 57, 1404-12	23
1548	Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. 2012 , 30, 1540-7	14
1547	Role of operative therapy in non-cirrhotic patients with metastatic hepatocellular carcinoma. 2012 , 16, 1516-23	2
1546	Hepatic artery injection of ¹²⁵ I-labelled metuximab combined with chemoembolization for intermediate hepatocellular carcinoma: a prospective nonrandomized study. 2012 , 39, 1306-15	21
1545	Switching the loaded agent from epirubicin to cisplatin: salvage transcatheter arterial chemoembolization with drug-eluting microspheres for unresectable hepatocellular carcinoma. 2012 , 35, 555-62	21
1544	Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study. 2012 , 22, 1214-23	41
1543	Austrian Joint ÖGH-ÖIR-ÖHO-ASSO position statement on the use of transarterial chemoembolization (TACE) in hepatocellular carcinoma. 2012 , 124, 104-10	12
1542	Short-term reductions in non-protein respiratory quotient and prealbumin can be associated with the long-term deterioration of liver function after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. 2012 , 47, 704-14	20
1541	Systemtherapie des Leberzellkarzinoms. 2012 , 18, 602-610	

1540	Chimioembolisation et hpatocarcinome: pour quel type de patient ?. 2012 , 14, 174-178	
1539	Concomitant chemoradiation using gemcitabine in locally advanced hepatocellular carcinoma. 2012 , 11, 130-133	1
1538	How does hepatitis B virus infection react to hepatocellular carcinoma treatment?. 2012 , 27, 1-2	7
1537	Synergy in cancer treatment between liposomal chemotherapeutics and thermal ablation. 2012 , 165, 424-37	53
1536	Liver transplantation for hepatocellular carcinoma: long-term results suggest excellent outcomes. 2012 , 215, 19-28; discussion 28-30	40
1535	The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma. 2012 , 8, 164-71	23
1534	Interventional oncology. 2012 , 18, 15-20	1
1533	A rare occurrence of hepatocellular carcinoma metastasis to the mandible: report of a case and review of the literature. 2012 , 70, 1219-23	10
1532	Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma. 2012 , 35, 1343-50	70
1531	Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma. 2012 , 27, 1051-6	43
1530	Targeted therapy of hepatocellular carcinoma: present and future. 2012 , 27, 862-72	63
1529	Limitation of repeated radiofrequency ablation in hepatocellular carcinoma: proposal of a three (times) B (years) index. 2012 , 27, 1044-50	7
1528	Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study. 2012 , 12, 16	28
1527	Clinical trial of cisplatin-conjugated gelatin microspheres for patients with hepatocellular carcinoma. 2012 , 30, 62-8	12
1526	Interventional radiological treatment of hepatocellular carcinoma: an update. 2012 , 74, 91-9	13
1525	Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy. 2012 , 33, 33-40	37
1524	[Transarterial ablation of hepatocellular carcinoma. Status and developments]. 2012 , 52, 44-55	7
1523	Augmentation of chemotherapeutic infusion effect by TSU-68, an oral targeted antiangiogenic agent, in a rabbit VX2 liver tumor model. 2012 , 35, 168-75	3

1522	Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion. 2012 , 35, 82-9	16
1521	Chemoembolization via branches from the splenic artery in patients with hepatocellular carcinoma. 2012 , 35, 90-6	8
1520	Comparing the detectability of hepatocellular carcinoma by C-arm dual-phase cone-beam computed tomography during hepatic arteriography with conventional contrast-enhanced magnetic resonance imaging. 2012 , 35, 97-104	64
1519	Spontaneous liver rupture after treatment with drug-eluting beads. 2012 , 35, 198-202	11
1518	Comparison of the anti-tumor effects of two platinum agents (miriplatin and fine-powder cisplatin). 2012 , 35, 399-405	13
1517	Comparison of transcatheter arterial chemoembolization and microsphere embolization for treatment of unresectable hepatocellular carcinoma: a meta-analysis. 2012 , 138, 455-62	18
1516	External radiation treatment of malignant liver disease: a critical review. 2013 , 2, 249-262	
1515	Stereotactic radiosurgery for brain metastases from hepatocellular carcinoma. 2013 , 115, 45-51	5
1514	Imaging assessment of hepatocellular carcinoma response to locoregional and systemic therapy. 2013 , 201, 80-96	62
1513	Imaging tumor response following liver-directed intra-arterial therapy. 2013 , 38, 1286-99	25
1512	Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis. 2013 , 13, 60	112
1511	Meta-analysis: preoperative transcatheter arterial chemoembolization does not improve prognosis of patients with resectable hepatocellular carcinoma. 2013 , 13, 51	24
1510	AEG-1/MTDH/LYRIC in liver cancer. 2013 , 120, 193-221	36
1509	Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science. 2013 , 24, 1123-34	32
1508	Antitumor effect of miriplatin-lipiodol suspension/emulsion using a VX2 liver tumor model. 2013 , 31, 662-7	2
1507	Is transarterial chemoembolization beneficial for patients with diffuse infiltrative hepatocellular carcinoma?. 2013 , 7, 676-82	6
1506	Persistent elevated C-reactive protein after treatment is an independent marker of a poor prognosis in patients with hepatocellular carcinoma. 2013 , 15, 575-81	6
1505	Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis. 2013 , 139, 653-9	40

1504	Hepatocellular carcinoma and other malignancies in autoimmune hepatitis. 2013 , 58, 1459-76	35
1503	TGF- β secreted by hepatocellular carcinoma induces the expression of the Foxp3 gene and suppresses antitumor immunity in the tumor microenvironment. 2013 , 58, 1644-52	22
1502	Predisposing factors of hepatocellular carcinoma recurrence following complete remission in response to transarterial chemoembolization. 2013 , 58, 1758-65	21
1501	The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients. 2013 , 20, 4305-11	66
1500	Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. 2013 , 133, 2165-71	158
1499	Lipiodol trans-arterial chemoembolization of hepatocellular carcinoma with idarubicin: first experience. 2013 , 36, 1039-46	18
1498	Dense accumulation of lipiodol emulsion in hepatocellular carcinoma nodule during selective balloon-occluded transarterial chemoembolization: measurement of balloon-occluded arterial stump pressure. 2013 , 36, 706-13	86
1497	Predictive factors of downstaging of hepatocellular carcinoma beyond the Milan criteria treated with intra-arterial therapies. 2013 , 36, 433-9	27
1496	Liver tumor-initiating cells as a therapeutic target for hepatocellular carcinoma. 2013 , 338, 101-9	48
1495	Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. 2013 , 119, 1042-9	28
1494	Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer. 2013 , 24, 805-12	16
1493	The size of the problem: clinical algorithms. 2013 , 31, 95-103	5
1492	Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). 2013 , 33, 327-37	52
1491	Factors affecting survival following chemoembolization with doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma. 2013 , 24, 257-65	8
1490	Hepatocellular carcinoma: illustrated guide to systematic radiologic diagnosis and staging according to guidelines of the American Association for the Study of Liver Diseases. 2013 , 33, 1653-68	69
1489	Inflammatory markers are associated with outcome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization. 2013 , 20, 923-8	53
1488	Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma. 2013 , 24, 307-15	57
1487	A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. 2013 , 108, 1252-9	99

1486 Management of Hepatocellular Carcinoma. **2013**, 544-551

1485 Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with primary liver cancer: a phase II-study (NCT00356161). **2013**, 13, 125 12

1484 Tackling hepatitis B virus-associated hepatocellular carcinoma--the future is now. **2013**, 32, 229-68 17

1483 TACE combined with liver resection versus liver resection alone in the treatment of resectable HCC: a meta-analysis. **2013**, 12, 532-536 3

1482 Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma. **2013**, 30, 730 13

1481 Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature. **2013**, 58, 3389-96 57

1480 A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo. **2013**, 13, 527 12

1479 Transarterial chemoembolization of hepatocellular carcinoma. Agents and drugs: an overview. Part 1. **2013**, 10, 679-90 22

1478 Yttrium-90 radioembolization for hepatocellular carcinoma: what we know and what we need to know. **2013**, 84 Suppl 1, 34-9 15

1477 Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age?. **2013**, 13, 1355-61 11

1476 Antitumor efficacy of C-X-C motif chemokine ligand 14 in hepatocellular carcinoma in vitro and in vivo. **2013**, 104, 1523-31 36

1475 A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. **2013**, 24, 2565-2570 200

1474 Targeted doxorubicin delivery by chitosan-galactosylated modified polymer microbubbles to hepatocarcinoma cells. **2013**, 110, 434-42 42

1473 Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. **2013**, 36, 714-23 96

1472 Symptom clusters and symptom interference of HCC patients undergoing TACE: a cross-sectional study in China. **2013**, 21, 475-83 22

1471 Efficacy of transcatheter arterial chemoembolization combined with ganfule on advanced hepatocellular carcinoma. **2013**, 12, 25-29 0

1470 The evolving landscape of therapeutic drug development for hepatocellular carcinoma. **2013**, 36, 605-15 7

1469 Prospective study of transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: an Asian cooperative study between Japan and Korea. **2013**, 24, 490-500 59

1468	Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma. 2013 , 6, 511-9	29
1467	Chemoembolization and radioembolization for hepatocellular carcinoma. 2013 , 11, 604-11; quiz e43-4	59
1466	Debulking surgery followed by intraarterial 5-fluorouracil chemotherapy plus subcutaneous interferon alfa for massive hepatocellular carcinoma with multiple intrahepatic metastases: a pilot study. 2013 , 39, 1364-70	8
1465	Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. 2013 , 58, 609-18	112
1464	Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. 2013 , 58, 1181-7	93
1463	Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a single center experience including 221 patients. 2013 , 25, 143-50	8
1462	Transarterial chemoembolization treatment: association between multiple treatments, cumulative expenditures, and survival. 2013 , 16, 760-8	13
1461	Treatment of hepatocellular carcinoma in Child-Pugh B patients. 2013 , 45, 852-8	25
1460	Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. 2013 , 45, 712-23	128
1459	Cyclin G1 expands liver tumor-initiating cells by Sox2 induction via Akt/mTOR signaling. 2013 , 12, 1796-804	39
1458	Sorafenib prolongs liver regeneration after hepatic resection in rats. 2013 , 184, 847-54	6
1457	Result and cost of hepatic chemoembolisation with drug eluting beads in 21 patients. 2013 , 94, 53-9	9
1456	High-frequency induction heating of Ti-coated mild steel rod for minimally invasive ablation therapy of human cancer. 2013 , 331, 168-173	3
1455	Résultat et coût de la chimioembolisation hépatique avec des billes chargées chez 21 patients. 2013 , 94, 52-59	1
1454	Inhibition of nuclear factor- κ B enhances the antitumor effect of tumor necrosis factor- α gene therapy for hepatocellular carcinoma in mice. 2013 , 154, 468-78	14
1453	Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma: usefulness of contrast saturation features on cone-beam computed tomography imaging for predicting short-term tumor response. 2013 , 24, 483-9	29
1452	Intratumoral gas in hepatocellular carcinoma following transarterial chemoembolization: associated factors and clinical impact. 2013 , 24, 1623-31	6
1451	Radioembolization with Yttrium-90 resin microspheres in treatment of HCC with or without PVT: Initial Egyptian experience. 2013 , 44, 215-222	2

1450	Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review. 2013 , 88, 530-49	131
1449	Modified cisplatin-based transcatheter arterial chemoembolization for large hepatocellular carcinoma: multivariate analysis of predictive factors for tumor response and survival in a 163-patient cohort. 2013 , 24, 1639-46	18
1448	HBV infection and hepatocellular carcinoma. 2013 , 17, 375-97	33
1447	Molecular targeted therapy with transarterial chemoembolization. 2013 , 2, 78-81	1
1446	New progress of non-surgical treatments for hepatocellular carcinoma. 2013 , 30, 381	20
1445	Electrochemical identification of hepatocellular carcinoma based on the assay of human cervical cancer oncoprotein-1 in serum. 2013 , 27, 38-41	12
1444	Prognostic value of α -fetoprotein and des- γ -carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization. 2013 , 13, 5	48
1443	Risk factors and a predictive model for acute hepatic failure after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. 2013 , 33, 197-202	27
1442	Transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: recent progression and perspective. 2013 , 84 Suppl 1, 28-33	10
1441	Medical therapies for hepatocellular carcinoma: a critical view of the evidence. 2013 , 10, 34-42	243
1440	Combining transarterial chemoembolization with radiofrequency ablation for hepatocellular carcinoma: one step forward?. 2013 , 31, 406-8	14
1439	Photo-cross-linked and pH-sensitive biodegradable micelles for doxorubicin delivery. 2013 , 5, 3108-17	55
1438	Treatment of hepatocellular carcinoma: present and future. 2013 , 13, 469-79	21
1437	Sorafenib and TRAIL have synergistic effect on hepatocellular carcinoma. 2013 , 42, 101-8	12
1436	Comprehensive application of modern technologies in precise liver resection. 2013 , 12, 244-50	26
1435	Endothelial transdifferentiation in hepatocellular carcinoma: loss of Stabilin-2 expression in peri-tumourous liver correlates with increased survival. 2013 , 33, 1428-40	36
1434	[Therapy of hepatocellular carcinoma before liver transplantation]. 2013 , 84, 385-90	3
1433	pH-sensitive pullulan-based nanoparticle carrier of methotrexate and combretastatin A4 for the combination therapy against hepatocellular carcinoma. 2013 , 34, 7181-90	95

1432	Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90. 2013 , 84, 311-8	114
1431	Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study. 2013 , 14, 181-90	70
1430	Suppression of tumor proliferation and angiogenesis of hepatocellular carcinoma by HS-104, a novel phosphoinositide 3-kinase inhibitor. 2013 , 328, 176-87	11
1429	Traditional herbal medicine in preventing recurrence after resection of small hepatocellular carcinoma: a multicenter randomized controlled trial. 2013 , 11, 90-100	66
1428	Rupture of hepatocellular carcinoma following transarterial embolization/chemoembolization: two cases report and systematic review. 2013 , 12, 76-82	
1427	Surgical resection improves the survival of selected hepatocellular carcinoma patients in Barcelona clinic liver cancer stage C. 2013 , 45, 510-5	17
1426	Toxicity of doxorubicin on pig liver after chemoembolization with doxorubicin-loaded microspheres: a pilot DNA-microarrays and histology study. 2013 , 36, 204-12	11
1425	Microwave coagulation for liver metastases. 2013 , CD010163	11
1424	Transarterial (chemo)embolisation versus no intervention or placebo intervention for liver metastases. 2013 , CD009498	16
1423	Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we?. 2013 , 2, 93-107	30
1422	The promise of clinical interventions for hepatocellular carcinoma from the west to mainland China. 2013 , 11, 503-22	4
1421	Hepatocellular carcinoma: high hepatitis B viral load and mortality in patients treated with transarterial chemoembolization. 2013 , 267, 638-47	24
1420	Role of C-arm CT for transcatheter arterial chemoembolization of hepatocellular carcinoma: diagnostic performance and predictive value for therapeutic response compared with gadoxetic acid-enhanced MRI. 2013 , 201, 675-83	25
1419	Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy. 2013 , 268, 431-9	47
1418	[Neoplastic lesions of the digestive tract: diagnosis and treatment through imaging]. 2013 , 78 Suppl 1, 19-21	
1417	[Diagnosis of and therapy for hepatocellular carcinoma]. 2013 , 51, 1269-326	67
1416	Transcatheter arterial chemoembolization combined with radiofrequency ablation for the treatment of hepatocellular carcinoma. 2013 , 84 Suppl 1, 40-3	18
1415	Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part I. Identification and validation of volumetric functional response criteria. 2013 , 268, 420-30	37

1414	Fermented wheat germ extract induced cell death and enhanced cytotoxicity of Cisplatin and 5-Fluorouracil on human hepatocellular carcinoma cells. 2013 , 2013, 121725	10
1413	Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial. 2013 , 9, 403-10	21
1412	Liver abscess after transarterial chemoembolization in patients with bilioenteric anastomosis: frequency and risk factors. 2013 , 200, 1370-7	75
1411	High-dose hypofractionated X-ray radiotherapy for hepatocellular carcinoma: Tumor responses and toxicities. 2013 , 6, 1514-1520	10
1410	Combining locoregional therapies in the treatment of hepatocellular carcinoma. 2013 , 30, 74-81	14
1409	mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). 2013 , 24, 965-73	85
1408	Blocking autophagic flux enhances matrine-induced apoptosis in human hepatoma cells. 2013 , 14, 23212-30	28
1407	Safety and efficacy of transcatheter arterial chemoembolization in the real-life management of unresectable hepatocellular carcinoma. 2013 , 13, e7070	8
1406	Chemoembolization of hepatocellular carcinoma. 2013 , 30, 3-11	131
1405	Gallbladder perforation following transarterial chemoembolisation; a rare but serious complication. 2013 , 4, 135-137	2
1404	A systematic review of sorafenib in Child-Pugh A patients with unresectable hepatocellular carcinoma. 2013 , 47, 871-80	15
1403	Prognostic importance of 18F-FDG uptake pattern of hepatocellular cancer patients who received SIRT. 2013 , 38, e283-9	15
1402	Intermediate hepatocellular carcinoma: current treatments and future perspectives. 2013 , 24 Suppl 2, ii24-9	59
1401	Consider the perspectives: interventional radiology. 2013 , 47 Suppl, S43-6	
1400	Enhancement of antitumor activity of low-dose 5-fluorouracil by combination with Fuzheng-Yiliu granules in hepatoma 22 tumor-bearing mice. 2013 , 12, 174-81	12
1399	Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellular carcinoma. 2013 , 29, 840-6	64
1398	Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. 2013 , 31, 426-32	326
1397	Tunicamycin potentiates cisplatin anticancer efficacy through the DPAGT1/Akt/ABCG2 pathway in mouse Xenograft models of human hepatocellular carcinoma. 2013 , 12, 2874-84	44

1396	Recurrences of hepatocellular carcinoma following complete remission by transarterial chemoembolization or radiofrequency therapy: Focused on the recurrence patterns. 2013 , 43, 1304-12	29
1395	Selective accumulation of platinum and formation of platinum-DNA adducts in hepatocellular carcinoma after transarterial chemoembolization with miriplatin. 2013 , 43, 1093-9	5
1394	Comparison of the antitumor efficacy of transcatheter arterial chemoembolization with a miriplatin-iodized oil suspension and a cisplatin-iodized oil suspension for hepatocellular carcinoma. 2013 , 43, 1071-7	8
1393	Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy. 2013 , 28, 456-63	58
1392	The role of bridging therapy in hepatocellular carcinoma. 2013 , 2013, 419302	15
1391	Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial. 2013 , 132, 2448-58	75
1390	If portal hypertension predicts outcome in cirrhosis, why should this not be the case after surgical resection?. 2013 , 33, 1454-6	4
1389	NC-6300, an epirubicin-incorporating micelle, extends the antitumor effect and reduces the cardiotoxicity of epirubicin. 2013 , 104, 920-5	98
1388	Outcomes after hepatic resection and subsequent multimodal treatment of recurrence for multifocal hepatocellular carcinoma. 2013 , 100, 1516-22	21
1387	Overexpressed nuclear BAG-1 in human hepatocellular carcinoma is associated with poor prognosis and resistance to doxorubicin. 2013 , 114, 2120-30	17
1386	Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma. 2013 , 33, 595-604	63
1385	Improved survival trend of patients with hepatocellular carcinoma at an Australian tertiary hospital between 1995-2009. 2013 , 43, 197-203	9
1384	Systematic review of radiofrequency ablation versus percutaneous ethanol injection for small hepatocellular carcinoma up to 3 cm. 2013 , 28, 793-800	39
1383	Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. 2013 , 31, 1631-9	525
1382	Recombinant Ganoderma lucidum immunomodulatory protein modified with polyethylene glycol. 2013 , 7, 975-80	1
1381	PI3-kinase inhibition synergistically promoted the anti-tumor effect of lupeol in hepatocellular carcinoma. 2013 , 13, 108	30
1380	Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective. 2013 , 25, 639-51	27
1379	Electro-coagulation for liver metastases. 2013 , CD009497	2

1378	Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma. 2013 , CD003046		53
1377	Cryotherapy for liver metastases. 2013 , CD009058		10
1376	Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. <i>Hepatology</i> , 2013 , 58, 1065-73	11.2	102
1375	Percutaneous ethanol injection for liver metastases. 2013 , CD008717		8
1374	Evaluation of the response to selective internal radiation therapy in patients with hepatocellular cancer according to pretreatment (99m)Tc-MAA uptake. 2013 , 38, 252-5		6
1373	Hypertonic saline-enhanced radiofrequency versus chemoembolization sequential radiofrequency in the treatment of large hepatocellular carcinoma. 2013 , 25, 628-33		5
1372	High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma. 2013 , 8, 250		131
1371	In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma. 2013 , 24, 251-9		21
1370	Effect of transcatheter arterial chemoembolization prior to surgical resection for hepatocellular carcinoma. 2013 , 42, 151-60		30
1369	Multidisciplinary management of hepatocellular carcinoma: a model for therapy. 2013 , 6, 189-95		20
1368	[A case of epidural abscess occurred after liver abscess complicated by transarterial chemoembolization in a patient with metastatic cancer to liver]. 2013 , 61, 225-9		2
1367	Development of a miR-26 companion diagnostic test for adjuvant interferon-alpha therapy in hepatocellular carcinoma. 2013 , 9, 303-12		21
1366	Clinical significance of the thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase mRNA expressions in hepatocellular carcinoma patients receiving 5-fluorouracil-based transarterial chemoembolization treatment. 2013 , 6, 811-8		7
1365	Recent advance in international management of hepatocellular carcinoma. 2013 , 56, 972		2
1364	Reduction in non-protein respiratory quotient is related to overall survival after hepatocellular carcinoma treatment. 2013 , 8, e55441		3
1363	Local targeted therapy of liver metastasis from colon cancer by galactosylated liposome encapsulated with doxorubicin. 2013 , 8, e73860		27
1362	Transarterial (chemo)embolisation versus other nonsurgical ablation methods for liver metastases. 2013 ,		2
1361	Drug-eluting bead transarterial chemoembolisation for unresectable hepatocellular carcinoma. 2013 ,		

1360	Transcatheter arterial chemoembolization based on hepatic hemodynamics for hepatocellular carcinoma. 2013 , 2013, 479805	18
1359	Interventional radiology in liver cancer. 2013 , 22, 20120010	
1358	Estimation of Secondary Scattered Dose from Intensity-modulated Radiotherapy for Liver Cancer Cases. 2013 , 24, 295	3
1357	The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE). 2014 , 4, 736-44	24
1356	Chemoembolization with drug-eluting microspheres (DEM-TACE) for hepatocellular carcinoma: single-center review of safety and efficacy. 2014 , 1, 187-93	3
1355	Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments. 2014 , 1, 163-82	14
1354	Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. 2014 , 20, 3069-77	52
1353	Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis. 2014 , 9, e100305	78
1352	The effect of using different embolic agents on survival in transarterial chemoembolization of hepatocellular carcinoma: gelfoam versus polyvinyl alcohol. 2014 , 20, 323-9	11
1351	Hepatocellular carcinoma review: current treatment, and evidence-based medicine. 2014 , 20, 4115-27	288
1350	Transcatheter arterial chemoembolization therapy for patients with unresectable hepatocellular carcinoma. 2014 , 14, e25792	6
1349	Molecular mechanisms of gender disparity in hepatitis B virus-associated hepatocellular carcinoma. 2014 , 20, 6252-61	35
1348	Molecular Determinants of Prognosis in Hepatocellular Carcinoma. 2014 , 2, 31-6	3
1347	Survival after 131I-labeled lipiodol therapy for hepatocellular carcinoma. A single-center study based on a long-term follow-up. 2014 , 53, 46-53	4
1346	A Role for Acyclic Retinoid in the Chemoprevention of Hepatocellular Carcinoma: Therapeutic Strategy Targeting Phosphorylated Retinoid X Receptor- β . 2014 , 2, 226-242	2
1345	Latin American Association for the Study of the Liver (LAASL) Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. 2014 , 13, S4-S40	17
1344	Preoperative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma: a single center analysis. 2014 , 13, 394-402	11
1343	Predictors of mortality in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. 2014 , 59, 2821-5	17

1342	Dysregulated expression of dickkopfs for potential detection of hepatocellular carcinoma. 2014 , 14, 535-48	14
1341	Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: a systematic review. 2014 , 35, 8451-9	21
1340	Hepatocellular carcinoma and cholangiocarcinoma: an update. 2014 , 8, 63-82	15
1339	Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. 2014 , 41, 6575-82	29
1338	Preresection transarterial chemoembolization for hepatocellular carcinoma: an experience with 23 patients. 2014 , 33, 432-9	5
1337	Quality assessment of clinical research on liver cancer treated by intra-arterial infusion of Chinese medicine. 2014 , 20, 870-5	2
1336	Genetic variants in the KDR gene is associated with the prognosis of transarterial chemoembolization treated hepatocellular carcinoma. 2014 , 35, 11473-81	12
1335	Pharmacokinetics of gelatin sponge microparticles in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization. 2014 , 35, 10905-10	12
1334	Plasmalemmal Vesicle Associated Protein (PLVAP) as a therapeutic target for treatment of hepatocellular carcinoma. 2014 , 14, 815	26
1333	Transcatheter arterial chemoembolization combined with radiofrequency ablation delays tumor progression and prolongs overall survival in patients with intermediate (BCLC B) hepatocellular carcinoma. 2014 , 14, 849	55
1332	Survival benefit of radioembolization for inoperable hepatocellular carcinoma using yttrium-90 microspheres. 2014 , 29, 1897-904	11
1331	Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization. 2014 , 87, 330-41	116
1330	Castacin inhibits epithelial-mesenchymal transition of liver cancer stem cells of the SMMC-7721 cell line through downregulating Twist. 2014 , 7, 1625-1631	14
1329	Mexican consensus on the diagnosis and management of hepatocellular carcinoma. 2014 , 79, 250-262	
1328	Current and future challenges in the surgical treatment of hepatocellular carcinoma: a review. 2014 , 99, 779-86	7
1327	Diabetes mellitus and the neutrophil to lymphocyte ratio predict overall survival in non-viral hepatocellular carcinoma treated with transarterial chemoembolization. 2014 , 7, 1704-1710	12
1326	Systemic therapy for hepatocellular carcinoma. 2014 , 1, 23-38	
1325	Sorafenib for the treatment of hepatocellular carcinoma. 2014 , 1, 189-204	5

1324	Mexican consensus on the diagnosis and management of hepatocellular carcinoma. 2014 , 79, 250-62	10
1323	Evidence-based integration of selective internal radiation therapy into hepatocellular carcinoma management. 2014 , 10, 7-11	1
1322	Small single-nodule hepatocellular carcinoma: comparison of transarterial chemoembolization, radiofrequency ablation, and hepatic resection by using inverse probability weighting. 2014 , 271, 909-18	76
1321	Computed tomography predictors of hepatocellular carcinoma tumour necrosis after chemoembolization. 2014 , 16, 327-35	17
1320	Synergistic effect of simvastatin plus NS398 on inhibition of proliferation and survival in hepatocellular carcinoma cell line. 2014 , 29, 1299-307	9
1319	Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma. 2014 , 34, 612-20	15
1318	Bland embolization versus chemoembolization of hepatocellular carcinoma before transplantation. 2014 , 20, 536-43	23
1317	Dynamic changes of the inflammation-based index predict mortality following chemoembolisation for hepatocellular carcinoma: a prospective study. 2014 , 40, 1270-81	23
1316	Radiofrequency ablation combined with transarterial chemoembolization for intermediate hepatocellular carcinoma. 2014 , 44, 194-200	26
1315	Ethnic disparities and liver transplantation rates in hepatocellular carcinoma patients in the recent era: results from the Surveillance, Epidemiology, and End Results registry. 2014 , 20, 528-35	47
1314	Yttrium-90 radioembolization is a safe and effective treatment for unresectable hepatocellular carcinoma: a single centre experience of 45 consecutive patients. 2014 , 12, 1403-8	14
1313	Stimuli-responsive nanocomposite: potential injectable embolization agent. 2014 , 35, 579-84	20
1312	Response stratification and survival analysis of hepatocellular carcinoma patients treated with intra-arterial therapy using MR imaging-based arterial enhancement fraction. 2014 , 40, 1103-11	6
1311	Risk factors for 1-year mortality in patients with intermediate-stage hepatocellular carcinoma treated solely with transcatheter arterial chemoembolization. 2014 , 1, 126-131	1
1310	Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial. 2014 , 39, 1301-13	41
1309	Transarterial chemoembolisation and radioembolisation for the treatment of primary liver cancer and secondary liver cancer: a review of the literature. 2014 , 58, 341-52	38
1308	Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma. 2014 , 34, 305-12	21
1307	Chemoembolization outcomes for hepatocellular carcinoma in cirrhotic patients with compromised liver function. 2014 , 16, 648-55	9

1306	Editorial: IDASPHERE phase I trial for chemoembolisation of HCC. 2014 , 40, 209-10	0
1305	Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: Consensus recommendations and review by an International Expert Panel. 2014 , 34, 174-83	53
1304	Long-term survival after surgical resection for huge hepatocellular carcinoma: comparison with transarterial chemoembolization after propensity score matching. 2014 , 29, 1043-8	26
1303	Viable hepatocellular carcinoma around retained iodized oil after transarterial chemoembolization: radiofrequency ablation of viable tumor plus retained iodized oil versus viable tumor alone. 2014 , 203, 1127-31	4
1302	Effect of combined treatment with the epirubicin-incorporating micelles (NC-6300) and 1,2-diaminocyclohexane platinum (II)-incorporating micelles (NC-4016) on a human gastric cancer model. 2014 , 135, 214-23	33
1301	Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics. 2014 , 8, 71-6	105
1300	Treatment strategies of intermediate-stage hepatocellular carcinomas in Japan (Barcelona Clinic Liver Cancer stage B). 2014 , 87 Suppl 1, 78-81	13
1299	Addition of local hepatic therapy to sorafenib in patients with advanced hepatocellular carcinoma (stage BCLC C). 2014 , 90, 219-28	6
1298	Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study. 2014 , 19, 1169-78	50
1297	Immunogenic Cell Death Markers in Liver Cancer. 2014 , 1-18	
1296	Complete remission of diffuse hepatocellular carcinoma in a young adult after GSP-TACE: a case report. 2014 , 12, 300	6
1295	Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability. 2014 , 48, e22-9	18
1294	Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry. 2014 , 48, 279-89	64
1293	Stereotactic ablative radiotherapy for unresectable hepatocellular carcinoma patients who failed or were unsuitable for transarterial chemoembolization. 2014 , 26, 345-52	20
1292	The use of proton therapy in the treatment of gastrointestinal cancers: liver. 2014 , 20, 371-7	15
1291	Vascular invasion in hepatocellular carcinoma: prevalence, determinants and prognostic impact. 2014 , 48, 734-41	55
1290	Enhancement of cisplatin-based TACE by a hemoglobin-based oxygen carrier in an orthotopic rat HCC model. 2014 , 42, 229-36	15
1289	Treatment of hepatocellular carcinoma. 2014 , 32, 554-63	29

1288	Prognostic factors for hepatocellular carcinoma recurrence. 2014 , 20, 5935-50	105
1287	Association of transarterial chemoembolization with survival in patients with unresectable hepatocellular carcinoma. 2014 , 2, 203-206	9
1286	Transarterial therapy: an evolving treatment modality of hepatocellular carcinoma. 2014 , 20, 333-41	4
1285	Transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis: prognostic factors in a single-center study of 188 patients. 2014 , 2014, 194278	34
1284	Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib. 2014 , 44, 1179-85	32
1283	Multimodal treatment of hepatocellular carcinoma. 2014 , 25, 430-7	65
1282	Safety and feasibility of same-day discharge of patients with hepatocellular carcinoma treated with transarterial chemoembolization with drug-eluting beads in a liver transplantation program. 2014 , 25, 1012-7	16
1281	Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinoma. 2014 , 46, 358-62	12
1280	Advanced age is not a contraindication for liver resection in cases of large hepatocellular carcinoma. 2014 , 40, 214-9	8
1279	Radiotherapy for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels: efficacy and outcomes. 2014 , 29, 352-7	26
1278	Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. 2014 , 49, 932-40	33
1277	Radiofrequency ablation following first-line transarterial chemoembolization for patients with unresectable hepatocellular carcinoma beyond the Milan criteria. 2014 , 14, 11	24
1276	Treatment of liver tumours with yttrium radioembolisation. 2014 , 2, 165-182	2
1275	Hepatocellular carcinoma: clinical frontiers and perspectives. 2014 , 63, 844-55	953
1274	Molecular therapies in hepatocellular carcinoma: what can we target?. 2014 , 59, 1688-97	34
1273	Treatment options and surveillance strategies after therapy for hepatocellular carcinoma. 2014 , 21, 758-66	33
1272	Prognostic value of serum vascular endothelial growth factor receptor 2 response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. 2014 , 31, 843	12
1271	Nonsurgical treatment for localized hepatocellular carcinoma. 2014 , 16, 373	11

1270	[Therapy of hepatocellular carcinoma]. 2014 , 55, 23-4, 26-30	4
1269	Hepatic artery complications following liver transplantation. Does preoperative chemoembolization impact the postoperative course?. 2014 , 28, 598-605	28
1268	Palliation: treating patients with inoperable biliary tract and primary liver tumors. 2014 , 23, 383-97	7
1267	Hepatocellular carcinoma and other hepatic malignancies: MR imaging. 2014 , 52, 683-707	25
1266	Hepatocellular carcinoma: diagnosis, management, and prognosis. 2014 , 23, 289-311	49
1265	The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. 2014 , 60, 118-26	96
1264	Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: an up-to-date meta-analysis. 2014 , 35, 7407-13	38
1263	Pilot study of high-intensity focused ultrasound ablation as a bridging therapy for hepatocellular carcinoma patients wait-listed for liver transplantation. 2014 , 20, 912-21	30
1262	Bio-responsive chitin-poly(L-lactic acid) composite nanogels for liver cancer. 2014 , 113, 394-402	31
1261	Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. 2014 , 111, 255-64	349
1260	How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. 2014 , 61, 1287-96	104
1259	Transcatheter arterial chemoembolization for hepatocellular carcinoma: Comparison of the therapeutic efficacies between miriplatin and epirubicin. 2014 , 44, 1072-80	8
1258	Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma. 2014 , 29, 920-5	79
1257	Identification of transmembrane protein 98 as a novel chemoresistance-conferring gene in hepatocellular carcinoma. 2014 , 13, 1285-97	22
1256	Image-guided interventions in oncology. 2014 , 23, 937-55	8
1255	Long-term outcomes of second treatment after initial transarterial chemoembolization in patients with hepatocellular carcinoma. 2014 , 34, 1278-86	6
1254	Predictors of repeat transarterial chemoembolization in the treatment of hepatocellular carcinoma. 2014 , 16, 1095-101	12
1253	Systemic treatment. 2014 , 28, 921-35	9

1252	Chemoembolization and radioembolization. 2014 , 28, 909-19	14
1251	Pilot study evaluating catheter-directed contrast-enhanced ultrasound compared to catheter-directed computed tomography arteriography as adjuncts to digital subtraction angiography to guide transarterial chemoembolization. 2014 , 69, 1056-61	7
1250	The drug discovery by nanomedicine and its clinical experience. 2014 , 44, 515-25	68
1249	Treatment of intermediate-stage hepatocellular carcinoma. 2014 , 11, 525-35	315
1248	New advances in local therapy for colorectal cancer metastases to the liver. 2014 , 3, 183-193	
1247	Management of patients with hepatitis B who require immunosuppressive therapy. 2014 , 11, 209-19	167
1246	Transarterial chemoembolization and sorafenib in hepatocellular carcinoma. 2014 , 14, 831-45	16
1245	Prognosis prediction and staging. 2014 , 28, 855-65	15
1244	Chemoembolization of intermediate stage hepatocellular carcinomas: results from a Nordic tertiary liver cancer center. 2014 , 33, 322-9	5
1243	TACE performed in patients with a single nodule of hepatocellular carcinoma. 2014 , 14, 601	28
1242	Hypoxia inducible factors in liver disease and hepatocellular carcinoma: current understanding and future directions. 2014 , 61, 1397-406	113
1241	Prognosis of patients with intermediate-stage hepatocellular carcinomas based on the Child-Pugh score: subclassifying the intermediate stage (Barcelona Clinic Liver Cancer stage B). 2014 , 32, 644-9	32
1240	[National S3 guidelines on hepatocellular carcinoma]. 2014 , 54, 642-53	6
1239	Hepatocellular carcinomas within the Milan criteria: predictors of histologic necrosis after drug-eluting beads transarterial chemoembolization. 2014 , 37, 1018-26	12
1238	ACG clinical guideline: the diagnosis and management of focal liver lesions. 2014 , 109, 1328-47; quiz 1348	215
1237	Arsenic trioxide: marked suppression of tumor metastasis potential by inhibiting the transcription factor Twist in vivo and in vitro. 2014 , 140, 1125-36	9
1236	Transarterial (chemo)embolization for curative resection of hepatocellular carcinoma: a systematic review and meta-analyses. 2014 , 140, 1159-70	47
1235	Comparison of survival of patients with BCLC stage A hepatocellular carcinoma after hepatic resection or transarterial chemoembolization: a propensity score-based analysis. 2014 , 21, 3069-76	37

1234	Subgrouping of intermediate-stage (BCLC stage B) hepatocellular carcinoma based on tumor number and size and Child-Pugh grade correlated with prognosis after transarterial chemoembolization. 2014 , 32, 260-5	61
1233	Analysis of survival factors in patients with intermediate-advanced hepatocellular carcinoma treated with transcatheter arterial chemoembolization combined with sorafenib. 2014 , 16, 1012-7	3
1232	Growth inhibition and apoptosis induced by 6-fluoro-3-formylchromone in hepatocellular carcinoma. 2014 , 14, 62	3
1231	Risk of secondary cancers from scattered radiation during intensity-modulated radiotherapies for hepatocellular carcinoma. 2014 , 9, 109	20
1230	Liver cancer: time to evolve trial design after everolimus failure. 2014 , 11, 506-7	47
1229	Resection and radiofrequency ablation for hepatocellular cancer. 2014 , 191, 309-10	1
1228	Arterial portography during transarterial chemoembolization: still a necessity in the age of contrast-enhanced cross-sectional imaging?. 2014 , 25, 41-6	3
1227	Clinical and prognostic role of circulating MMP-2 and its inhibitor TIMP-2 in HCC patients prior to and after trans-hepatic arterial chemo-embolization. 2014 , 47, 184-90	20
1226	TACE vs. surgical resection for BCLC stage B HCC. 2014 , 61, 3-4	17
1225	Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: a systematic review of the literature. 2014 , 91, 1-8	48
1224	Is there a role for proton therapy in the treatment of hepatocellular carcinoma? A systematic review. 2014 , 111, 1-10	39
1223	Tamoxifen compared to best supportive care in advanced hepatocellular carcinoma: A retrospective matched-cohort study. 2014 , 26, 1-7	1
1222	The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive and evidence-based comparison and review. 2014 , 120, 2824-38	179
1221	Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. 2014 , 25, 1075-84	35
1220	Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma. 2014 , 4, S112-21	22
1219	Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres. 2014 , 45, 761-769	1
1218	The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations. 2014 , 4, S3-S26	38
1217	Hepatocellular carcinoma: surgical perspectives beyond the barcelona clinic liver cancer recommendations. 2014 , 20, 7525-33	43

1216	How to define transarterial chemoembolization failure or refractoriness: a European perspective. 2014 , 3, 119-24	90
1215	Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma: past, present, and future. 2014 , 3, 9-17	45
1214	Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma. 2014 , 3, 405-16	13
1213	Liver transplantation for hepatocellular carcinoma: how far have we come and what is the future?. 2014 , 1, 309-321	
1212	Increased metastatic potential of residual carcinoma after transarterial embolization in rat with McA-RH7777 hepatoma. 2014 , 31, 95-102	9
1211	Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: A Single-Center Experience. 2015 , 89 Suppl 2, 27-32	19
1210	Tyrosine kinase inhibitors for unresectable hepatocellular carcinoma in adults. 2015 ,	
1209	CCAAT/enhancer binding protein β predicts poorer prognosis and prevents energy starvation-induced cell death in hepatocellular carcinoma. <i>Hepatology</i> , 2015 , 61, 965-78	11.2 52
1208	Hepatectomy for hepatocellular carcinoma larger than 10 cm: preoperative risk stratification to prevent futile surgery. 2015 , 17, 611-23	27
1207	TIGAR regulates DNA damage and repair through pentosephosphate pathway and Cdk5-ATM pathway. 2015 , 5, 9853	40
1206	Portal vein tumor thrombus in advanced hepatocellular carcinoma: A case report. 2015 , 9, 2495-2498	2
1205	Effectiveness of Initial Transarterial Chemoembolization for Hepatocellular Carcinoma Among Medicare Beneficiaries. 2015 , 13, 1102-10	9
1204	Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC). 2015 , 15, 707	19
1203	Radiotherapy for liver tumors. 2015 , 2, 133-146	6
1202	Dosimetric comparison of carbon ion radiotherapy and stereotactic body radiotherapy with photon beams for the treatment of hepatocellular carcinoma. 2015 , 10, 187	33
1201	Sequential Use of Transhepatic Arterial Chemoembolization and Bipolar Radiofrequency Ablation in the Clinical Therapy of Hepatocellular Carcinoma. 2015 , 30, 427-32	8
1200	Transarterial chemoembolization with drug-eluting beads is effective for the maintenance of the Milan-in status in patients with a small hepatocellular carcinoma. 2015 , 21, 1259-69	31
1199	p53 gene therapy-based transarterial chemoembolization for unresectable hepatocellular carcinoma: A prospective cohort study. 2015 , 30, 1651-6	11

1198	A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib. 2015 , 35, 2147-54	26
1197	The role of AEG-1 in the development of liver cancer. 2015 , 2, 303-312	15
1196	Hepatic resection as a safe and effective treatment for hepatocellular carcinoma involving a single large tumor, multiple tumors, or macrovascular invasion. 2015 , 94, e396	85
1195	Management of cancer of the liver, gallbladder and biliary tract. 196-211	
1194	2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. 2015 , 16, 465-522	143
1193	Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers. 2015 , 11, 1603-12	9
1192	Transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol-doxorubicin versus doxorubicin-loaded beads for the treatment of hepatocellular carcinoma. 2015 , 16, 125-32	33
1191	A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. 2015 , 3, 221-252	1
1190	Hepatocellular carcinoma: From diagnosis to treatment. 2015 , 7, 1020-9	108
1189	Sorafenib continuation or discontinuation in patients with unresectable hepatocellular carcinoma after a complete response. 2015 , 6, 24550-9	6
1188	Yttrium-90 radioembolization for advanced inoperable hepatocellular carcinoma. 2015 , 8, 3457-64	7
1187	Hapten-enhanced overall survival time in advanced hepatocellular carcinoma by ultra-minimum incision personalized intratumoral chemoimmunotherapy. 2015 , 2, 57-68	1
1186	Cyberknife treatment for advanced or terminal stage hepatocellular carcinoma. 2015 , 21, 13101-12	11
1185	Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization. 2015 , 21, 5582-90	20
1184	The Safety and Clinical Outcomes of Chemoembolization in Child-Pugh Class C Patients with Hepatocellular Carcinomas. 2015 , 16, 1283-93	9
1183	MRI Findings and Prediction of Time to Progression of Patients with Hepatocellular Carcinoma Treated with Drug-eluting Bead Transcatheter Arterial Chemoembolization. 2015 , 30, 965-73	10
1182	Addition of n-butyl cyanoacrylate to classic transarterial chemoembolization may improve the radiological response in patients with hepatocellular carcinoma. 2015 , 70, 781-9	1
1181	Sorafenib for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis: a systematic review of comparative studies. 2015 , 10, 142-7	7

1180	Active hexose correlated compound potentiates the antitumor effects of low-dose 5-fluorouracil through modulation of immune function in hepatoma 22 tumor-bearing mice. 2015 , 9, 129-36	11
1179	MRI-detectable polymeric micelles incorporating platinum anticancer drugs enhance survival in an advanced hepatocellular carcinoma model. 2015 , 10, 4137-47	10
1178	Efficacy and adverse events of transcatheter arterial chemoembolization in combination with sorafenib in the treatment of unresectable hepatocellular carcinoma. 2015 , 3, 929-935	12
1177	Management of hepatocellular carcinoma with portal vein thrombosis. 2015 , 21, 3462-71	68
1176	Transarterial chemoembolization for hepatocellular carcinoma: an evidence-based review of its place in therapy. 2015 , 2, 123-9	13
1175	Brazilian society of hepatology recommendations for the diagnosis and treatment of hepatocellular carcinoma. 2015 , 52 Suppl 1, 2-14	10
1174	Radiomics and circulating tumor cells: personalized care in hepatocellular carcinoma?. 2015 , 21, 78-84	12
1173	CT Appearance of Hepatocellular Carcinoma after Locoregional Treatments: A Comprehensive Review. 2015 , 2015, 670965	15
1172	Hepatocellular carcinoma in a large medical center of China over a 10-year period: evolving therapeutic option and improving survival. 2015 , 6, 4440-50	54
1171	Current management of hepatocellular carcinoma: an Eastern perspective. 2015 , 21, 3826-42	39
1170	Transarterial chemoembolisation in intermediate-stage hepatocellular carcinoma. Survey on clinical practice in hospitals in the Madrid Region. 2015 , 14, 207-217	1
1169	Development of Intra-Arterial Chemoembolization for Various Types of Cancer in Humans. 2015 , 61, 220-227	
1168	Drug-eluting bead transarterial chemoembolisation for unresectable hepatocellular carcinoma. 2015 ,	
1167	New challenges in clinical research on hepatocellular carcinoma. 2016 , 108, 485-93	11
1166	Diagnostic and therapeutic management of hepatocellular carcinoma. 2015 , 21, 12003-21	53
1165	Current and future treatments for hepatocellular carcinoma. 2015 , 21, 8478-91	112
1164	Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and future. 2015 , 21, 344-8	21
1163	Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system. 2015 , 21, 10327-35	79

1162	Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients. 2015 , 7, 2009-19	62
1161	Clusterin: Review of research progress and looking ahead to direction in hepatocellular carcinoma. 2015 , 21, 8262-70	18
1160	Treatment of hepatocellular carcinoma: beyond international guidelines. 2015 , 35 Suppl 1, 129-38	47
1159	Treatment of hepatocellular carcinomas by thermal ablation and hepatic transarterial chemoembolization. 2015 , 96, 637-46	11
1158	Suppression of Hepatocellular Carcinoma by Inhibition of Overexpressed Ornithine Aminotransferase. 2015 , 6, 840-4	27
1157	Advances in targeted therapies for hepatocellular carcinoma in the genomic era. 2015 , 12, 408-24	318
1156	Hepatocellular carcinoma in variegate porphyria: a case report and literature review. 2015 , 52, 407-12	6
1155	The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). 2015 , 141, 1301-9	103
1154	Combination of individualized local control and target-specific agent to improve unresectable liver cancer managements: a matched case-control study. 2015 , 10, 287-95	8
1153	Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment. 2015 , 9, 335-48	43
1152	Osthole promotes anti-tumor immune responses in tumor-bearing mice with hepatocellular carcinoma. 2015 , 37, 301-7	17
1151	Combination of transarterial chemoembolisation (TACE) plus antivirals for the management of hepatitis B-related hepatocellular carcinoma: A systematic review of the literature. 2015 , 16, 40-5	3
1150	Minimal invasive treatments for liver malignancies. 2015 , 27, 659-667	6
1149	. 2015 ,	
1148	Intermediate hepatocellular carcinoma: the role of transarterial therapy. 2015 , 2, 399-408	9
1147	Traitement des carcinomes h�patocellulaires par thermodestruction et chimioembolisation intra-art�rielle h�patique. 2015 , 96, 192-201	
1146	Post-embolization syndrome as an early predictor of overall survival after transarterial chemoembolization for hepatocellular carcinoma. 2015 , 17, 1137-44	24
1145	Role of Transarterial Chemoembolization to Downstage Hepatocellular Carcinoma Within the Milan Criteria. 2015 , 47, 2631-3	6

1144	Inter-observer variability of response evaluation criteria for hepatocellular carcinoma treated with chemoembolization. 2015 , 47, 682-8	5
1143	Reply to: "Repeated transarterial chemoembolization: An overfitting effort?". 2015 , 62, 1442-3	2
1142	Management of vascular lake phenomenon on angiography during chemoembolization with superabsorbent polymer microspheres. 2015 , 33, 741-8	23
1141	Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs. 2015 , 57, 496-504	10
1140	Treatment of hepatocellular carcinoma in the community: disparities in standard therapy. 2015 , 4, 70-83	23
1139	Prognosis of untreated hepatocellular carcinoma. <i>Hepatology</i> , 2015 , 61, 184-90	11.2 117
1138	In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?. 2015 , 35, 627-35	66
1137	Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. 2015 , 62, 1304-10	108
1136	Neoadjuvant transcatheter arterial chemoembolization does not provide survival benefit compared to curative therapy alone in single hepatocellular carcinoma. 2015 , 31, 77-82	9
1135	BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. 2015 , 35, 223-31	30
1134	Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC. 2015 , 35, 620-6	63
1133	Radiofrequency ablation plus drug-eluting beads transcatheter arterial chemoembolization for the treatment of single large hepatocellular carcinoma. 2015 , 47, 242-8	36
1132	Immediate post-doxorubicin drug-eluting beads chemoembolization Mr Apparent diffusion coefficient quantification predicts response in unresectable hepatocellular carcinoma: A pilot study. 2015 , 42, 981-9	19
1131	Microwave ablation versus transarterial chemoembolization in large hepatocellular carcinoma: prospective analysis. 2015 , 50, 479-84	29
1130	Hepatocellular carcinoma. 2015 , 94-104	
1129	Enhancement of radiofrequency ablation of the liver combined with transarterial embolization using various embolic agents. 2015 , 40, 1821-8	0
1128	CT-guided high-dose-rate brachytherapy of unresectable hepatocellular carcinoma. 2015 , 191, 405-12	21
1127	Consensus statements from a multidisciplinary expert panel on the utilization and application of a liver-specific MRI contrast agent (gadoteric acid). 2015 , 204, 498-509	61

1126	RNAi Knockdown of Hypoxia-Inducible Factor-1 β Decreased the Proliferation, Migration, and Invasion of Hypoxic Hepatocellular Carcinoma Cells. 2015 , 71, 1677-84	8
1125	Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein. 2015 , 7, 1553-61	32
1124	New molecular therapies for hepatocellular carcinoma. 2015 , 39 Suppl 1, S80-5	27
1123	Chimioembolisation des carcinomes h \acute{e} patocellulaires : une vieille m \acute{e} thode au go \hat{u} t du jour. 2015 , 96, 162-171	
1122	Clinical decision tool for optimal delivery of liver stereotactic body radiation therapy: Photons versus protons. 2015 , 5, 209-18	43
1121	Preoperative transarterial chemoembolization does not increase hepatic artery complications after liver transplantation: A single center 12-year experience. 2015 , 39, 451-7	10
1120	Interleukin-8 level as a prognostic marker in patients with hepatitis B virus-associated hepatocellular carcinoma treated with transarterial chemoembolization. 2015 , 76, 449-457	12
1119	Locoregional Therapy for Hepatocellular Carcinoma with and without Extrahepatic Spread. 2015 , 26, 1112-21	7
1118	Synthesis and characterization of image-able polyvinyl alcohol microspheres for image-guided chemoembolization. 2015 , 26, 198	27
1117	Treatment of Liver Cancer. 2015 , 5, a021535	144
1116	Liver cancer: Approaching a personalized care. 2015 , 62, S144-56	175
1115	Transarterial chemoembolization for hepatocellular carcinoma: An old method, now flavor of the day. 2015 , 96, 607-15	18
1114	Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process. 2015 , 62, 855-62	100
1113	In situ gelling silk-elastinlike protein polymer for transarterial chemoembolization. 2015 , 57, 142-52	42
1112	Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs. 2015 , 57, 496-504	15
1111	Intermediate-stage HCC--upfront resection can be feasible. 2015 , 12,	17
1110	Charged particle therapy versus photon therapy for patients with hepatocellular carcinoma: a systematic review and meta-analysis. 2015 , 114, 289-95	81
1109	New treatment modalities for hepatocellular cancer. 2015 , 17, 442	7

1108	Volumetric assessment of tumour response using functional MR imaging in patients with hepatocellular carcinoma treated with a combination of doxorubicin-eluting beads and sorafenib. 2015 , 25, 380-90	21
1107	A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. 2015 , 50, 445-54	100
1106	Bildgesteuerte, minimalinvasive Verfahren in der Onkologie. 2015 , 10, 6-12	
1105	Liver transplantation for hepatocellular carcinoma. 2015 , 17, 11	7
1104	The predictive value of metabolic tumor volume on FDG PET/CT for transarterial chemoembolization and transarterial chemotherapy infusion in hepatocellular carcinoma patients without extrahepatic metastasis. 2015 , 29, 400-8	22
1103	Prognostic factors for prediction of survival of hepatocellular cancer patients after selective internal radiation therapy. 2015 , 29, 426-30	7
1102	Multimodal treatment of unresectable hepatocellular carcinoma to achieve complete response results in improved survival. 2015 , 17, 454-60	4
1101	Hong Kong consensus recommendations on the management of hepatocellular carcinoma. 2015 , 4, 51-69	35
1100	Contrast-enhanced ultrasound evaluation of residual blood flow to hepatocellular carcinoma after treatment with transarterial chemoembolization using drug-eluting beads: a prospective study. 2015 , 34, 859-67	27
1099	Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions. 2015 , 88, 20140564	22
1098	Rab17 inhibits the tumourigenic properties of hepatocellular carcinomas via the Erk pathway. 2015 , 36, 5815-24	13
1097	2014 KLCSSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma. 2015 , 9, 267-317	140
1096	Transarterial chemoembolization: modalities, indication, and patient selection. 2015 , 62, 1187-95	163
1095	Hepatic Resection Improved the Long-Term Survival of Patients with BCLC Stage B Hepatocellular Carcinoma in Asia: a Systematic Review and Meta-Analysis. 2015 , 19, 1271-80	29
1094	Efficacy of RECIST and mRECIST criteria as prognostic factors in patients undergoing repeated iodized oil chemoembolization of intermediate stage hepatocellular carcinoma. 2015 , 56, 1437-45	5
1093	Functional magnetic resonance imaging response of targeted tumor burden and its impact on survival in patients with hepatocellular carcinoma. 2015 , 50, 283-9	14
1092	Proteomic and metabolomic biomarkers for hepatocellular carcinoma: a comprehensive review. 2015 , 112, 1141-56	86
1091	MicroRNA-423-5p Promotes Autophagy in Cancer Cells and Is Increased in Serum From Hepatocarcinoma Patients Treated With Sorafenib. 2015 , 4, e233	107

1090	Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis. 2015 , 20, 1417-24	56
1089	Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial. 2015 , 15, 392	39
1088	Matrine derivative WM130 inhibits hepatocellular carcinoma by suppressing EGFR/ERK/MMP-2 and PTEN/AKT signaling pathways. 2015 , 368, 126-134	47
1087	Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations. 2015 , 17, 52-65	17
1086	Radiofrequency ablation versus transarterial chemoembolization for unresectable solitary hepatocellular carcinomas sized 5-8 cm. 2015 , 17, 226-31	10
1085	Transarterial chemoembolization aggravated peritumoral fibrosis via hypoxia-inducible factor-1 β dependent pathway in hepatocellular carcinoma. 2015 , 30, 925-32	20
1084	Prognostic role of magnetic resonance imaging vs. computed tomography for hepatocellular carcinoma undergoing chemoembolization. 2015 , 35, 1722-30	13
1083	Nomograms for Predicting Outcomes after Chemoembolization in Patients with Nonmetastatic Hepatocellular Carcinoma. 2015 , 26, 1093-1101.e1	3
1082	Immunological landscape and immunotherapy of hepatocellular carcinoma. 2015 , 12, 681-700	344
1081	Hepatoma Rupture following Drug-Eluting Bead Chemoembolization. 2015 , 32, 225-30	1
1080	Quality of Cancer Care in Patients with Cirrhosis and Hepatocellular Carcinoma. 2015 , 17, 34	5
1079	Intra-Arterial Therapies for Liver Masses: Data Distilled. 2015 , 53, 973-84	7
1078	Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo. 2015 , 277, 903-12	46
1077	Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?. 2015 , 11, 2371-3	10
1076	The response of Golgi protein 73 to transcatheter arterial chemoembolization in patients with hepatocellular carcinoma may relate to the influence of certain chemotherapeutics. 2015 , 14, 406-12	3
1075	Pharmacokinetic strategies to improve drug penetration and entrapment within solid tumors. 2015 , 219, 269-277	45
1074	[Current management of hepatocellular carcinoma]. 2015 , 19, 410-5	3
1073	TPX2 Level Correlates with Hepatocellular Carcinoma Cell Proliferation, Apoptosis, and EMT. 2015 , 60, 2360-72	43

1072	Novel X-Ray Imaging Technology Allows Substantial Patient Radiation Reduction without Image Quality Impairment in Repetitive Transarterial Chemoembolization for Hepatocellular Carcinoma. 2015 , 22, 1361-7	5
1071	Role of procalcitonin in diagnosis of bacterial infection in trans-arterial chemoembolisation treated hepatocellular carcinoma patients. 2015 , 16, 10-3	5
1070	Is radioembolization ((90)Y) better than doxorubicin drug eluting beads (DEBDOX) for hepatocellular carcinoma with portal vein thrombosis? A retrospective analysis. 2015 , 24, 270-5	19
1069	Managing complications in cirrhotic patients. 2015 , 3, 80-94	9
1068	Clinical and economic impact of drug eluting beads in transarterial chemoembolization for hepatocellular carcinoma. 2015 , 40, 83-90	10
1067	Management of hepatocellular carcinoma. 2015 , 141, 861-76	79
1066	Transarterial chemoembolization for primary liver malignancies and colorectal liver metastasis. 2015 , 24, 149-66	13
1065	Efficacy and safety of cisplatin versus miriplatin in transcatheter arterial chemoembolization and transarterial infusion chemotherapy for hepatocellular carcinoma: A randomized controlled trial. 2015 , 45, 514-22	15
1064	Epigenetic therapy as a novel approach in hepatocellular carcinoma. 2015 , 145, 103-19	47
1063	Transarterial chemoembolization for hepatocellular carcinoma with a new generation of beads: clinical-radiological outcomes and safety profile. 2015 , 38, 129-34	44
1062	New advances in hepatocellular carcinoma. 2016 , 8, 421-38	102
1061	MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma. 2016 , 7, 7207-15	39
1060	Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis. 2016 , 22, 6851-63	38
1059	Minimally invasive image-guided therapies for hepatocellular carcinoma. 2016 , 3, 55-61	8
1058	Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma. 2016 , 31, 242-52	26
1057	Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016. 2016 , 23, e605-e614	6
1056	Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma. 2016 , 22, 8853-8861	26
1055	Management of hepatocellular carcinoma: an overview of major findings from meta-analyses. 2016 , 7, 34703-51	51

1054	Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation. 2016 , 22, 232-52	31
1053	Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments. 2016 , 8, 703-15	21
1052	Prognostic nomogram for post-surgical treatment with adjuvant TACE in hepatitis B virus-related hepatocellular carcinoma. 2016 , 7, 58302-58314	11
1051	Does the Degree of Hepatocellular Carcinoma Tumor Necrosis following Transarterial Chemoembolization Impact Patient Survival?. 2016 , 2016, 4692139	6
1050	A Meta-Analysis of Arsenic Trioxide Combined with Transcatheter Arterial Chemoembolization for Treatment of Primary Hepatic Carcinoma. 2016 , 2016, 3428370	6
1049	Quality of Life in Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization. 2016 , 2016, 6120143	21
1048	A nonrandomized cohort and a randomized study of local control of large hepatocarcinoma by targeting intratumoral lactic acidosis. 2016 , 5,	41
1047	Transcatheter Arterial Chemoembolization Plus I-Labelled Metuximab versus Transcatheter Arterial Chemoembolization Alone in Intermediate/Advanced Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. 2016 , 17, 882-892	3
1046	Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review. 2016 , 17, 472-88	30
1045	Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma. 2016 , 8, 69-74	16
1044	Transcatheter arterial chemoembolisation (TACE) plus S-1 for the treatment of BCLC stage B hepatocellular carcinoma refractory to TACE. 2016 , 20, 468-474	4
1043	Value of diffusion-weighted MRI in evaluation of solid hepatic focal lesions in patients with renal insufficiency. 2016 , 47, 1265-1274	
1042	Hepatocellular carcinoma: a review. 2016 , 3, 41-53	568
1041	What determines treatment success and future perspectives?. 2016 , 92, 123-4	
1040	The Therapeutic Efficacy and Safety of Compound Kushen Injection Combined with Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma: An Update Systematic Review and Meta-Analysis. 2016 , 7, 70	39
1039	Combination of three-dimensional conformal radiotherapy and transcatheter arterial chemoembolisation versus transcatheter arterial chemoembolisation for primary hepatocellular carcinoma. 2016 ,	2
1038	Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma. 2016 , 22, 4034-40	25
1037	Notch and Wnt/ β -catenin signaling pathway play important roles in activating liver cancer stem cells. 2016 , 7, 5754-68	88

1036	Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016. 2016 , 22, 7289-300		96
1035	Volatile oil from <i>Saussurea lappa</i> exerts antitumor efficacy by inhibiting epithelial growth factor receptor tyrosine kinase-mediated signaling pathway in hepatocellular carcinoma. 2016 , 7, 79761-79773		11
1034	Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma. 2016 , 11, 69		20
1033	Temporal variations in stump pressure and assessment of images obtained from cone-beam computed tomography during balloon-occluded transarterial chemoembolization. 2016 , 46, 468-76		4
1032	Efficacy of the treatment of transarterial chemoembolization combined with radiotherapy for hepatocellular carcinoma with portal vein tumor thrombus: A propensity score analysis. 2016 , 46, 1088-1098		32
1031	Hepatocellular carcinoma: asphyxiate and then cook. 2016 , 3, 1-3		
1030	Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. <i>Hepatology</i> , 2016 , 64, 106-16	11.2	319
1029	Diagnostics and Treatment of Hepatocellular Carcinoma in 2016: Standards and Developments. 2016 , 32, 116-20		33
1028	Acetyl-coenzyme A carboxylase alpha promotion of glucose-mediated fatty acid synthesis enhances survival of hepatocellular carcinoma in mice and patients. <i>Hepatology</i> , 2016 , 63, 1272-86	11.2	74
1027	Raltitrexed plus oxaliplatin-based transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. 2016 , 27, 689-94		13
1026	Efficacy and Safety of Intensity-Modulated Radiotherapy Following Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma. 2016 , 95, e3789		11
1025	Combination Therapy of Radiofrequency Ablation and Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Retrospective Study. 2016 , 95, e3754		30
1024	Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study. 2016 , 108,		49
1023	Efficacy of additional radiofrequency ablation after transcatheter arterial chemoembolization for intermediate hepatocellular carcinoma. 2016 , 46, 312-9		25
1022	Bibliometric analysis of the top-cited gastroenterology and hepatology articles. 2016 , 6, e009889		29
1021	Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis. 2016 , 5, 175-89		27
1020	In vitro clearance of doxorubicin with a DNA-based filtration device designed for intravascular use with intra-arterial chemotherapy. 2016 , 18, 98		9
1019	Molecular alterations in the carcinogenesis and progression of hepatocellular carcinoma: Tumor factors and background liver factors. 2016 , 12, 3662-3668		12

1018	Interventional radiology in the management of hepatopancreatobiliary malignancy and surgical complications. 2016 , 100-119	
1017	Surgery for Intermediate and Advanced Hepatocellular Carcinoma: A Consensus Report from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). 2016 , 5, 245-256	48
1016	Multimodal Imaging of Nanocomposite Microspheres for Transcatheter Intra-Arterial Drug Delivery to Liver Tumors. 2016 , 6, 29653	32
1015	Interleukin-6-stimulated progranulin expression contributes to the malignancy of hepatocellular carcinoma cells by activating mTOR signaling. 2016 , 6, 21260	45
1014	Antiangiogenic and antihepatocellular carcinoma activities of the Juniperus chinensis extract. 2016 , 16, 277	5
1013	Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience. 2016 , 21, 1442-1449	20
1012	Duodenal perforation and esophageal ischemia following transarterial chemoembolization for hepatocellular carcinoma: A case report. 2016 , 95, e3987	6
1011	Hepatic resection versus transarterial chemoembolization for patients with Barcelona Clinic Liver Cancer intermediate stage Child-Pugh A hepatocellular carcinoma. 2016 , 12, 3813-3819	17
1010	Survival of patients with intermediate stage hepatocellular carcinoma treated with superselective transarterial chemoembolization using doxorubicin-loaded DC Bead under cone-beam computed tomography control. 2016 , 50, 418-426	14
1009	Efficacy and safety of radiofrequency ablation and transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: A meta-analysis. 2016 , 46, 58-71	28
1008	Multifunctional microbeads for drug delivery in TACE. 2016 , 13, 1289-300	16
1007	The Clinical Impact of Transcatheter Arterial Chemoembolization (TACE)-Induced c-Met Upregulation on TACE Refractoriness in Hepatocellular Carcinoma. 2016 , 61, 1572-81	6
1006	PPAR α activation reduces ischemia/reperfusion-induced metastasis in a murine model of hepatocellular carcinoma. 2016 , 11, 387-396	12
1005	Interventional oncology for hepatocellular carcinoma. 2016 , 40, 530-537	6
1004	Comparative analysis of current guidelines for the treatment of hepatocellular carcinoma. 2016 , 3, 119-136	7
1003	Recognition and killing of cancer stem-like cell population in hepatocellular carcinoma cells by cytokine-induced killer cells via NKG2d-ligands recognition. 2016 , 5, e1086060	27
1002	Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents. 2016 , 1860, 1417-30	83
1001	Activation of mPTP-dependent mitochondrial apoptosis pathway by a novel pan HDAC inhibitor resminostat in hepatocellular carcinoma cells. 2016 , 477, 527-533	26

1000	Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality. 2016 , 10, 883-892	24
999	MEK-ERK inhibition potentiates WAY-600-induced anti-cancer efficiency in preclinical hepatocellular carcinoma (HCC) models. 2016 , 474, 330-337	10
998	Changes of HBV DNA After Chemoembolization for Hepatocellular Carcinoma and the Efficacy of Antiviral Treatment. 2016 , 61, 2465-76	9
997	Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis. 2016 , 39, 1580-1588	68
996	Prognostic sub-classification of intermediate-stage hepatocellular carcinoma: a multicenter cohort study with propensity score analysis. 2016 , 33, 114	3
995	Imaging prediction of residual hepatocellular carcinoma after locoregional therapy in patients undergoing liver transplantation or partial hepatectomy. 2016 , 41, 2161-2168	11
994	Hepatitis B and Hepatocellular Carcinoma. 2016 , 20, 703-720	23
993	Carcinoma hepatocelular. 2016 , 12, 683-692	0
992	Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment. 2016 , 15, 234-56	30
991	Serie de casos de pacientes con hepatocarcinoma tratados con sorafenib como terapia puente a quimioembolización y finalmente como paliativo. 2016 , 15, 195-198	
990	Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. 2016 , 146, 511.e1-511.e22	1
989	Gelatin sponge microparticles for the treatment of the spontaneous rupture of hepatocellular carcinoma hemorrhage. 2016 , 12, 2201-2207	5
988	Evaluation of Surefire's precision direct-to-tumor embolization device to augment therapeutic response to intra-arterial, liver-directed therapies for patients with primary and secondary liver cancers. 2016 , 13, 435-43	3
987	Long noncoding RNA CCHE1 indicates a poor prognosis of hepatocellular carcinoma and promotes carcinogenesis via activation of the ERK/MAPK pathway. 2016 , 83, 450-455	57
986	Ultrasound-guided therapeutic modulation of hepatocellular carcinoma using complementary microRNAs. 2016 , 238, 272-280	50
985	Liver-Directed Radiotherapy for Hepatocellular Carcinoma. 2016 , 5, 198-209	20
984	mTOR inhibition sensitizes human hepatocellular carcinoma cells to resminostat. 2016 , 477, 556-562	7
983	Treatment of hepatocellular carcinoma: beyond international guidelines. 2016 , 36 Suppl 1, 124-9	57

982	Serum cell death biomarker mirrors liver cancer regression after transarterial chemoembolisation. 2016 , 44, 747-54	6
981	A novel sulfamethazine-based pH-sensitive copolymer for injectable radiopaque embolic hydrogels with potential application in hepatocellular carcinoma therapy. 2016 , 7, 5805-5818	24
980	Targeted Therapy for Hepatocellular Carcinoma. 2016 , 26, 338-43	17
979	Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. 2016 , 151, 1155-1163.e2	318
978	Efficacy of low dose capecitabine and sorafenib in patients with advanced alfa-fetoprotein secreting hepatocellular carcinoma: a 1 year experience. 2016 , 5, 1675	1
977	Early Prediction of the Outcome Using Tumor Markers and mRECIST in Unresectable Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization. 2016 , 91, 317-330	15
976	Matrine induces cell cycle arrest and apoptosis with recovery of the expression of miR-126 in the A549 non-small cell lung cancer cell line. 2016 , 14, 4042-4048	47
975	Derived neutrophil to lymphocyte ratio predicts prognosis for patients with HBV-associated hepatocellular carcinoma following transarterial chemoembolization. 2016 , 11, 2987-2994	23
974	"Hepatocellular carcinoma: A life-threatening disease". 2016 , 84, 1679-1688	60
973	Hepatocellular carcinoma. 2016 , 2, 16018	1274
972	Effective hepatic artery chemoembolization for advanced hepatocellular carcinoma with multiple tumor thrombi and pulmonary metastases: A case report. 2016 , 12, 2103-2106	
971	A Recent Advance in Image-Guided Locoregional Therapy for Hepatocellular Carcinoma. 2016 , 3, 90-102	12
970	Bildgeführte Therapie des hepatozellulären Karzinoms. 2016 , 11, 391-399	
969	Postsurgical treatment with adjuvant transarterial chemoembolization in patients with hepatitis B-related hepatocellular carcinoma: A strobe-compliant article. 2016 , 95, e5517	2
968	Evaluation of Hepatocellular Carcinoma Tumor Response After Transcatheter Arterial Chemoembolization Using Gadobenate Dimeglumine-Enhanced Liver Magnetic Resonance. 2016 , 40, 856-862	
967	Reply: Which is the Best Chemotherapeutic Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma?. 2016 , 39, 955-6	
966	C6 ceramide sensitizes the anti-hepatocellular carcinoma (HCC) activity by AZD-8055, a novel mTORC1/2 dual inhibitor. 2016 , 37, 11039-48	12
965	Induction Chemotherapy for Hepatocellular Carcinoma. 2016 , 269-284	

964	Overexpression of DLX2 is associated with poor prognosis and sorafenib resistance in hepatocellular carcinoma. 2016 , 101, 58-65	16
963	Multimodality Imaging of Ethiodized Oil-loaded Radiopaque Microspheres during Transarterial Embolization of Rabbits with VX2 Liver Tumors. 2016 , 279, 741-53	17
962	Iodine-125 implantation plus transarterial chemoembolization for the treatment of hepatocellular carcinoma of 3-5cm: A propensity score matching study. 2016 , 48, 1082-7	12
961	Comparison of surgical resection and transarterial chemoembolization for patients with intermediate stage hepatocellular carcinoma. 2016 , 3, 34-38	2
960	A case of miriplatin-induced lung injury. 2016 , 22, 486-9	4
959	Combination of radiofrequency ablation with transarterial chemoembolization for treatment of hepatocellular carcinoma: experience from a Danish tertiary liver center. 2016 , 57, 844-51	4
958	Benefits of stereotactic ablative radiotherapy combined with incomplete transcatheter arterial chemoembolization in hepatocellular carcinoma. 2016 , 11, 22	15
957	ART score and hepatocellular carcinoma: An appraisal of its applicability. 2016 , 40, 705-714	10
956	TACE vs DEB-TACE: Who wins?. 2016 , 48, 796-7	8
955	Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial-embolization prognostic score. 2016 , 36, 100-7	51
954	Improved stability of lipiodol-drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin. 2016 , 26, 601-9	23
953	Postoperative Adjuvant Transcatheter Arterial Chemoembolization After R0 Hepatectomy Improves Outcomes of Patients Who have Hepatocellular Carcinoma with Microvascular Invasion. 2016 , 23, 1344-51	94
952	Hepatocellular carcinoma: modern image-guided therapies. 2016 , 92, 165-71	6
951	Initial Experience with Balloon-Occluded Trans-catheter Arterial Chemoembolization (B-TACE) for Hepatocellular Carcinoma. 2016 , 39, 359-66	20
950	Change in Imaging Findings on Angiography-Assisted CT During Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma. 2016 , 39, 865-74	4
949	4SC-202 activates ASK1-dependent mitochondrial apoptosis pathway to inhibit hepatocellular carcinoma cells. 2016 , 471, 267-73	33
948	Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. 2016 , 64, 1090-1098	407
947	Parametric response mapping of contrast-enhanced biphasic CT for evaluating tumour viability of hepatocellular carcinoma after TACE. 2016 , 26, 3447-55	8

946	Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. 2016 , 150, 835-53	1012
945	Mechanisms of doxorubicin resistance in hepatocellular carcinoma. 2016 , 3, 57-59	77
944	GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization. 2016 , 17, 353-66	15
943	Antitumoral Effect of Sunitinib-eluting Beads in the Rabbit VX2 Tumor Model. 2016 , 280, 425-35	24
942	Hepatocellular carcinoma: From diagnosis to treatment. 2016 , 25, 74-85	248
941	Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress. 2016 , 95, 782-90	39
940	A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy. 2016 , 371, 205-13	25
939	Sociodemographic impact on survival in unresectable hepatocellular carcinoma: a survival epidemiology and end results study. 2016 , 12, 183-98	8
938	Randomized Clinical Trial Comparing Proton Beam Radiation Therapy with Transarterial Chemoembolization for Hepatocellular Carcinoma: Results of an Interim Analysis. 2016 , 95, 477-482	92
937	Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review. 2016 , 10, 501-10	29
936	Advances in Local and Systemic Therapies for Hepatocellular Cancer. 2016 , 18, 9	13
935	Transarterial Therapies for Hepatocellular Carcinoma. 2016 , 51, 95-105	4
934	[Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. 2016 , 146, 511.e1-511.e22	36
933	TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON. 2016 , 279, 630-40	85
932	Prospective Study of Transcatheter Arterial Chemoembolization (TACE) with Ginsenoside Rg3 versus TACE Alone for the Treatment of Patients with Advanced Hepatocellular Carcinoma. 2016 , 280, 630-9	43
931	Effectiveness of Transarterial Embolization of Hepatocellular Carcinoma as a Bridge to Transplantation. 2016 , 27, 39-45	13
930	Characteristics of liver cancer stem cells and clinical correlations. 2016 , 379, 230-8	52
929	Management strategies for hepatocellular carcinoma: old certainties and new realities. 2016 , 16, 243-56	23

928	Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: development of a prediction model. 2016 , 36, 92-9	41
927	Epigenetic mechanisms regulating the development of hepatocellular carcinoma and their promise for therapeutics. 2017 , 11, 45-53	35
926	Clinical features and prognosis of elderly patients with hepatocellular carcinoma not indicated for surgical resection. 2017 , 17, 189-201	18
925	Usefulness and limitations of balloon-occluded transcatheter arterial chemoembolization using miriplatin for patients with four or fewer hepatocellular carcinoma nodules. 2017 , 47, 338-346	12
924	Should we routinely use DEBTACE for unresectable HCC? cTACE versus DEBTACE: a single-center survival analysis. 2017 , 69, 67-73	14
923	Bridging Locoregional Therapy Prolongs Survival in Patients Listed for Liver Transplant with Hepatocellular Carcinoma. 2017 , 40, 410-420	9
922	Radiofrequency ablation combined with transarterial chemoembolization versus hepatectomy for patients with hepatocellular carcinoma within Milan criteria: a retrospective case-control study. 2017 , 19, 844-852	18
921	Prognostic factors of hepatocellular carcinoma patients with portal vein tumor thrombosis treated with transcatheter arterial chemoembolization. 2017 , 13, e331-e341	6
920	Long non-coding RNA UC001kfo promotes hepatocellular carcinoma proliferation and metastasis by targeting β 5MA. 2017 , 87, 669-677	14
919	Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. 2017 , 116, 448-454	46
918	Advances in Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. 2017 , 27, 247-255	66
917	Parametric response mapping of dynamic CT: enhanced prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization. 2017 , 42, 1871-1879	4
916	Bridging locoregional therapy: Longitudinal trends and outcomes in patients with hepatocellular carcinoma. 2017 , 31, 136-143	6
915	ADC ratio and D ratio derived from intravoxel incoherent motion early after TACE are independent predictors for survival in hepatocellular carcinoma. 2017 , 46, 820-830	16
914	Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality. 2017 , 152, 1954-1964	116
913	Arterial dissections during transcatheter arterial chemoembolization for hepatocellular carcinoma: a 19-year clinical experience at a single medical institution. 2017 , 58, 842-848	5
912	Loco-regional treatment of HCC: current status. 2017 , 72, 626-635	50
911	Development of Semiautomated Module for Preparation of I Labeled Lipiodol for Liver Cancer Therapy. 2017 , 32, 33-37	5

910	Gene Signature Associated with Upregulation of the Wnt/ β Catenin Signaling Pathway Predicts Tumor Response to Transarterial Embolization. 2017 , 28, 349-355.e1	11
909	[Hepatocellular carcinoma]. 2017 , 58, 469-479	3
908	Hepatocellular carcinoma treatment: a comparative review of emerging growth factor receptor antagonists. 2017 , 22, 191-200	3
907	NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization. 2017 , 29, 706-715	12
906	Systematic review and meta-analysis of hepatic resection versus transarterial chemoembolization for solitary large hepatocellular carcinoma. 2017 , 19, 653-658	11
905	N-Butyl-2-cyanoacrylate-based injectable and in situ-forming implants for efficient intratumoral chemotherapy. 2017 , 24, 729-736	7
904	Review article: delivering precision oncology in intermediate-stage liver cancer. 2017 , 45, 1514-1523	19
903	Early treatment response to transcatheter arterial chemoembolization is associated with time to the development of extrahepatic metastasis and overall survival in intermediate-stage hepatocellular carcinoma. 2017 , 79, 81-88	6
902	Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply. 2017 , 8, e98	54
901	Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. 2017 , 11, 317-370	955
900	New idea for treatment strategies for Barcelona Clinic Liver Cancer stages based on a network meta-analysis. 2017 , 96, e6950	10
899	Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. 2017 , 2, 565-575	226
898	Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma. 2017 , 15, 1791-1799	51
897	Intrahepatic biloma following transcatheter arterial chemoembolization for hepatocellular carcinoma: Incidence, imaging features and management. 2017 , 6, 937-943	9
896	Advances in management of hepatocellular carcinoma. 2017 , 29, 288-295	31
895	Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: A single-center randomized controlled trial. 2017 , 18, 433-438	65
894	Reversed lipid-based nanoparticles dispersed in oil for malignant tumor treatment via intratumoral injection. 2017 , 24, 857-866	8
893	Decision Making: Intra-arterial Therapies for Cholangiocarcinoma-TACE and TARE. 2017 , 34, 92-100	25

892	Hepatocellular carcinoma. 2017 , 1333-1338.e2	1
891	Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization. 2017 , 11, 292-299	5
890	The value of paradoxical uptake of hepatocellular carcinoma on the hepatobiliary phase of gadoteric acid-enhanced liver magnetic resonance imaging for the prediction of lipiodol uptake after transcatheter arterial chemoembolization. 2017 , 89, 169-176	2
889	New concepts in embolotherapy of HCC. 2017 , 34, 58	42
888	Constraints for symptomatic radiation pneumonitis of helical tomotherapy hypofractionated simultaneous multitarget radiotherapy for pulmonary metastasis from hepatocellular carcinoma. 2017 , 123, 246-250	3
887	The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. 2017 , 67, 173-183	106
886	Distribution of tumor stage and initial treatment modality in patients with primary hepatocellular carcinoma. 2017 , 19, 891-897	13
885	A SEER Database Analysis of the Survival Advantage of Transarterial Chemoembolization for Hepatocellular Carcinoma: An Underutilized Therapy. 2017 , 28, 231-237.e2	14
884	Safety and efficacy of transcatheter arterial chemoembolization with embospheres in treatment of hepatocellular carcinoma. 2017 , 18, 31-39	5
883	The diagnosis and treatment of hepatocellular carcinoma. 2017 , 34, 153-159	278
882	Cancer-directed therapy and potential impact on survivals in nonresected hepatocellular carcinoma: SEER-Medicare population study. 2017 , 13, 2021-2033	4
881	Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. 2017 , 18, 1624-1636	400
880	Neutrophil-lymphocyte Ratio Plus Prognostic Nutritional Index Predicts the Outcomes of Patients with Unresectable Hepatocellular Carcinoma After Transarterial Chemoembolization. 2017 , 7, 13873	13
879	Long non-coding RNA CASC15 is upregulated in hepatocellular carcinoma and facilitates hepatocarcinogenesis. 2017 , 51, 1722-1730	42
878	Local Arterial Therapies in the Management of Unresectable Hepatocellular Carcinoma. 2017 , 18, 67	1
877	The ART-SCORE is not an effective tool for optimizing patient selection for DEB-TACE retreatment. A multicentre Spanish study. 2017 , 40, 515-524	
876	Cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma. 2017 , 16, 493-498	6
875	Role and Future Directions of External Beam Radiotherapy for Primary Liver Cancer. 2017 , 24, 1073274817729342	42

874	Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. 2017 , 24, 1073274817729244	18
873	Switch to miriplatin for multinodular hepatocellular carcinoma unresponsive to transarterial chemoembolization with epirubicin: a prospective study. 2017 , 47, 1151-1156	1
872	Experiments for the Development of a Steerable Microcatheter. 2017 , 40, 1921-1926	8
871	Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients. 2017 , 209, 722-732	19
870	Drug-eluting embolic microspheres for local drug delivery - State of the art. 2017 , 262, 127-138	39
869	OCIAD2 suppressed tumor growth and invasion via AKT pathway in Hepatocellular carcinoma. 2017 , 38, 910-919	11
868	Current guidelines for chemoembolization for hepatocellular carcinoma: Room for improvement?. 2017 , 1, 338-346	9
867	The ART-SCORE is not an effective tool for optimizing patient selection for DEB-TACE retreatment. A multicentre Spanish study. 2017 , 40, 515-524	7
866	Bridging to liver transplantation in HCC patients. 2017 , 402, 863-871	21
865	Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres. 2017 , 71, e12972	28
864	Radiation Therapy for Hepatocellular Carcinoma: Clinical Data. 2017 , 179-198	
863	Treatment of hepatocellular carcinoma using transarterial chemoembolization: a real-life, single-centre study from Southern Brazil. 2017 , 29, 225-230	1
862	Cost-effectiveness analysis of potentially curative and combination treatments for hepatocellular carcinoma with person-level data in a Canadian setting. 2017 , 6, 2017-2033	12
861	An Update on Randomized Clinical Trials in Hepatocellular Carcinoma. 2017 , 26, 647-666	4
860	Nomogram for individualized prediction of recurrence after postoperative adjuvant TACE for hepatitis B virus-related hepatocellular carcinoma. 2017 , 96, e7390	3
859	Arteriopathy after transarterial chemo-lipiodolization for hepatocellular carcinoma. 2017 , 98, 827-835	3
858	Janus Gold Nanoplatfom for Synergetic Chemoradiotherapy and Computed Tomography Imaging of Hepatocellular Carcinoma. 2017 , 11, 12732-12741	108
857	Eradication of hepatitis C virus profoundly prolongs survival in hepatocellular carcinoma patients receiving transarterial chemoembolization. 2017 , 24, 1160-1167	8

856	The value of [C]-acetate PET and [F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab. 2017 , 44, 1732-1741	15
855	Role of curative treatment in patients with intermediate-stage hepatocellular carcinoma. 2017 , 35, 254-261	2
854	Traitements intra-arteriels des carcinomes hépatocellulaires : évidence clinique et perspectives à venir. 2017 , 19, 158-167	
853	Hepatocellular carcinoma: Therapeutic strategy in 2017. 2017 , 19, 177-183	
852	The antitumor activity of a lactosaminated albumin conjugate of doxorubicin in a chemically induced hepatocellular carcinoma rat model compared to sorafenib. 2017 , 49, 213-222	17
851	Risks factors for severe pain after selective liver transarterial chemoembolization. 2017 , 37, 583-591	10
850	Conventional versus drug-eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size. 2017 , 32, 487-496	24
849	Experience from a real-life cohort: outcome of 606 patients with hepatocellular carcinoma following transarterial chemoembolization. 2017 , 52, 116-124	11
848	Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine. 2017 , 28, 169-174	19
847	Haemodynamic changes in hepatocellular carcinoma and liver parenchyma under balloon occlusion of the hepatic artery. 2017 , 27, 2474-2481	1
846	Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: comparison between drug-eluting beads and lipiodol emulsion. 2017 , 27, 1431-1439	57
845	Stereotactic Body Radiation Therapy (SBRT) or Alternative Fractionation Schedules. 2017 , 171-202	
844	Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: A meta-analysis of randomized trials. 2017 , 5, 511-518	41
843	Short-term efficacy of transarterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres for hepatocellular carcinoma: comparison with conventional transarterial chemoembolization. 2017 , 42, 612-619	7
842	Hepatic resection or transarterial chemoembolization for hepatocellular carcinoma within Milan criteria: A propensity score matching analysis. 2017 , 96, e8933	4
841	Hepatocellular Carcinoma. 2017 , 977-988	
840	Expression of cluster of differentiation 151 prior to and following transcatheter arterial chemoembolization therapy in patients with hepatocellular carcinoma and its association with clinicopathological characteristics. 2018 , 15, 1133-1142	
839	Trends and outcomes of transarterial chemoembolization in hepatocellular carcinoma: a national survey. 2017 , 16, 624-630	4

838	Computed Tomographic Perfusion Imaging for the Prediction of Response and Survival to Transarterial Chemoembolization of Hepatocellular Carcinoma. 2018 , 52, 14-22	3
837	Baseline Tumor Lipiodol Uptake after Transarterial Chemoembolization for Hepatocellular Carcinoma: Identification of a Threshold Value Predicting Tumor Recurrence. 2017 , 51, 393-400	4
836	Diffuse Infiltrative Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Completely Cured by Transcatheter Arterial Chemoembolization: Case Report with 8-Year Follow-Up. 2016 , 10, 623-628	4
835	Multidisciplinary Management of Hepatocellular Carcinoma Improves Access to Therapy and Patient Survival. 2017 , 51, 845-849	33
834	Surgical treatment of liver tumors - own experience and literature review. 2017 , 3, 1-8	7
833	Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review. 2017 , 4, 105-110	40
832	Hepatic artery embolization and chemoembolization of liver tumors. 2017 , 1398-1416.e4	
831	Effects of marital status on survival of hepatocellular carcinoma by race/ethnicity and gender. 2018 , 10, 23-32	9
830	Clinical usefulness of transarterial chemoembolization response prior to liver transplantation as predictor of optimal timing for living donor liver transplantation. 2018 , 95, 111-120	3
829	Multidisciplinary Taiwan Consensus Recommendations for the Use of DEBDOX-TACE in Hepatocellular Carcinoma Treatment. 2018 , 7, 312-322	4
828	Identifying the Best Anticancer Agent Combination in TACE for HCC Patients: A Network Meta-analysis. 2018 , 9, 2640-2649	6
827	Decreased CRHBP expression is predictive of poor prognosis in patients with hepatocellular carcinoma. 2018 , 16, 3681-3689	4
826	Nitroglycerine use in transcatheter arterial (chemo) embolization in patients with hepatocellular carcinoma: Five-year retrospective study. 2018 , 42, 542-552	1
825	Transarterial chemoembolization plus iodine-125 implantation for hepatocellular carcinoma: a systematic review and meta-analysis. 2018 , 20, 795-802	10
824	HCC. 2018 , 43-82	
823	Efficacy and Safety of Transcatheter Arterial Chemoembolization and Transcatheter Arterial Chemotherapy Infusion in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. 2018 , 26, 231-239	17
822	Primary Malignant Neoplasms of the Liver. 2018 , 705-729	1
821	Optimal M-Switch Surveillance Policies for Liver Cancer in a Hepatitis C Infected Population. 2018 , 66, 673-696	5

820	Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). 2018 , 7, 235-260	291
819	Utility of the Virtual Liver Parenchymal Perfusion Area Using a Commercially Available Workstation in Transarterial Chemoembolization for Hepatocellular Carcinoma. 2019 , 42, 69-77	1
818	Computed tomographic perfusion with 160-mm coverage: comparative analysis of hepatocellular carcinoma treated by two transarterial chemoembolization courses relative to magnetic resonance imaging findings. 2019 , 44, 85-94	2
817	Alpha-fetoprotein response following transarterial chemoembolization indicates improved survival for intermediate-stage hepatocellular carcinoma. 2019 , 21, 107-113	14
816	Role of OCT1 in hepatocellular carcinoma. 2019 , 12, 6013-6022	6
815	S-Adenosylmethionine Affects Cell Cycle Pathways and Suppresses Proliferation in Liver Cells. 2019 , 10, 4368-4379	7
814	Comparison of macrovascular invasion-free survival in early-intermediate hepatocellular carcinoma after different interventions: A propensity score-based analysis. 2019 , 10, 4063-4071	1
813	Azido-galactose outperforms azido-mannose for metabolic labeling and targeting of hepatocellular carcinoma. 2019 , 7, 4166-4173	15
812	Insights into the success and failure of systemic therapy for hepatocellular carcinoma. 2019 , 16, 617-630	82
811	Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. 2019 , 71, 1164-1174	119
810	Clinical conditions and treatment requirements for long-term survival among hepatitis B-related hepatocellular carcinoma initially treated with chemoembolization. 2019 , 8, 5097-5107	5
809	YAP promotes multi-drug resistance and inhibits autophagy-related cell death in hepatocellular carcinoma via the RAC1-ROS-mTOR pathway. 2019 , 19, 179	49
808	Contrasting Some Differences in Managing Advanced Unresectable Hepatocellular Carcinoma Between the East and the West. 2019 , 31, 560-569	2
807	Stereotactic body radio therapy for inoperable large hepatocellular cancers: results from a clinical audit. 2019 , 92, 20181053	8
806	Comparison of Stereotactic Body Radiation Therapy and Transarterial Chemoembolization for Unresectable Medium-Sized Hepatocellular Carcinoma. 2019 , 105, 307-318	28
805	Robust GPU-based virtual reality simulation of radio-frequency ablations for various needle geometries and locations. 2019 , 14, 1825-1835	3
804	Minimally invasive gas embolization using acoustic droplet vaporization in a rodent model of hepatocellular carcinoma. 2019 , 9, 11040	7
803	Alpha-fetoprotein assessment for hepatocellular carcinoma after transarterial chemoembolization. 2019 , 44, 3304-3311	6

802	Database analysis of patients with hepatocellular carcinoma and treatment flow in early and advanced stages. 2019 , 7, e00486	8
801	Percutaneous image-guided therapies of primary liver tumors: Techniques and outcomes. 2019 , 48, e245-e250	2
800	Neutrophil/Lymphocyte Ratio Predicts Increased Risk of Immediate Progressive Disease Following Chemoembolization of Hepatocellular Carcinoma. 2019 , 30, 1887-1892	13
799	Recent clinical applications of external beam radiotherapy for hepatocellular carcinoma according to guidelines, major trials and meta-analyses. 2019 , 63, 812-821	10
798	Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study. 2019 , 19, 983	20
797	Improved Survival in Hepatocellular Carcinoma Patients with Cardiac Arrhythmia by Amiodarone Treatment through Autophagy. 2019 , 20,	4
796	C-arm cone-beam CT parenchymal blood volume imaging for transarterial chemoembolization of hepatocellular carcinoma: implications for treatment planning and response. 2019 , 3, 21	2
795	Smart Nanotherapeutic Targeting of Tumor Vasculature. 2019 , 52, 2703-2712	71
794	Clinical Trials with Combination of Cytokine-Induced Killer Cells and Dendritic Cells for Cancer Therapy. 2019 , 20,	16
793	Chemoembolization Combined with Radiofrequency Ablation for Medium-Sized Hepatocellular Carcinoma: A Propensity-Score Analysis. 2019 , 30, 1533-1543	25
792	Loco-regional intervention for hepatocellular carcinoma. 2019 , 2, 43-46	
791	Impact of antiviral therapy with nucleos(t)ide analog on survival of patients with HBV-related small hepatocellular carcinomas. 2019 , 11, 8475-8486	2
790	Liver abscesses after transcatheter arterial embolization. 2019 , 47, 1124-1130	11
789	Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study. 2019 , 70, 893-903	81
788	Considerations of heterogeneity in clinical trials for hepatocellular carcinoma. 2019 , 13, 615-621	3
787	Clinical Relevance of Reductive Hepatectomy for Barcelona Clinic Liver Cancer Stages B and C Advanced Hepatocellular Carcinoma: A Single-Center Experience of 102 Patients. 2019 , 43, 2571-2578	6
786	Scutellaria baicalensis Georgi. (Lamiaceae): a review of its traditional uses, botany, phytochemistry, pharmacology and toxicology. 2019 , 71, 1353-1369	118
785	Combination Suicide Gene Delivery with an Adeno-Associated Virus Vector Encoding Inducible Caspase-9 and a Chemical Inducer of Dimerization Is Effective in a Xenotransplantation Model of Hepatocellular Carcinoma. 2019 , 30, 1754-1762	7

784	Color coded perfusion imaging with contrast enhanced ultrasound (CEUS) for post-interventional success control following trans-arterial chemoembolization (TACE) of hepatocellular carcinoma. 2019 , 14, e0217599	9
783	The effect of propranolol on the prognosis of hepatocellular carcinoma: A nationwide population-based study. 2019 , 14, e0216828	6
782	Machine-learning Approach for the Development of a Novel Predictive Model for the Diagnosis of Hepatocellular Carcinoma. 2019 , 9, 7704	42
781	Segmental Distribution of Hepatocellular Carcinoma Correlates with Microvascular Invasion in Liver Explants Undergoing Transplantation. 2019 , 2019, 8534372	2
780	The Combination of Stereotactic Body Radiation Therapy and Immunotherapy in Primary Liver Tumors. 2019 , 2019, 4304817	9
779	Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis. 2019 , 64, 3660-3668	6
778	Analyses of a Panel of Transcripts Identified From a Small Sample Size and Construction of RNA Networks in Hepatocellular Carcinoma. 2019 , 10, 431	9
777	Silybin-Induced Apoptosis Occurs in Parallel to the Increase of Ceramides Synthesis and miRNAs Secretion in Human Hepatocarcinoma Cells. 2019 , 20,	12
776	N-Acetylcysteine Prevents Post-embolization Syndrome in Patients with Hepatocellular Carcinoma Following Transarterial Chemoembolization. 2019 , 64, 3337-3345	3
775	Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma. 2019 , 19, 363	7
774	Risk factors for local recurrence of hepatocellular carcinoma after transcatheter arterial chemoembolization with drug-eluting beads (DEB-TACE). 2019 , 37, 543-548	5
773	Immunotherapy in hepatocellular carcinoma. 2019 , 18, 291-297	44
772	Janus Microcarriers for Magnetic Field-Controlled Combination Chemotherapy of Hepatocellular Carcinoma. 2019 , 29, 1901384	12
771	Inhibition of PI3K/mTOR increased the sensitivity of hepatocellular carcinoma cells to cisplatin via interference with mitochondrial-lysosomal crosstalk. 2019 , 52, e12609	26
770	Long-term follow-up after conventional transarterial chemoembolization (c-TACE) with mitomycin for hepatocellular carcinoma (HCC). 2019 , 10, 348-353	5
769	Hepatocellular Carcinoma in Africa. 2019 , 149-162	
768	Prognostic impact of toll-like receptors 2 and 4 expression on monocytes in Egyptian patients with hepatocellular carcinoma. 2019 , 67, 157-165	12
767	Designing pH-triggered drug release iron oxide nanocomposites for MRI-guided photothermal-chemoembolization therapy of liver orthotopic cancer. 2019 , 7, 1842-1851	11

766	A Combination of UTMD-Mediated HIF-1 shRNA Transfection and TAE in the Treatment of Hepatic Cancer. 2019 , 2019, 1937460	8
765	HCC: Transarterial Therapies-What the Interventional Radiologist Can Offer. 2019 , 64, 959-967	9
764	Interventional oncology treatments for unresectable early stage HCC in patients with a high risk for intraprocedural bleeding: Is a single-step combined therapy safe and feasible?. 2019 , 114, 32-37	7
763	Dissecting the multinodular hepatocellular carcinoma subset: is there a survival benefit after hepatectomy?. 2019 , 71, 57-66	2
762	Neural Networks for Deep Radiotherapy Dose Analysis and Prediction of Liver SBRT Outcomes. 2019 , 23, 1821-1833	18
761	Liver resection versus transarterial chemoembolization for the treatment of intermediate-stage hepatocellular carcinoma. 2019 , 8, 1530-1539	4
760	The prognostic and predictive value of the combination of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma who receive transarterial chemoembolization therapy. 2019 , 11, 1391-1400	15
759	ϑThujaplicin induces autophagic cell death, apoptosis, and cell cycle arrest through ROS-mediated Akt and p38/ERK MAPK signaling in human hepatocellular carcinoma. 2019 , 10, 255	53
758	Dynamic Computed Tomography Perfusion Imaging: Complementary Diagnostic Tool in Hepatocellular Carcinoma Assessment From Diagnosis to Treatment Follow-up. 2019 , 26, 1675-1685	5
757	Locoregional Therapy, Immunotherapy and the Combination in Hepatocellular Carcinoma: Future Directions. 2019 , 8, 326-340	19
756	[Stereotactic body radiation therapy for hepatocellular carcinoma: Results from a retrospective multicentre study]. 2019 , 23, 104-115	3
755	Tumor-associated macrophages modulate resistance to oxaliplatin via inducing autophagy in hepatocellular carcinoma. 2019 , 19, 71	41
754	Controversies in the management of hepatocellular carcinoma. 2019 , 1, 17-29	26
753	Hepatocellular Carcinoma. 2019 , 380, 1450-1462	1441
752	Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. 2019 , 70, 1262-1277	90
751	Comparing stereotactic ablative radiotherapy (SABR) versus re-trans-catheter arterial chemoembolization (re-TACE) for hepatocellular carcinoma patients who had incomplete response after initial TACE (TASABR): a randomized controlled trial. 2019 , 19, 275	7
750	Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis. 2019 , 28, 228-235	14
749	Hepatic Cancers Overview: Surgical and Chemotherapeutic Options, How Do Y-90 Microspheres Fit in?. 2019 , 49, 170-181	3

748	Hepatocellular Carcinoma: Treatment. 2019 , 703-714	
747	Implementation of sorafenib treatment for advanced hepatocellular carcinoma: an illustration of current practice in Taiwan. 2019 , 11, 1013-1021	5
746	. 2019 ,	1
745	In-hospital mortality associated with transcatheter arterial embolization for treatment of hepatocellular carcinoma in patients on hemodialysis for end stage renal disease: a matched-pair cohort study using a nationwide database. 2019 , 1, 20190004	1
744	Cryotherapy for liver metastases. 2019 , 7, CD009058	5
743	Regional Chemotherapy for Biliary Tract Tumors and Hepatocellular Carcinoma. 2019 , 28, 717-729	4
742	Inoperable Biliary Tract and Primary Liver Tumors: Palliative Treatment Options. 2019 , 28, 745-762	0
741	Transcatheter arterial chemoembolisation followed by three-dimensional conformal radiotherapy versus transcatheter arterial chemoembolisation alone for primary hepatocellular carcinoma in adults. 2019 , 2, CD012244	2
740	Update on transarterial approaches to locoregional treatment in hepatocellular carcinoma. 2019 , 31, 339-345	3
739	Complex interaction networks of cytokines after transarterial chemotherapy in patients with hepatocellular carcinoma. 2019 , 14, e0224318	8
738	Gene signature predictive of hepatocellular carcinoma patient response to transarterial chemoembolization. 2019 , 15, 2654-2663	5
737	Effective therapeutic options for elderly patients with hepatocellular carcinoma: A nationwide cohort study. 2019 , 98, e16150	3
736	The outcome of the HCC patients underwent ALPPS: Retrospective study. 2019 , 98, e17182	3
735	An Nd-Sensitized Upconversion Fluorescent Sensor for Epirubicin Detection. 2019 , 9,	4
734	Repeat liver resection versus salvage liver transplant for recurrent hepatocellular carcinoma: A propensity score-adjusted and -matched comparison analysis. 2019 , 23, 305-312	5
733	Effectiveness of stereotactic ablative radiotherapy in patients with advanced hepatocellular carcinoma unsuitable for transarterial chemoembolization. 2019 , 11, 1758835919889002	3
732	Magnetic resonance imaging features predictive of an incomplete response to transarterial chemoembolization in patients with hepatocellular carcinoma: A STROBE-compliant study. 2019 , 98, e15592	4
731	Elemene injection combined with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A meta-analysis. 2019 , 98, e17813	3

730	Back to the Future: Lipiodol in Lymphography-From Diagnostics to Theranostics. 2019 , 54, 600-615	44
729	Diagnostic accuracy of MRI with extracellular vs. hepatobiliary contrast material for detection of residual hepatocellular carcinoma after locoregional treatment. 2019 , 44, 549-558	6
728	Nano-carriers for delivery and targeting of active ingredients of Chinese medicine for hepatocellular carcinoma therapy. 2019 , 25, 66-87	11
727	Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristic. 2019 , 34, 1066-1073	27
726	Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib. 2019 , 176, 787-800	30
725	Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. 2019 , 72, 28-36	163
724	A review discussing the use of polyethylene glycol microspheres in the treatment of hepatocellular carcinoma. 2019 , 15, 695-703	4
723	Time-to-progression following conventional compared with drug-eluting-bead transcatheter arterial chemoembolisation in patients with large hepatocellular carcinoma. 2019 , 74, 295-300	4
722	Efficacy and safety of selective internal radiotherapy versus sorafenib for intermediate-locally advanced hepatocellular carcinoma: a systematic review and meta-analysis. 2019 , 13, 271-279	4
721	Critical systematic review on hepatic resection and transarterial chemoembolization for hepatocellular carcinoma. 2019 , 15, 439-449	0
720	Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma. 2019 , 44, 1554-1561	13
719	RNA-binding protein RPS3 contributes to hepatocarcinogenesis by post-transcriptionally up-regulating SIRT1. 2019 , 47, 2011-2028	32
718	Radioablation by Image-Guided (HDR) Brachytherapy and Transarterial Chemoembolization in Hepatocellular Carcinoma: A Randomized Phase II Trial. 2019 , 42, 239-249	14
717	Reason of Discontinuation After Transarterial Chemoembolization Influences Survival in Patients with Hepatocellular Carcinoma. 2019 , 42, 230-238	5
716	Clinical trial for development of a steerable microcatheter. 2019 , 28, 1-5	9
715	2019 Update of Indian National Association for Study of the Liver 'Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations. 2020 , 10, 43-80	24
714	A biodegradable multifunctional porous microsphere composed of carrageenan for promoting imageable trans-arterial chemoembolization. 2020 , 142, 866-878	6
713	Paclitaxel nanocrystalline assemblies as a potential transcatheter arterial chemoembolization (TACE) candidate for unresectable hepatocellular carcinoma. 2020 , 107, 110315	10

7 ¹²	Utility of Contrast-Enhanced Ultrasound for Early Therapeutic Evaluation of Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization. 2020 , 39, 431-440	6
7 ¹¹	Efficacy of transarterial chemoembolization compared with radiofrequency ablation for the treatment of recurrent hepatocellular carcinoma after radiofrequency ablation. 2020 , 29, 344-352	2
7 ¹⁰	Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Apatinib in Patients with Advanced Hepatocellular Carcinoma. 2020 , 27, 704-709	15
7 ⁰⁹	Acetic acid versus radiofrequency ablation for the treatment of hepatocellular carcinoma: A randomized controlled trial. 2020 , 101, 101-110	3
7 ⁰⁸	Residual convolutional neural network for predicting response of transarterial chemoembolization in hepatocellular carcinoma from CT imaging. 2020 , 30, 413-424	59
7 ⁰⁷	Intra-arterial idarubicin_lipiodol without embolization can provide prolonged complete response in hepatocellular carcinoma: A case report. 2020 , 26, 507-510	1
7 ⁰⁶	A Matter of TACEte: Plain Vanilla or Combination?. 2020 , 65, 934-936	
7 ⁰⁵	Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. <i>Hepatology</i> , 2020 , 72, 198-212	11.2 47
7 ⁰⁴	A combination of Citrus reticulata peel and black tea inhibits migration and invasion of liver cancer via PI3K/AKT and MMPs signaling pathway. 2020 , 47, 507-519	5
7 ⁰³	Hyperactivation of IL-6/STAT3 pathway led to the poor prognosis of post-TACE HCCs by HIF-1 β /SNAIL axis-induced epithelial to mesenchymal transition. 2020 , 11, 570-582	16
7 ⁰²	Cell-free DNA in hepatocellular carcinoma. 2020 , 199-209	0
7 ⁰¹	Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches. 2020 , 473, 25-32	16
7 ⁰⁰	Isolated Right Ventricular Metastasis in a Woman with Advanced Hepatocellular Carcinoma after Palliative Therapy. 2019 , 13, 487-497	
6 ⁹⁹	Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. 2020 , 69, 1492-1501	164
6 ⁹⁸	Immunotherapy for Hepatocellular Carcinoma: A 2021 Update. 2020 , 12,	42
6 ⁹⁷	[Stereotaxic radiotherapy of primary extracranial tumors]. 2020 , 24, 513-522	1
6 ⁹⁶	Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials. 2020 , 9, 596-612	7
6 ⁹⁵	Transarterial chemoembolization combined with iodine-125 seed implantation for patients with hepatocellular carcinoma: a retrospective controlled study. 2020 , 48, 300060520944309	2

694	Efficacy and Safety of Transarterial Chemoembolization Combined With Anlotinib for Unresectable Hepatocellular Carcinoma: A Retrospective Study. 2020 , 19, 1533033820965587	3
693	Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies. 2020 , 12,	23
692	Ultrasound-mediated delivery of miRNA-122 and anti-miRNA-21 therapeutically immunomodulates murine hepatocellular carcinoma in vivo. 2020 , 321, 272-284	24
691	Reply to: "Toxicity and dosimetry in SORAMIC study". 2020 , 73, 735-736	
690	Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma. 2020 , 9, 382-396	24
689	Synergistic anti-tumor activity of miriplatin and radiation through PUMA-mediated apoptosis in hepatocellular carcinoma. 2020 , 55, 1072-1086	2
688	Role of tumor margin and ADC change in defining the need for additional treatments after the first TACE in patients with unresectable HCC. 2020 , 133, 109389	4
687	Transarterial Chemoembolization Combined With Hepatectomy for the Treatment of Intermediate-Stage Hepatocellular Carcinoma. 2020 , 10, 578763	4
686	Surgery versus external beam radiotherapy for hepatocellular carcinoma involving the inferior vena cava or right atrium: A systematic review and meta-analysis. 2020 ,	6
685	TAZ-regulated expression of IL-8 is involved in chemoresistance of hepatocellular carcinoma cells. 2020 , 693, 108571	2
684	Transarterial chemoembolization for hepatocellular carcinoma: a bibliometric analysis of the most cited articles. 2020 , 38, 1190-1196	0
683	Prediction of prognostic risk factors in hepatocellular carcinoma with transarterial chemoembolization using multi-modal multi-task deep learning. 2020 , 23, 100379	12
682	What's New in Percutaneous Ablative Strategies for Hepatocellular Carcinoma and Colorectal Hepatic Metastases? 2020 Update. 2020 , 22, 105	8
681	Hepatocellular Carcinoma: Eastern Experience. 2020 , 119-144	
680	A Pilot Trial Evaluating Stereotactic Body Radiation Therapy to Induce Hyperemia in Combination With Transarterial Chemoembolization for Hepatocellular Carcinoma. 2020 , 108, 1276-1283	6
679	Cancer-associated fibroblasts enhance the chemoresistance of CD73 hepatocellular carcinoma cancer cells via HGF-Met-ERK1/2 pathway. 2020 , 8, 856	11
678	LI-RADS Imaging Criteria for HCC Diagnosis and Treatment: Emerging Evidence. 2020 , 19, 437-447	2
677	TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma. 2020 , 11, 1130	2

676	Comparison of transcatheter arterial chemoembolization with raltitrexed plus liposomal doxorubicin tegafur plus pirarubicin for unresectable hepatocellular carcinoma. 2020 , 11, 747-759	4
675	Deterioration in liver function after liver-directed therapy for hepatocellular carcinoma measured by cholate clearance. 2020 , 2, 232-239	1
674	Comparison of Opioid Medication Use after Conventional Chemoembolization versus Drug-Eluting Embolic Chemoembolization. 2020 , 31, 1292-1299	3
673	[Immuno-oncology : No longer a need for interventional radiology?]. 2020 , 60, 687-692	
672	Construction and Validation of Novel Diagnostic and Prognostic DNA Methylation Signatures for Hepatocellular Carcinoma. 2020 , 11, 906	1
671	Serum deprivation initiates adaptation and survival to oxidative stress in prostate cancer cells. 2020 , 10, 12505	10
670	Clinical experience with distal transradial access for endovascular treatment of various noncoronary interventions in a multicenter study. 2020 , 15, e0237798	7
669	Stratification of portal vein-invaded hepatocellular carcinoma treated with transarterial chemoembolization monotherapy. 2020 , 3, 201-207	
668	Diagnosis, Staging, and Patient Selection for Locoregional Therapy to Treat Hepatocellular Carcinoma. 2020 , 37, 441-447	2
667	Response assessment of hepatocellular carcinoma treated with yttrium-90 radioembolization: inter-reader variability, comparison with 3D quantitative approach, and role in the prediction of clinical outcomes. 2020 , 133, 109351	4
666	Management of patients with intermediate stage hepatocellular carcinoma. 2020 , 12, 1758835920970840	9
665	Recent Updates of Transarterial Chemoembolization in Hepatocellular Carcinoma. 2020 , 21,	35
664	Anti-cancer properties of specific Chinese herbal medicines for hepatocellular carcinoma treatment. 2020 , 101215	
663	NEMESIS: Noninferiority, Individual-Patient Metaanalysis of Selective Internal Radiation Therapy with Y Resin Microspheres Versus Sorafenib in Advanced Hepatocellular Carcinoma. 2020 , 61, 1736-1742	17
662	Therapeutic benefits of combined sorafenib for intermediate hepatocellular carcinoma unresponsive to transarterial chemoembolization in a Chinese population. 2020 , 21, 462-467	
661	Combined conventional transarterial chemoembolization with Mitomycin and percutaneous ablation for unresectable hepatocellular carcinoma. 2020 , 11, 298-303	1
660	Efficacy evaluation of the combination therapy of sorafenib and transarterial chemoembolization for unresectable HCC: a systematic review and meta-analysis of comparative studies. 2020 , 8, 540	2
659	Transarterial chemoembolization of unresectable systemic chemotherapy refractory liver metastases: a retrospective single-center analysis. 2020 , 45, 2862-2870	4

658	The efficacy of surgery in advanced hepatocellular carcinoma: a cohort study. 2020 , 18, 119	1
657	PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma. 2020 , 39, 99	16
656	Is Postoperative Adjuvant Transcatheter Arterial Infusion Therapy Effective for Patients with Hepatocellular Carcinoma who Underwent Hepatectomy? A Prospective Randomized Controlled Trial. 2020 , 27, 4143-4152	3
655	Does Baking Soda Function as a Magic Bullet for Patients With Cancer? A Mini Review. 2020 , 19, 1534735420922579	
654	Characteristics and Prognosis of Hepatocellular Carcinoma in Multi-Transfused Patients with β -Thalassemia. Experience of a Single Tertiary Center. 2020 , 12, e2020013	2
653	Tumor Seeding along the Puncture Tract in CT-Guided Interstitial High-Dose-Rate Brachytherapy. 2020 , 31, 720-727	3
652	Adipose Tissue-Derived Mesenchymal Stem Cells Suppress Growth of Huh7 Hepatocellular Carcinoma Cells via Interferon (IFN)- β Mediated JAK/STAT1 Pathway. 2020 , 17, 609-619	7
651	Risk Factors for Liver Function Deterioration after Transarterial Chemoembolization Refractoriness in Child-Pugh Class A Hepatocellular Carcinoma Patients. 2020 , 75, 147-156	1
650	Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases. 2020 , 3, CD009498	4
649	Evaluation of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma. 2020 , 15, e0229696	5
648	A-kinase interacting protein 1 (AKIP1) associates with advanced overall disease condition, tumor properties, and unfavorable prognosis in hepatocellular carcinoma patients. 2020 , 34, e23213	5
647	Tescalcin is an unfavorable prognosis factor that regulates cell proliferation and survival in hepatocellular carcinoma patients. 2020 , 40, 355-369	2
646	Hybrid Modelling of Transarterial Chemoembolisation Therapies (TACE) for Hepatocellular Carcinoma (HCC). 2020 , 10, 10571	3
645	Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. 2020 , 19, 546-569	6
644	Stereotactic Body Radiotherapy for Large Unresectable Hepatocellular Carcinomas - A Single Institution Phase II Study. 2020 , 32, 423-432	6
643	Lipiodol as an Imaging Biomarker of Tumor Response After Conventional Transarterial Chemoembolization: Prospective Clinical Validation in Patients with Primary and Secondary Liver Cancer. 2020 , 13, 100742	8
642	Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma. 2020 , 146, 1033-1050	8
641	Postembolization fever after transarterial chemoembolization is a sign of unfavorable therapeutic response in hepatocellular carcinoma patients. 2020 , 7, 83-92	1

640	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. 2020 , 31, 334-351	64
639	Diagnostic value of serum glypican-3 alone and in combination with AFP as an aid in the diagnosis of liver cancer. 2020 , 79, 54-60	20
638	Efficacy of transcatheter arterial chemoembolization combined with sorafenib in inhibiting tumor angiogenesis in a rabbit VX2 liver cancer model. 2020 , 3, 27-33	0
637	Hepatocellular Carcinoma-How to Determine Therapeutic Options. 2020 , 4, 342-354	8
636	mRECIST for HCC: Performance and novel refinements. 2020 , 72, 288-306	86
635	Milestones in the pathogenesis and management of primary liver cancer. 2020 , 72, 209-214	22
634	Survival analysis of 230 patients with unresectable hepatocellular carcinoma treated with bland transarterial embolization. 2020 , 15, e0227711	4
633	Safety and efficacy of stereotactic radiofrequency ablation for very large (8 cm) primary and metastatic liver tumors. 2020 , 10, 1618	19
632	Percutaneous ethanol injection for liver metastases. 2020 , 2, CD008717	1
631	The Antiproliferative Activity of Oxypeucedanin via Induction of G/M Phase Cell Cycle Arrest and p53-Dependent MDM2/p21 Expression in Human Hepatoma Cells. 2020 , 25,	3
630	Results of trials assessing transarterial chemoembolization for treating hepatocellular carcinoma are critically underreported. 2020 , 30, 5633-5640	3
629	Minimally invasive microwave ablation provides excellent long-term outcomes for otherwise inaccessible hepatocellular cancer. 2020 , 121, 1218-1224	2
628	Multiple imaging modality-guided radiofrequency ablation combined with transarterial chemoembolization for hepatocellular carcinoma in special locations. 2020 , 26, 131-139	2
627	Hepatocellular Carcinoma Brain Metastases: A Single-Institution Experience. 2020 , 140, e27-e32	2
626	Platelet membrane-coated nanoparticles for targeted drug delivery and local chemo-photothermal therapy of orthotopic hepatocellular carcinoma. 2020 , 8, 4648-4659	27
625	Homotypic cell membrane-cloaked biomimetic nanocarrier for the accurate photothermal-chemotherapy treatment of recurrent hepatocellular carcinoma. 2020 , 18, 60	6
624	The suppressing effects of VEGF-mediated angiogenesis at different administration sequences of apatinib and transarterial embolization .. 2020 , 9, 1133-1143	
623	Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. <i>Hepatology</i> , 2021 , 73 Suppl 1, 158-191	11.2 63

622	ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma. 2021 , 42, 160-170	27
621	Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study. 2021 , 45, 101464	3
620	The Effects of Supplement Therapy on HCV-Related HCC: a Case Report of a Patient Who Had Undergone TACE for Six Times. 2021 , 52, 802-808	1
619	Transarterial chemoembolization with drug-eluting beads in patients with hepatocellular carcinoma: response analysis with mRECIST. 2021 , 27, 85-93	1
618	Data driven decision-making for older patients with hepatocellular carcinoma. 2021 , 47, 576-582	1
617	Development and evaluation of an ultrasound-triggered microbubble combined transarterial chemoembolization (TACE) formulation on rabbit VX2 liver cancer model. 2021 , 11, 79-92	7
616	Value of gadoxetic acid-enhanced MR imaging and DWI in classification, characterization and confidence in diagnosis of solid focal liver lesions. 2021 , 56, 72-80	0
615	Nanocarriers-loaded with natural actives as newer therapeutic interventions for treatment of hepatocellular carcinoma. 2021 , 18, 489-513	2
614	Identification and analysis of immune-related subtypes of hepatocellular carcinoma. 2021 , 246, 667-677	
613	Australian recommendations for the management of hepatocellular carcinoma: a consensus statement. 2021 , 214, 475-483	12
612	Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma. 2021 , 79, 36-46	11
611	Metabolic activity assessment by F-fluorodeoxyglucose positron emission tomography in patients with hepatocellular carcinoma undergoing Yttrium-90 transarterial radioembolization. 2021 , 36, 1679-1684	0
610	Published trials of TACE for HCC are often not registered and subject to outcome reporting bias. 2021 , 3, 100196	0
609	Predictive factors of severe abdominal pain during and after transarterial chemoembolization for hepatocellular carcinoma. 2021 , 31, 3267-3275	0
608	Post-TACE changes in ADC histogram predict overall and transplant-free survival in patients with well-defined HCC: a retrospective cohort with up to 10 years follow-up. 2021 , 31, 1378-1390	3
607	Repeated Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. 2021 , 11, 44-52	3
606	Adding Sorafenib-eluting Microspheres to TACE: The Next Step in Hepatocellular Carcinoma Treatment. 2021 , 3, e200132	
605	Association Between Curative Treatment after Transarterial Radioembolization and Better Survival Outcomes in Patients with Hepatocellular Carcinoma. 2021 , 39, 274-283	0

604	Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study. 2021 , 13,	10
603	Hepatozelluläres Karzinom. 2021 , 447-454	
602	Liver Cancer (Current Therapies). 2021 ,	1
601	Effectiveness of intraprocedural dual-phase cone-beam computed tomography in detecting hepatocellular carcinoma and improving treatment outcomes following conventional transarterial chemoembolization. 2021 , 16, e0245911	1
600	Radiomic analysis of MRI to Predict Sustained Complete Response after Radiofrequency Ablation in Patients with Hepatocellular Carcinoma - A Pilot Study. 2021 , 76, e2888	1
599	Transarterial Chemoembolization Plus External Beam Radiotherapy. 2021 , 181-189	
598	Recent advances in the surgical management of hepatocellular carcinoma. 2021 , 34, 453-465	1
597	Survival and morbidity following stereotactic radiotherapy of hepatocellular carcinoma: a ten-year, single institution experience. 2021 , 56, 259-265	1
596	A review of cutting-edge therapies for hepatocellular carcinoma (HCC): Perspectives from patents. 2021 , 18, 3066-3081	5
595	An Overview of Hepatocellular Carcinoma (HCC) in Lebanon: A Focus on Hepatitis B- and Thalassemia-Related HCC. 2021 , 375-386	
594	Transarterial chemoembolization with or without sorafenib for hepatocellular carcinoma: A real-world propensity score-matched study.. 2022 , 34, 219-225	1
593	Updates on the Diagnosis and Management of Hepatocellular Carcinoma. 2021 , 11, 32-40	3
592	Development and Validation of Sorafenib-eluting Microspheres to Enhance Therapeutic Efficacy of Transcatheter Arterial Chemoembolization in a Rat Model of Hepatocellular Carcinoma. 2021 , 3, e200006	8
591	Diagnostic performance of Liver Imaging Reporting and Data System treatment response algorithm: a systematic review and meta-analysis. 2021 , 31, 4785-4793	6
590	COCH predicts survival and adjuvant TACE response in patients with HCC. 2021 , 21, 275	2
589	Glypican-3 targeted delivery of Zr and Y as a theranostic radionuclide platform for hepatocellular carcinoma. 2021 , 11, 3731	3
588	Predicting Therapeutic Efficacy of Transarterial Chemoembolization with Drug-Eluting Beads for Hepatocellular Carcinoma Using Contrast-Enhanced Ultrasound. 2021 , 11,	2
587	Validation of the "Six-and-Twelve" Prognostic Score in Transarterial Chemoembolization-Treated Hepatocellular Carcinoma Patients. 2021 , 12, e00310	2

586	Prognostic Value of Preoperative Prognostic Nutritional Index and Body Mass Index Combination in Patients with Unresectable Hepatocellular Carcinoma After Transarterial Chemoembolization. 2021 , 13, 1637-1650	4
585	Comparison of Trans-Arterial Chemoembolization and Bland Embolization for the Treatment of Hepatocellular Carcinoma: A Propensity Score Analysis. 2021 , 13,	4
584	Transarterial chemoembolisation in patients with hepatocellular carcinoma: low-dose doxorubicin reduces post-embolisation syndrome without affecting survival-prospective interventional study. 2021 , 5, 10	1
583	Combined Ultrasound and CT-Guided Iodine-125 Seeds Implantation for Treatment of Residual Hepatocellular Carcinoma Located at Complex Sites After Transcatheter Arterial Chemoembolization. 2021 , 11, 582544	3
582	Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR/FRI). 2021 , 45, 101590	2
581	Hepatocellular Carcinoma: Downstaging to Liver Transplantation as Curative Therapy. 2021 , 9, 220-226	1
580	Feasibility of SBRT for hepatocellular carcinoma in Brazil - a prospective pilot study. 2021 , 26, 226-236	
579	Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naïve patients: a propensity score matching analysis. 2021 , 31, 7512-7522	3
578	Combination of Sorafenib and Transarterial Chemoembolization in Selected Patients with Advanced-Stage Hepatocellular Carcinoma: A Retrospective Cohort Study at Three German Liver Centers. 2021 , 13,	5
577	Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS. 2021 , 31, 8291-8301	2
576	Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects. 2021 , 27, 236-245	7
575	The Impact of Sorafenib in Combination with Transarterial Chemoembolization on the Outcomes of Intermediate-Stage Hepatocellular Carcinoma. 2021 , 22, 1217-1224	1
574	Assessing locoregional treatment response to Hepatocellular Carcinoma: comparison of hepatobiliary contrast agents to extracellular contrast agents. 2021 , 46, 3565-3578	1
573	Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation. Part two: noncurative intention. 2021 , 46, 3540-3548	2
572	Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8-9. 2021 , 12, 634087	2
571	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. 2021 , 156, 463.e1-463.e30	2
570	Efficacy and safety of selective internal radiation therapy with yttrium-90 for the treatment of unresectable hepatocellular carcinoma. 2021 , 21, 216	2
569	Effects of transarterial chemoembolization on the immunological function of patients with hepatocellular carcinoma. 2021 , 22, 554	9

568	Exosomal microRNAs in hepatocellular carcinoma. 2021 , 21, 254	2
567	Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide. 2021 , 8, 403-419	10
566	Transcatheter arterial infusion chemotherapy with cisplatin in combination with transcatheter arterial chemoembolization decreases intrahepatic distant recurrence of unresectable hepatocellular carcinoma. 2021 , 5, 705-711	1
565	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. 2021 , 156, 463.e1-463.e30	0
564	Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression. 2021 , 13, 4013-4029	2
563	Hepatocellular carcinoma: a clinical and pathological overview. 2021 , 113, 203-217	6
562	CaCO -Encapsulated Microspheres for Enhanced Transhepatic Arterial Embolization Treatment of Hepatocellular Carcinoma. 2021 , 10, e2100748	4
561	Locoregional therapy in hepatocellular carcinoma: when to start and when to stop and when to revisit. 2021 , 6, 100129	2
560	Hepatocellular Carcinoma and the Role of Liver Transplantation: A Review. 2021 , 9, 738-748	2
559	Current and Future Scenario of Immunotherapy for the Treatment of Hepatocellular Carcinoma. 2021 , 17, 148-158	
558	Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome and Risk Signature Analysis. 2021 , 11, 662408	2
557	Locoregional therapies for the treatment of locally advanced hepatocellular carcinoma. 2021 , 54, IX-X	
556	Neutrophil-to-Lymphocyte Ratio as a Biomarker Predicting Overall Survival after Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma. 2021 , 13,	7
555	Donafenib treatment for hepatocellular carcinoma: A case report. 2021 , 100, e26373	1
554	Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management. 2021 , 12, S361-S373	6
553	Hepatic Arterial Infusion Chemotherapy Followed by Lipiodol Infusion for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Single-Center Experience. 2021 , 57,	2
552	Prognostic factors of patients after liver cancer surgery: Based on Surveillance, Epidemiology, and End Results database. 2021 , 100, e26694	0
551	The correlation with tumor radiological characteristics and prognosis of patients with early-stage hepatocellular carcinoma receiving transcatheter arterial chemoembolization. 2021 , 100, e26414	

550	Effect of Transarterial Chemoembolization on ALBI Grade in Intermediate-Stage Hepatocellular Carcinoma: Criteria for Unsuitable Cases Selection. 2021 , 13,	1
549	Xenograft Zebrafish Models for the Development of Novel Anti-Hepatocellular Carcinoma Molecules. 2021 , 14,	2
548	Chemoembolization for Lung Neoplasms: Exuberant Expectations versus Meticulous Investigation. 2021 , 301, 485-486	1
547	Review of Use of Y90 as a Bridge to Liver Resection and Transplantation in Hepatocellular Carcinoma. 2021 , 25, 2690-2699	0
546	The Role of Hepatic Arterial Infusion Chemotherapy in the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. 2021 , 66, 124-133	1
545	Investigation of the Physical Properties and Clinical Application of Embosphere Microspheres. 2021 , 66, 139-155	
544	Thermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (. 2021 , 76, 123-129	1
543	ADAM15 correlates with prognosis, immune infiltration and apoptosis in hepatocellular carcinoma. 2021 , 13, 20395-20417	3
542	One-step preparation of photoclick method for embolic microsphere synthesis and assessment for transcatheter arterial embolization. 2021 , 166, 94-102	2
541	Differences in radiotherapy application according to regional disease characteristics of hepatocellular carcinoma. 2021 , 21, 113-123	1
540	Biocompatible copper sulfide-based nanocomposites for artery interventional chemo-photothermal therapy of orthotropic hepatocellular carcinoma. 2021 , 12, 100128	3
539	Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy. 2021 , 9,	6
538	Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020). 2021 , 161, 879-898	27
537	SOP Transarterielle Chemoembolisation zur Tumorthherapie. 2021 , 3, 189-195	
536	The safety and efficacy of transarterial chemoembolisation with bleomycin for hepatocellular carcinoma unresponsive to doxorubicin: a prospective single-centre study. 2021 , 76, 864.e7-864.e12	1
535	Predicting Long-Term Hepatocellular Carcinoma Response to Transarterial Radioembolization Using Contrast-Enhanced Ultrasound: Initial Experiences. 2021 , 47, 2523-2531	1
534	Paradigm shift in the treatment options of hepatocellular carcinoma. 2021 ,	3
533	Editorial Comment: A Cautionary Experience With Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma. 2021 , 217, 944	

532	Arterial chemoembolisation with cisplatin versus epirubicin for hepatocellular carcinoma (ACE 500 study): A multicentre, randomised controlled phase 2/3 trial. 2021 , 157, 373-382	1
531	Comparison of Drug-Eluting Embolics versus Conventional Transarterial Chemoembolization for the Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. 2021 , 32, 2-12.e1	3
530	Electrocoagulation for liver metastases. 2021 , 1, CD009497	
529	Brachytherapy of Primary Liver Lesions. 2021 , 91-103	
528	The clinical significance of microvascular invasion in the surgical planning and postoperative sequential treatment in hepatocellular carcinoma. 2021 , 11, 2415	6
527	Intra-arterial Chemotherapy and Transarterial Chemoembolization in Hepatocellular Carcinoma. 2021 , 171-187	
526	Targeting c-Met and AXL Crosstalk for the Treatment of Hepatocellular Carcinoma. 2021 , 333-364	
525	Clinical Applications of Outcome Measurement. 2021 , 19-27	
524	A prognostic score model for predicting the survival benefits of patients undergoing sorafenib plus transarterial chemoembolization for hepatocellular carcinoma with portal vein invasion. 2021 , 46, 1967-1976	0
523	Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. 2021 , 18, 293-313	80
522	Hepatocellular carcinoma. 2021 , 7, 6	563
521	Immune Checkpoint Inhibitors in the Treatment of HCC. 2020 , 10, 601240	22
520	Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). 2021 , 10, 451-460	3
519	Percutaneous ethanol injection for liver metastases.	3
518	Cryotherapy for liver metastases.	3
517	Transarterial (chemo)embolisation for liver metastases.	3
516	What is the Value of Country-Based Surveillance Programmes?. 97-104	0
515	Hepatocellular Carcinoma. 2010 , 650-660	1

514	Viral Hepatitis and Hepatocellular Carcinoma. 2009 , 431-447	2
513	Staging of Hepatocellular Carcinoma. 2012 , 161-175	1
512	Other Bridge Therapies for Liver Transplantation: RFA, TACE, and TARE. 2020 , 183-191	1
511	Medical Therapy of HCC. 2016 , 489-512	1
510	Hepatocellular Carcinoma: Surgical Management and Evolving Therapies. 2016 , 168, 165-83	2
509	Role of Tumor Microenvironment in Hepatocellular Carcinoma Resistance. 2017 , 45-64	1
508	Results in Hepatocellular Carcinoma. 2008 , 107-115	1
507	Hepatocellular Carcinoma, Gallbladder Cancer, and Cholangiocarcinoma. 221-243	1
506	Transplantation for hepatocellular carcinoma: the North American experience. 2013 , 190, 145-64	12
505	Transarterial therapies for hepatocellular carcinoma. 2013 , 190, 195-206	13
504	Encyclopedia of Cancer. 2011 , 2072-2073	2
503	Encyclopedia of Cancer. 2015 , 1-3	1
502	HCC. 2015 , 31-54	1
501	Tumors and Cysts of the Liver. 2010 , 1569-1592.e6	2
500	Curative Irradiation Treatment of Hepatocellular Carcinoma: A Multicenter Phase 2 Trial. 2020 , 107, 116-125	28
499	Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma. 2018 , 119, 80-88	48
498	SOP Transarterielle Chemoembolisation zur Tumorthherapie. 2020 , 16, 201-208	1
497	Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy. 2011 , 34, 125-9	9

496	Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). 2020 , 9, 682-720	108
495	Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. 2009 , 119, 465-77	266
494	Assessment of hepatocellular carcinoma treatment response with LI-RADS: a pictorial review. 2019 , 10, 121	18
493	Glycoregulatory Enzymes as Early Diagnostic Markers during Premalignant Stage in Hepatocellular Carcinoma. 2013 , 1, 14-19	9
492	Effect of double platinum agents, combination of miriplatin-transarterial oily chemoembolization and cisplatin-hepatic arterial infusion chemotherapy, in patients with hepatocellular carcinoma: Report of two cases. 2017 , 5, 238-246	2
491	Growth inhibition and apoptosis induced by osthole, a natural coumarin, in hepatocellular carcinoma. 2012 , 7, e37865	79
490	Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review. 2012 , 7, e42879	34
489	Tumor angiogenesis after heated lipiodol infusion via the hepatic artery in a rabbit model of VX2 liver cancer. 2013 , 8, e61583	11
488	Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization. 2013 , 8, e68193	116
487	Genetic variants in the EPCAM gene is associated with the prognosis of transarterial chemoembolization treated hepatocellular carcinoma with portal vein tumor thrombus. 2014 , 9, e93416	8
486	Efficient induction of apoptosis by wee1 kinase inhibition in hepatocellular carcinoma cells. 2014 , 9, e100495	21
485	Preclinical Evaluation of Liposomal C8 Ceramide as a Potent anti-Hepatocellular Carcinoma Agent. 2016 , 11, e0145195	14
484	CC-223 blocks mTORC1/C2 activation and inhibits human hepatocellular carcinoma cells in vitro and in vivo. 2017 , 12, e0173252	14
483	Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101. 2017 , 12, e0174769	37
482	Short-term imaging response after drug-eluting embolic trans-arterial chemoembolization delivered with the Surefire Infusion System for the treatment of hepatocellular carcinoma. 2017 , 12, e0183861	4
481	Transcatheter arterial chemoembolization after stopping sorafenib therapy for advanced hepatocellular carcinoma. 2017 , 12, e0188999	4
480	Treatment patterns and survival in hepatocellular carcinoma in the United States and Taiwan. 2020 , 15, e0240542	5
479	Impact of Different Embolic Agents for Transarterial Chemoembolization (TACE) Procedures on Systemic Vascular Endothelial Growth Factor (VEGF) Levels. 2016 , 4, 288-292	31

478	Role of Locoregional Therapies in Patients With Hepatocellular Cancer Awaiting Liver Transplantation. 2021 , 116, 57-67	7
477	Efficacy and safety of transarterial chemoembolization combined to conformal radiotherapy for uninodular hepatocellular carcinoma. 2014 , 2, 020410	2
476	Long-term outcomes of liver resection for multiple hepatocellular carcinomas: Single-institution experience with 187 patients. 2020 , 24, 437-444	2
475	RECOMMENDATIONS FOR INVASIVE PROCEDURES IN PATIENTS WITH DISEASES OF THE LIVER AND BILIARY TRACT: REPORT OF A JOINT MEETING OF THE BRAZILIAN SOCIETY OF HEPATOLOGY (SBH), BRAZILIAN SOCIETY OF DIGESTIVE ENDOSCOPY (SOBED) AND BRAZILIAN SOCIETY OF INTERVENTIONAL RADIOLOGY AND ENDOVASCULAR SURGERY (SOBRICE). 2019 , 56, 213-231	2
474	BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA. 2020 , 57, 1-20	10
473	Identification and validation of the angiogenic genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma. 2020 , 12, 7848-7873	8
472	Metformin mediates resensitization to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP. 2016 , 7, 46230-46241	33
471	Nomogram for preoperative estimation of long-term survival of patients who underwent curative resection with hepatocellular carcinoma beyond Barcelona clinic liver cancer stage A1. 2016 , 7, 61378-61389	13
470	Combination treatment including targeted therapy for advanced hepatocellular carcinoma. 2016 , 7, 71036-71051	5
469	Targeting endogenous DLK1 exerts antitumor effect on hepatocellular carcinoma through initiating cell differentiation. 2016 , 7, 71466-71476	8
468	A mixed analysis comparing nine minimally invasive surgeries for unresectable hepatocellular carcinoma patients. 2017 , 8, 5460-5473	1
467	Meta-analysis of transcatheter arterial chemoembolization plus radiofrequency ablation versus transcatheter arterial chemoembolization alone for hepatocellular carcinoma. 2017 , 8, 2960-2970	22
466	Identification of mTOR as a primary resistance factor of the IAP antagonist AT406 in hepatocellular carcinoma cells. 2017 , 8, 9466-9475	4
465	Identification of sphingosine kinase 1 (SphK1) as a primary target of icaritin in hepatocellular carcinoma cells. 2017 , 8, 22800-22810	33
464	Pre-radiotherapy neutrophil-to-lymphocyte ratio as an independent prognostic factor in patients with locally advanced hepatocellular carcinoma treated with radiotherapy. 2017 , 8, 16964-16971	8
463	Tumor stage and primary treatment of hepatocellular carcinoma at a large tertiary hospital in China: A real-world study. 2017 , 8, 18296-18302	35
462	Transarterial chemoembolization combined with Jie-du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma. 2017 , 8, 45234-45241	5
461	Surrogate endpoint for overall survival in assessment of adjuvant therapies after curative treatment for hepatocellular carcinoma: a re-analysis of meta-analyses of individual patients' data. 2017 , 8, 90291-90300	2

460	Transcatheter hepatic arterial chemoembolization and sorafenib for hepatocellular carcinoma: a meta-analysis of randomized, double-blind controlled trials. 2017 , 8, 59601-59608	10
459	Therapeutic vaccine to cure large mouse hepatocellular carcinomas. 2017 , 8, 52061-52071	6
458	Combination of sorafenib and TACE inhibits portal vein invasion for intermediate stage HCC: a single center retrospective controlled study. 2017 , 8, 79012-79022	10
457	Kaempferol induces autophagic cell death of hepatocellular carcinoma cells via activating AMPK signaling. 2017 , 8, 86227-86239	28
456	Mechanism of action and efficacy of LY2109761, a TGF- β receptor inhibitor, targeting tumor microenvironment in liver cancer after TACE. 2018 , 9, 1130-1142	13
455	Characterization of aptamer-mediated gene delivery system for liver cancer therapy. 2018 , 9, 6830-6840	4
454	Targeting the microRNA-21/AP1 axis by 5-fluorouracil and pirarubicin in human hepatocellular carcinoma. 2015 , 6, 2302-14	27
453	Osteopontin promotes a cancer stem cell-like phenotype in hepatocellular carcinoma cells via an integrin-NF- κ B-HIF-1 β pathway. 2015 , 6, 6627-40	57
452	Hepatic resection versus transarterial chemoembolization for the initial treatment of hepatocellular carcinoma: A systematic review and meta-analysis. 2015 , 6, 18715-33	50
451	Hepatic resection alone versus in combination with pre- and post-operative transarterial chemoembolization for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis. 2015 , 6, 36838-59	44
450	Identifying the optimal criteria of radiotherapeutic parameters for patients with unresectable locally advanced hepatocellular carcinoma. 2015 , 6, 42372-9	2
449	MEK1 signaling promotes self-renewal and tumorigenicity of liver cancer stem cells via maintaining SIRT1 protein stabilization. 2016 , 7, 20597-611	15
448	Review of therapies for intermediate and advanced stage hepatocellular carcinoma, not suitable for curative therapies: a rapidly changing landscape. 2019 , 5,	1
447	Novel implications in the treatment of hepatocellular carcinoma. 2017 , 30, 23-32	23
446	Precision surgery for primary liver cancer. 2019 , 16, 475-485	4
445	Effect of Inhibiting Tumor Angiogenesis After Embolization in the Treatment of HCC with Apatinib-Loaded p-(Isopropyl-Acrylamide-Butyl Methyl Acrylate) Temperature-Sensitive Nanogel. 2020 , 7, 447-456	7
444	Glycolysis Inhibition as a Strategy for Hepatocellular Carcinoma Treatment?. 2019 , 19, 26-40	21
443	Risk Factors for Postembolization Syndrome After Transcatheter Arterial Chemoembolization. 2019 , 15, 380-385	7

442	VEROnA Protocol: A Pilot, Open-Label, Single-Arm, Phase 0, Window-of-Opportunity Study of Vandetanib-Eluting Radiopaque Embolic Beads (BTG-002814) in Patients With Resectable Liver Malignancies. 2019 , 8, e13696	3
441	The Effect of New Therapeutic and Diagnostic Agents on the Prognosis of Hepatocellular Carcinoma in Japan [An Analysis of Data from the Kanagawa Cancer Registry. 2017 , 18, 2471-2476	5
440	Radionuclide therapy of hepatocellular carcinoma. 2006 , 2, e40	8
439	Cumulative Radiation Exposures during Diagnosis and Treatments with Diagnostic Radiology Tools: In Patient with Hepatocellular Carcinoma. 2013 , 69, 243	3
438	Morphologic Features of Puncture Sites after ExoSeal Vascular Closure Device Implantation: Changes on Follow-Up Computed Tomography. 2017 , 76, 326	1
437	2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. 2019 , 20, 1042-1113	96
436	A case of necrotizing pancreatitis subsequent to transcatheter arterial chemoembolization in a patient with hepatocellular carcinoma. 2012 , 18, 321-5	18
435	New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis. 2015 , 21, 115-21	34
434	Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma. 2016 , 22, 250-8	33
433	Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma. 2017 , 23, 265-272	28
432	Switching to systemic therapy after locoregional treatment failure: Definition and best timing. 2020 , 26, 155-162	21
431	Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients. 2019 , 25, 381-389	9
430	[Recent developments in systemic chemotherapy for hepatocellular carcinoma]. 2008 , 14, 4-11	1
429	Molecular targeting for treatment of advanced hepatocellular carcinoma. 2009 , 15, 299-308	5
428	[Practice guidelines for management of hepatocellular carcinoma 2009]. 2009 , 15, 391-423	213
427	[Comparison of radiofrequency ablation and transarterial chemoembolization for the treatment of a single hepatocellular carcinoma smaller than 4 cm]. 2009 , 15, 474-85	4
426	A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma. 2010 , 16, 355-61	30
425	Analysis of prognostic factors and 5-year survival rate in patients with hepatocellular carcinoma: a single-center experience. 2012 , 18, 48-55	32

424	Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease. 2020 , 27, S165-S172	5
423	Is human hepatocellular carcinoma a hormone-responsive tumor?. 2008 , 14, 1682-9	37
422	Complete hepatocellular carcinoma necrosis following sequential porto-arterial embolization. 2008 , 14, 6869-72	7
421	Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: a cohort study. 2009 , 15, 1843-8	31
420	Current management strategy of hepatocellular carcinoma. 2009 , 15, 3210-6	111
419	Effect of preoperative transcatheter arterial chemoembolization on angiogenesis of hepatocellular carcinoma cells. 2009 , 15, 4582-6	31
418	Systemic chemo-immunotherapy for advanced-stage hepatocellular carcinoma. 2005 , 11, 2526-9	14
417	Successful management of postoperative recurrence of hepatocellular carcinoma with p53 gene therapy combining transcatheter arterial chemoembolization. 2005 , 11, 3803-5	16
416	Outcome of transarterial chemoembolization in patients with inoperable hepatocellular carcinoma eligible for radiofrequency ablation. 2005 , 11, 4465-71	30
415	Inhibition of hepatic tumor cell proliferation in vitro and tumor growth in vivo by taltobulin, a synthetic analogue of the tripeptide hemiasterlin. 2006 , 12, 6771-8	5
414	Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. 2006 , 12, 7561-7	215
413	Predictive factors of tumor response to trans-catheter treatment in cirrhotic patients with hepatocellular carcinoma: a multivariate analysis of pre-treatment findings. 2007 , 13, 6022-6	15
412	Ferucarbotran versus Gd-DTPA-enhanced MR imaging in the detection of focal hepatic lesions. 2007 , 13, 4891-6	4
411	p53 gene therapy in combination with transcatheter arterial chemoembolization for HCC: one-year follow-up. 2011 , 17, 2143-9	37
410	Transarterial injection of H101 in combination with chemoembolization overcomes recurrent hepatocellular carcinoma. 2011 , 17, 2353-5	12
409	Hemihepatic versus total hepatic inflow occlusion during hepatectomy: a systematic review and meta-analysis. 2011 , 17, 3158-64	19
408	Health-related quality of life evaluated by tumor node metastasis staging system in patients with hepatocellular carcinoma. 2012 , 18, 2689-94	24
407	Puncture injection of para-toluenesulfonamide combined with chemoembolization for advanced hepatocellular carcinoma. 2012 , 18, 6861-4	6

406	Therapeutic efficacy of transarterial chemo-embolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma. 2013 , 19, 2242-8	5
405	Clinical significance and risk factors of postembolization fever in patients with hepatocellular carcinoma. 2013 , 19, 284-9	17
404	Epidemiology, clinical-treatment patterns and outcome in 256 hepatocellular carcinoma cases. 2013 , 19, 3207-16	12
403	Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma. 2013 , 19, 3872-82	112
402	Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis. 2013 , 19, 4679-88	29
401	Molecular targeted therapy for hepatocellular carcinoma: current and future. 2013 , 19, 6144-55	60
400	Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. 2013 , 19, 7515-30	80
399	Extravascular use of drug-eluting beads: a promising approach in compartment-based tumor therapy. 2013 , 19, 7586-93	1
398	131I-labeled metuximab combined with chemoembolization for unresectable hepatocellular carcinoma. 2013 , 19, 9104-10	18
397	Staging systems of hepatocellular carcinoma: a review of literature. 2014 , 20, 4141-50	73
396	Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma. 2014 , 20, 745-54	16
395	Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. 2014 , 20, 10960-8	4
394	Current surgical treatment strategies for hepatocellular carcinoma in North America. 2014 , 20, 15007-17	17
393	Transcatheter arterial infusion for advanced hepatocellular carcinoma: Who are candidates?. 2015 , 21, 8888-93	3
392	Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients. 2015 , 21, 10443-52	18
391	Sub-classification of intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinomas. 2015 , 21, 10604-8	15
390	Outcome of transarterial chemoembolization-based multi-modal treatment in patients with unresectable hepatocellular carcinoma. 2015 , 21, 2395-404	22
389	Molecular imaging and therapy targeting copper metabolism in hepatocellular carcinoma. 2016 , 22, 221-31	27

388	Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review. 2016 , 22, 407-16	49
387	Evaluation of the relationship between hepatocellular carcinoma location and transarterial chemoembolization efficacy. 2017 , 23, 6437-6447	5
386	Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis. 2019 , 25, 3607-3618	10
385	Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma. 2019 , 25, 3870-3896	40
384	Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions. 2019 , 25, 4614-4628	42
383	Idarubicin doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma. 2020 , 26, 324-334	4
382	Clinical significance and functional role of transmembrane protein 47 (TMEM47) in chemoresistance of hepatocellular carcinoma. 2020 , 57, 956-966	3
381	miR-378 in combination with ultrasonic irradiation and SonoVue microbubbles transfection inhibits hepatoma cell growth. 2020 , 21, 2493-2501	2
380	Immunotherapy a New Hope for Cancer Treatment: A Review. 2018 , 21, 135-150	9
379	Radiofrequency ablation or microwave ablation combined with transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma by comparing with radiofrequency ablation alone. 2014 , 26, 112-8	21
378	Transcatheter embolization therapy in liver cancer: an update of clinical evidences. 2015 , 27, 96-121	51
377	Quality of life and hepatocellular carcinoma. 2014 , 5, 296-317	34
376	ART and science in using transarterial chemoembolization for retreating patients with hepatocellular carcinoma. 2014 , 3, 415-8	8
375	Survival analysis of transarterial radioembolization with yttrium-90 for hepatocellular carcinoma patients with HBV infection. 2014 , 3, 185-93	10
374	I Radioactive Seeds Implantation Therapy for Hepatocellular Carcinoma. 2009 , 2, 141-147	5
373	Preliminary evaluation of indigenous Y-labelled microspheres for therapy of hepatocellular carcinoma. 2016 , 143, S74-S81	4
372	Influence of limonin on Wnt signalling molecule in HepG2 cell lines. 2013 , 4, 126-33	18
371	A comparison between radiofrequency ablation combined with transarterial chemoembolization and surgical resection in hepatic carcinoma: A meta-analysis. 2019 , 15, 1617-1623	4

370	Computed tomography-guided iodine-125 brachytherapy for unresectable hepatocellular carcinoma. 2019 , 15, 1553-1560	7
369	What family physicians should know about interventional radiology?. 2020 , 27, 85-90	1
368	Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib. 2018 , 50, 366-373	8
367	Proton Therapy Results in the Treatment of Hepatocellular Carcinoma According to the Barcelona-Clinic Liver Cancer (BCLC) Staging System. 2015 , 04, 96-103	3
366	Current approach in the treatment of hepatocellular carcinoma. 2010 , 2, 348-59	69
365	Efficacy of intra-arterial contrast-enhanced ultrasonography during transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. 2018 , 10, 95-104	6
364	Systematic review of the outcomes of surgical resection for intermediate and advanced Barcelona Clinic Liver Cancer stage hepatocellular carcinoma: A critical appraisal of the evidence. 2018 , 10, 433-447	16
363	Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. 2018 , 10, 485-495	19
362	Multidisciplinary approach for multifocal, bilobar hepatocellular carcinoma: A case report and literature review. 2019 , 11, 119-126	1
361	Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions. 2020 , 12, 738-753	6
360	A survey on herbal management of hepatocellular carcinoma. 2011 , 3, 175-83	12
359	Management of hepatocellular carcinoma: Enlightening the gray zones. 2013 , 5, 302-10	29
358	Update in management of hepatocellular carcinoma in Eastern population. 2015 , 7, 1562-71	19
357	Image-guided therapies in the treatment of hepatocellular carcinoma: A multidisciplinary perspective. 2015 , 7, 235-44	7
356	Diagnosis and treatment of hepatocellular carcinoma: An update. 2015 , 7, 362-76	88
355	Recommendations for the use of chemoembolization in patients with hepatocellular carcinoma: Usefulness of scoring system?. 2015 , 7, 521-31	7
354	Recent advances in multidisciplinary management of hepatocellular carcinoma. 2015 , 7, 673-87	67
353	Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. 2015 , 7, 738-52	43

352	Hepatocellular carcinoma: Surgeon's view on latest findings and future perspectives. 2015 , 7, 1168-83	29
351	Transarterial radioembolization vs chemoembolization for hepatocarcinoma patients: A systematic review and meta-analysis. 2016 , 8, 770-8	42
350	Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinoma. 2016 , 8, 881-90	20
349	Preoperative portal vein embolization for hepatocellular carcinoma: Consensus and controversy. 2016 , 8, 439-45	22
348	Strategies to tackle the challenges of external beam radiotherapy for liver tumors. 2017 , 9, 645-656	9
347	Evaluation of cancer treatment in the abdomen: Trends and advances. 2013 , 5, 126-42	2
346	Locoregional treatment for hepatocellular carcinoma: The best is yet to come. 2015 , 7, 306-18	18
345	Transarterial chemoembolization using 40 µm drug eluting beads for hepatocellular carcinoma. 2017 , 9, 245-252	18
344	Treatment of hepatocellular carcinoma with portal vein thrombosis by sorafenib combined with hepatic arterial infusion chemotherapy. 2010 , 4, 423-7	12
343	The optimal selection of radiotherapy treatment for hepatocellular carcinoma. 2012 , 6, 139-48	19
342	DC Bead Transarterial Chemoembolization Is Effective in Hepatocellular Carcinoma Refractory to Conventional Transarterial Chemoembolization: A Pilot Study. 2013 , 7, 89-95	17
341	Management of Hepatocellular Carcinoma: Current Status and Future Directions. 2015 , 9, 437-48	41
340	2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. 2019 , 13, 227-299	151
339	Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines. 2012 , 32, 174-99	19
338	Super-Selective Transarterial Chemoembolization with Doxorubicin-Loaded Drug-Eluting Beads Sized Below and Above 100 Microns in Hepatocellular Carcinoma: A Comparative Study. 2019 , 103, 47	8
337	Loco-regional therapies for patients with hepatocellular carcinoma awaiting liver transplantation: Selecting an optimal therapy. 2016 , 6, 306-13	11
336	Hepatic arterial infusion in hepatocellular carcinoma: a single center experience. 2015 , 159, 139-44	3
335	Neoadjuvant Transarterial Chemoembolization Improves Survival After Liver Transplant in Patients With Hepatocellular Carcinoma. 2019 , 17, 638-643	2

334	Interventional Radiologic Treatment of Hepatocellular Carcinoma. 2017 , 15, 25-30	7
333	Geographic Variations of Potentially Curative Treatments for Hepatocellular Carcinoma in the United States: A SEER-Medicare Study. 2020 , 18, 729-736	2
332	Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. 2021 , 19, 541-565	74
331	Three treatment methods via the hepatic artery for hepatocellular carcinoma - a retrospective study. 2013 , 14, 2491-4	10
330	Lobaplatin-TACE combined with radioactive 125I seed implantation for treatment of primary hepatocellular carcinoma. 2014 , 15, 5155-60	15
329	In vivo experimental study on the effects of fluid in increasing the efficiency of radiofrequency ablation. 2014 , 15, 5799-804	4
328	Hepatic Resection after Initial Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone for the Treatment of Hepatocellular Carcinoma: A Meta-analysis of Observational Studies. 2015 , 16, 7871-4	6
327	Polymorphisms in genes of the de novo lipogenesis pathway and overall survival of hepatocellular carcinoma patients undergoing transarterial chemoembolization. 2015 , 16, 1051-6	5
326	Current trends and recent advances in diagnosis, therapy, and prevention of hepatocellular carcinoma. 2015 , 16, 3595-604	65
325	Genetic Variants in ASCT2 Gene are Associated with the Prognosis of Transarterial Chemoembolisation-Treated Early- Stage Hepatocellular Carcinoma. 2015 , 16, 4103-7	4
324	In the Era of Systemic Therapy for Hepatocellular Carcinoma Is Transarterial Chemoembolization Still a Card to Play?. 2021 , 13,	0
323	Current epidemiology in hepatocellular carcinoma. 2021 , 15, 1295-1307	15
322	Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies. 2021 ,	3
321	Predictors of Macrovascular Invasion and Extrahepatic Metastasis in Treatment Naive Hepatocellular Carcinoma: When Is [F] FDG PET/CT Relevant?. 2021 , 55, 293-301	0
320	Circulating DNA changes are predictive of disease progression after transarterial chemoembolization. 2022 , 150, 532-541	0
319	CIRSE Standards of Practice on Hepatic Transarterial Chemoembolisation. 2021 , 44, 1851-1867	7
318	Optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis. 2021 , 14, 101238	5
317	Visceral Arteries. 2004 , 286-322	

- 316 Ablation for Hepatocellular Carcinoma. **2005**, 322-331
- 315 Gastrointestinale Tumoren. **2006**, 500-539
- 314 Hepatocellular Carcinoma. **2006**, 1109-1131
- 313 Patient with hepatocellular carcinoma related to prior acute arsenic intoxication and occult HBV: epidemiological, clinical and therapeutic results after 14 years of follow-up. **2006**, 12, 1972-4
- 312 Hepatozelluläres Karzinom (HCC). **2006**, 4045-4070
- 311 Hepatic, Splenic, and Portal Vascular Systems. **2006**, 269-319 1
- 310 Radiotherapy of Liver Tumors. **2007**, 1246-1268
- 309 Hepatocellular Carcinoma. **2007**, 1152-1158
- 308 Is there a surgical oncology?. **2007**, 25-28
- 307 Small bowel and appendiceal tumors. **2007**, 181-188
- 306 Carcinoma hepatocelular. **2008**, 419-429
- 305 Hepatocellular carcinoma: future perspectives. **2008**, 241-258
- 304 Avancès thérapeutiques dans le carcinome hépatocellulaire. **2008**, 192, 23-32 1
- 303 Liver. **2008**, 943-961
- 302 Liver Transplantation for Hepatocellular Carcinoma. **2009**, 467-490
- 301 Medical Therapy of HCC. **2009**, 527-568
- 300 Medical treatment of hepatocellular carcinoma. **2009**, 1, e2009021 2
- 299 Sequential Arterial and Portal Vein Embolization before Right Hepatectomy in Patients with Cirrhosis and Hepatocellular Carcinoma. **2009**, 146-152

298 Chemoembolization, Radioembolization and Other Novel Intra-arterial Therapies. **2009**, 124-133

297 Interventionelle Radiologie. **2010**, 341-352

296 Laparoscopy. **2010**, 485-510

1

295 Chemoembolization for Hepatocellular Carcinoma. **2010**, 161-164

294 Hepatocellular Carcinoma. **2010**, 649-653.e1

293 Biology of Hepatocellular Carcinoma: Past, Present and Beyond. **2010**, 3-17

292 The Course of Circulating Nucleosomes in Liver Cancer Patients Undergoing Transarterial Chemoembolization Therapy. **2010**, 73-77

291 Malignant Tumors. **2010**, 1305-1350

290 A case of hepatocellular carcinoma in the caudate lobe successfully treated by transcatheter arterial chemoembolization using drug-eluting beads. **2010**, 16, 405-9

1

289 Treatment outcome of hepatocellular carcinoma patients with high-risk vascular invasion: a retrospective analysis. **2010**, 4, 491-496

288 Liver Transplant for Hepatocellular Carcinoma. **2011**, 219-237

287 Laparoscopic Liver Surgery for the Management of Hepatocellular Carcinoma: The American Perspective. **2011**, 207-217

286 Multidisciplinary Care of the Hepatocellular Carcinoma Patient. **2011**, 81-88

285 Transarterial Chemoembolization. **2011**, 287-297

284 Chemoembolization with Drug-Eluting Beads. **2011**, 299-317

283 Encyclopedia of Cancer. **2011**, 1673-1677

282 Clinical Outcomes for Hepatocellular Carcinoma. **2011**, 179-189

281 Efficacy of Novel Transcatheter Arterial Therapy for Hepatocellular Carcinoma. **2011**, 60, 173-178

1

280 Proton Therapy for Thoracoabdominal Tumors. **2012**, 207-222

279 Clinical Indications for Carbon Ion Radiotherapy and Radiation Therapy with Other Heavier Ions. **2012**, 179-192

278 Chronic HCV and Hepatocellular Carcinoma. **2012**, 47-60

277 Hepatocellular Carcinoma. 978-989

276 Are Drug-Eluting Beads Worth using?. 136-141

275 Hepatocellular Carcinoma. **2012**, 273-287

274 Emerging Therapies for Hepatocellular Carcinoma. **2012**, 263-290

273 Treatment of HCC: Resection, Local-Regional Therapy, Systemic Therapy, and Liver Transplantation. **2012**, 199-214

272 Recurrence: Prevention and Management. **2012**, 215-227

271 Interventional Imaging in the Oncologic Patient. **2012**, 667-677

270 Tumors of the Liver. 773-785

269 Interventionelle Radiologie. **2013**, 133-143

268 A Case of Hemolytic Uremic Syndrome after Transarterial Chemoembolization with Cisplatin. **2013**, 85, 67

267 Induktionschemotherapie bei hepatozellulären Karzinomen. **2013**, 225-236

266 Chemoembolization and Radioembolization in the Treatment of Primary Liver Cancers. **2013**, 327-338

265 Elite portuguese soccer players Use of psychological techniques: where, when and why. **2013**, 8, 847-860 1

264 Hepatocellular Carcinoma. **2013**, 1567-1578

263 Transvaskuläre Therapie des hepatozellulären Karzinoms. **2013**, 299-322 1

262 Diagnosis and Staging of Premalignant and Malignant Diseases of the Liver. 229-241

261 Hepatic Tumors: An Oncologist's Perspective. 273-282

260 Chemoembolizations and Hepatic Intra-arterial Chemotherapies. **2014**, 115-133

259 Hepatic Artery Embolizations. **2014**, 95-113

258 Revisiting the role of pathological analysis in transarterial chemoembolization-treated hepatocellular carcinoma after transplantation. **2014**, 20, 13538-45 4

257 Aspects post-thérapeutiques des carcinomes hépatocellulaires. **2014**, 137-166

256 Clinical Activity of Metronomic Chemotherapy in Liver Cancers. **2014**, 189-202

255 Microwave Ablation of Large (8.0 cm) Hepatocellular Carcinoma. **2015**, 41-51

254 Percutaneous Microwave Ablation for Liver Tumors Adjacent to Large Vessels. **2015**, 79-87 1

253 Hepatocellular Carcinoma. **2015**, 335-352

252 Diagnostische und therapeutische Verfahren in der Viszeralmedizin. **2015**, 37-68

251 Visceral Fat Accumulation Is Associated with Increased Mortality Rate after Transcatheter Arterial Chemoembolization in Patients with Hepatocellular Carcinoma. **2015**, 06, 1124-1136 1

250 Encyclopedia of Cancer. **2015**, 1-5

249 Immunogenic Cell Death Markers in Liver Cancer. **2015**, 303-324

248 Minimally Invasive Therapies for Hepatocellular Cancer: Catheter-Directed Therapies. **2015**, 85-91

247 Lebertumoren. **2015**, 1-10

246 Expression of epidermal growth factor-like domain 7 is increased by transcatheter arterial embolization of liver tumors. **2015**, 16, 1191-6 3

245 Early-stage hepatocellular carcinoma: the percutaneous approach. **2015**, 217-224

- 244 Trans-arterial Chemo-Embolization in Treating Elderly Patients with Hepatocellular Carcinoma. **2015**, 16, 7201-4
- 243 Treatments of Hepatocellular Carcinoma Patients with Hepatitis B Virus Infection: Treat HBV-related HCC. **2016**, 3, 162-178
- 242 Diagnosis and Management of Hepatocellular Carcinoma. **2017**, 285-306
- 241 Malignant Liver Lesions. **2017**, 71-88
- 240 Primary Liver Cancer: Background and Clinical Evidence. **2017**, 103-117
- 239 Encyclopedia of Cancer. **2017**, 2049-2052
- 238 Hepatozelluläres Karzinom beim alten und geriatrischen Patienten. **2017**, 1-7
- 237 Encyclopedia of Cancer. **2017**, 2535-2537
- 236 Stereotactic body radiation therapy for hepatocellular carcinoma: Experience from a tertiary cancer care center in India. **2017**, 54, 316-320 o
- 235 Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria. **2017**, 8, 47555-47564
- 234 Liver: Oncology/Trauma. **2018**, 75-100
- 233 Hepatocellular Carcinoma. **2018**, 27-51
- 232 Effects of Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma Using a Combination of Platinum Agents (Cisplatin plus Miriplatin): A Retrospective Comparison with Cisplatin Monotherapy. **2018**, 08, 260-273
- 231 Hepatocellular Carcinoma. **2018**, 668-692.e9 1
- 230 Midterm Outcomes and Prognostic Factors of Patients Treated Using Microballoon-Occluded Transarterial Chemoembolization with Miriplatin: A Retrospective Study of 37 Cases. **2018**, 3, 97-109
- 229 Hepatozelluläres Karzinom beim alten und geriatrischen Patienten. **2018**, 343-349
- 228 Outcome and predictors of transarterial chemo embolization in decompensate cirrhotic hepatocellular carcinoma patients. **2018**, 9,
- 227 Transarterial Embolization Therapies in Hepatocellular Carcinoma: Principles of Management. **2019**, 123-138 1

226 Hepatocellular Carcinoma. **2019**, 1541-1555

225 Palliative Chirurgie hepatobiliärer Tumoren. **2019**, 253-265

224 Hepatocellular Carcinoma. **2019**, 207-234

223 VERO_nA Protocol: A Pilot, Open-Label, Single-Arm, Phase 0, Window-of-Opportunity Study of Vandetanib-Eluting Radiopaque Embolic Beads (BTG-002814) in Patients With Resectable Liver Malignancies (Preprint).

222 Complex interaction networks of cytokines after transarterial chemotherapy in patients with hepatocellular carcinoma. 1

221 Cisplatin chemotherapy-induced miRNA-210 signaling inhibits hepatocellular carcinoma cell growth.. **2019**, 8, 626-634

220 THE ROLE OF TRANSARTERIAL CHEMOEMBOLIZATION IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN THE STAGE B OF BCLC. **2019**, 37-42

219 Transradial access chemoembolization for hepatocellular carcinoma in comparison with transfemoral access.. **2019**, 8, 1795-1805 1

218 Comparison between C-arm cone beam computed tomography and interventional angiography in transarterial chemoembolization of hepatocellular carcinoma. **2019**, 50,

217 Percutaneous Transcatheter Particle Therapies. **2020**, 265-279

216 Regional Therapies in Hepatocellular Carcinoma and Cholangiocarcinoma. **2020**, 311-322

215 Chemoembolization for Colorectal Liver Metastases. **2020**, 507-518

214 Camptothecin and analogs: role in anticancer activities. **2020**, 103-140 1

213 Cancer primitif du foie (carcinome hépatocellulaire). **2020**, 218-226.e3

212 Hepatocellular Carcinoma. **2020**, 151-162

211 Enhanced therapeutic effect of transcatheter arterial chemoembolization combined with radioactive I-125 seed implantation on liver cancer. **2020**, 20, 2493-2498 3

210 [Gallbladder Perforation after Transarterial Chemoembolization in a Patient with a Huge Hepatocellular Carcinoma]. **2020**, 75, 351-355

209 Treatment of Hepatocellular Carcinomas by Hepatic Transarterial Chemoembolization, Case Presentation and Review of the Literature. **2020**, 25, 32-35

208	Drug-eluting bead transarterial chemoembolization with medium-sized versus small-sized CalliSpheres microspheres in unresectable primary liver cancer. 2021,	0
207	Current role of systemic therapy in transarterial chemotherapy refractory hepatocellular carcinoma patients. 2021, 10, 183-188	
206	Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database. 2021, 21, 1157	5
205	Report from the Western Canadian Gastrointestinal Cancer Consensus Conference Virtual Education Series-Transition from Local to System Therapy and Optimal Sequencing of Systemic Therapy for HCC.. 2021, 28, 4317-4327	0
204	Comparison of metabolic and immunologic responses to transarterial chemoembolization with different chemoembolic regimens in a rabbit VX2 liver tumor model. 2021, 1	1
203	Therapy of Intermediate-Stage Hepatocellular Carcinoma: Current Evidence and Clinical Practice. 2020, 37, 456-465	3
202	Embolization Therapy for Liver Cancer. 2020, 667-672	
201	Chemoembolization for Hepatocellular Carcinoma. 2020, 282-286.e2	
200	Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. 2020, 26, S1-S40	4
199	Primary and secondary liver tumours. 2020, 3178-3190	
198	Liver Cancer. 2020, 341-368	
197	Hepatocellular Carcinoma: Western Experience. 2020, 81-118	
196	Proposal and Validation of a Novel Scoring System for Hepatocellular Carcinomas Beyond Curability Borders. 2021,	0
195	Transarterial Chemoembolization with LC Bead LUMI followed by Stereotactic Body Radiation Therapy in Treatment of Hepatocellular Carcinoma.. 2022, 7, 100830	
194	Apparent diffusion coefficient can predict therapy response of hepatocellular carcinoma to transcatheter arterial chemoembolization. 2021,	3
193	Cancer of the Liver and Bile Ducts. 2006, 752-770	
192	Embolotherapy: Basic Principles and Applications. 2006, 3-13	
191	Algorithms of diagnosis and options of hepatocellular carcinoma therapy. 2008, 252-265	

190 Medical Therapy of Hepatocellular Carcinoma. **2005**, 233-264

189 Hepatozelluläres Karzinom. 734-739

188 Regionale Therapie hepatischer Tumoren [Methodik und Indikationen regional wirksamer
Therapieverfahren. 838-852

187 Liver Tumors. **2007**, 311-330

186 Transarterial Chemoembolization (TACE) in Primary and Secondary Liver Tumors. **2008**, 47-62

185 Surgical Aspects of Hepato-Pancreato-Biliary Surgery. **2021**, 369-387

184 Transarterial Chemoembolisation and Combined Therapy. **2021**, 283-317

183 Transarterial 90Yttrium Radioembolisation. **2021**, 319-347

182 Is Transarterial Chemoembolization Only Treatment Option in Patients with Intermediate Stage of
Hepatocellular Carcinoma?: in Perspectives of Surgery. **2020**, 20, 113-119

181 Onkologische Embolisation. **2021**, 409-504

180 Surgery versus external beam radiotherapy for hepatocellular carcinoma involving the inferior vena
cava or right atrium: A systematic review and meta-analysis.

179 Regression of hepatocellular carcinoma after treatment of hepatitis C: a case report. **2015**, 6, E52-4 4

178 Accomplishments in 2008 in the management of hepatobiliary cancers. **2009**, 3, S28-36 3

177 A multidisciplinary approach to the management of hepatocellular carcinoma. **2010**, 6, 1-16 7

176 Updates in the management of hepatocellular carcinoma. **2011**, 7, 16-24 37

175 Emerging agents for the medical therapy of hepatocellular carcinoma. **2007**, 3, 600-2

174 Anti-angiogenesis in hepatocellular carcinoma treatment: current evidence and future
perspectives. **2011**, 17, 3075-81 18

173 Does external beam radiation therapy improve survival following transarterial chemoembolization
for unresectable hepatocellular carcinoma?. **2012**, 5, 13-7 6

172	The transcription factor LSF: a novel oncogene for hepatocellular carcinoma. 2012 , 2, 269-85	23
171	Radio frequency ablation for primary liver cancer: an evidence-based analysis. 2004 , 4, 1-50	28
170	A comparative study between Embosphere(®) and conventional transcatheter arterial chemoembolization for treatment of unresectable liver metastasis from GIST. 2014 , 26, 124-31	10
169	Liver transplantation for hepatocellular carcinoma: past, present and future. 2013 , 5, 181-92	4
168	Current management of hepatocellular carcinoma. 2014 , 10, 153-61	70
167	Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma. 2013 , 9, 1-24	5
166	Challenges in combining antiangiogenic therapy with transarterial chemoembolization for hepatocellular carcinoma. 2014 , 7, 98-102	4
165	Postoperative adjuvant transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond the Milan criteria: a retrospective analysis. 2015 , 5, 450-7	18
164	Down-regulation of Rab17 promotes tumourigenic properties of hepatocellular carcinoma cells via Erk pathway. 2015 , 8, 4963-71	8
163	TCM matrine induces cell arrest and apoptosis with recovery expression of the hepato-specific miR122a in human hepatocellular carcinoma Hep G2 cell line. 2015 , 8, 9004-12	7
162	Transarterial chemoembolization (TACE) plus percutaneous ethanol injection (PEI) for the treatment of unresectable hepatocellular carcinoma: a meta-analysis of randomized controlled trials. 2015 , 8, 10388-400	15
161	Hepatocellular Carcinoma in an HIV Patient "Cured" of Hepatitis C Virus. 2006 , 2, 599-602	
160	Targeting autophagy in chemotherapy-resistant of hepatocellular carcinoma. 2018 , 8, 354-365	21
159	Nanocomposite Carriers for Transarterial Chemoembolization of Liver Cancer. 2016 , 4, E173-E182	1
158	Thalidomide Combined with Transcatheter Arterial Chemoembolization (TACE) for Intermediate or Advanced Hepatocellular Carcinoma: A Systematic Review and GRADE Approach. 2018 , 19, 2043-2055	2
157	To determine the prognostic value of the albumin-bilirubin grade (ALBI) in patients underwent transarterial chemoembolization for unresectable hepatocellular carcinoma. 2019 , 12, 110-115	3
156	Serum Golgi protein 73 is a prognostic biomarker of liver transplantation patients. 2017 , 10, 8626-8632	2
155	Hepatozelluläres Karzinom. 2022 , 283-290	

154	Long Term Survival Analysis in a Cohort of 125 Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using Small Drug Eluting Beads. 2021 , 45, 54	
153	Changes in therapeutic options for hepatocellular carcinoma in Asia. 2021 ,	1
152	Combination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progress. 2021 , 1-13	1
151	The Efficacy of Transarterial Chemoembolization plus Apatinib or Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma. 2021 , 2021, 8169012	
150	Combined Use of Transjugular Intrahepatic Portosystemic Shunt and Transarterial Chemoembolization in the Treatment of Esophageal and Gastric Variceal Bleeding: A Retrospective Study of 80 Patients with Hepatocellular Carcinoma and Portal Hypertension. 2021 , 27, e934436	
149	Repeated loco-regional therapies for hepatocellular carcinoma is associated with inferior outcome after living donor liver transplantation in cirrhotic patients. 2021 ,	
148	Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma. 2021 , 22,	0
147	Hepatic Interventional Oncology. 2022 , 415-441	
146	Engineering hairy cellulose nanocrystals for chemotherapy drug capture.. 2022 , 23, 100711-100711	1
145	Clinical effects and safety of different transarterial chemoembolization methods for bridging and palliative treatments in hepatocellular carcinoma.. 2022 , 1	1
144	Green-Synthesized Silver Nanoparticle-Assisted Radiofrequency Ablation for Improved Thermal Treatment Distribution.. 2022 , 12,	2
143	Evaluation of staging systems to predict prognosis in hepatocellular carcinoma patients treated with radioembolization.. 2022 , 8, e08770	
142	Targets of immunotherapy for hepatocellular carcinoma: An update.. 2022 , 14, 140-157	2
141	High platelet count predicts poor prognosis in HCC patients undergoing TACE: a propensity score-matched analysis.. 2022 ,	0
140	Efficacy of Local-regional Treatment Plus Sorafenib in Intermediate-stage Hepatocellular Carcinoma Patients Refractory to Transarterial Chemoembolization.	
139	Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma.	3
138	A step toward a better understanding of hepatocellular progression after transarterial embolization.. 2022 ,	0
137	Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment.. 2022 , 45, 405	1

136	Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication.. 2022 ,	1
135	Adrenocortical carcinoma with multiple liver metastases controlled by bland transarterial embolization and surgery resulting in long-term survival.. 2022 , 17, 1095-1098	0
134	Recent advances of nanotechnology-based tumor vessel-targeting strategies.. 2021 , 19, 435	5
133	Trans-Arterial Chemoembolization with 50 μ m Degradable Starch Microspheres Versus 300-500 μ m Drug Eluting Beads in Hepatocellular Carcinoma: A Comparative Analysis of Initial Treatment Outcomes.. 2022 , 106, 10	1
132	A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma.. 2022 , 21, 15330338221075174	0
131	Updates on the staging and treatment of hepatocellular carcinoma. 2022 , 307-319	
130	Hepatopancreaticobiliary Cancer in Older Adults with Frailty. 2022 , 421-445	
129	LI-RADS Treatment Response versus Modified RECIST for Diagnosing Viable Hepatocellular Carcinoma after Locoregional Therapy: A Systematic Review and Meta-Analysis of Comparative Studies. 2022 , 83, 331	0
128	Comparison of tumor response following conventional versus drug-eluting bead transarterial chemoembolization in early- and very early-stage hepatocellular carcinoma.. 2022 , 5, 10-14	1
127	[Transarterial chemoembolization of hepatocellular carcinoma].. 2022 , 62, 225	0
126	Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma.. 2022 , 22, 270	1
125	Artificial Nanoplatelets Depend on Size for Precisely Inducing Thrombosis in Tumor Vessels.. 2022 , e2101474	
124	Safety and Efficacy of Transarterial Chemoembolization in Elderly Patients with Intermediate Hepatocellular Carcinoma.. 2022 , 14,	
123	A clinical and pathological update on hepatocellular carcinoma. 2022 , 22, 14-22	2
122	Loco-regional treatments of unresectable hepatocellular carcinoma: safety first.. 2022 , 11, 324-326	
121	Emerging Immunotherapy for Hepatocellular Carcinoma: A Guide for Hepatologists.. <i>Hepatology</i> , 2022 ,	11.2 7
120	Efficacy and Safety of Central Memory T Cells Combined With Adjuvant Therapy to Prevent Recurrence of Hepatocellular Carcinoma With Microvascular Invasion: A Pilot Study.. 2021 , 11, 781029	0
119	Comparison of local recurrence in transcatheter arterial chemoembolization of hepatocellular carcinoma with or without accumulation of iodized oil beyond corona enhancement area: Short-term results.. 2021 ,	0

- 118 Low Inorganic Phosphate Stress Inhibits Liver Cancer Progression: from In Vivo to In Vitro. **2022**, 5, 2100224 2
- 117 Why may citrate sodium significantly increase the effectiveness of transarterial chemoembolization in hepatocellular carcinoma?. **2021**, 100790 3
- 116 Transarterial Chemoembolization Combined With Endoscopic Therapy Is Beneficial for Unresectable Hepatocellular Carcinoma With Esophagogastric Varices.. **2021**, 11, 783574
- 115 A simple CD4+ T cells to FIB-4 ratio for evaluating prognosis of BCLC-B hepatocellular carcinoma: a retrospective cohort study.. **2022**, 22, 311 1
- 114 Prophylactic Use of Antibiotics for Postsurgical Infection in c-TACE and DEB-TACE High-Risk Patients: A Case-Control Study.. **2022**, 2022, 6203817
- 113 Design, synthesis and biological evaluation of 3-arylisquinoline derivatives as topoisomerase I and II dual inhibitors for the therapy of liver cancer.. **2022**, 237, 114376
- 112 Transarterial Chemoembolization (TACE) in Primary and Secondary Liver Tumors. **2008**, 47-62
- 111 Image_1.TIF. **2020**,
- 110 Image_2.TIF. **2020**,
- 109 Table_1.XLSX. **2020**,
- 108 Table_2.DOCX. **2020**,
- 107 Table_3.DOCX. **2020**,
- 106 Table_4.DOCX. **2020**,
- 105 Table_5.DOCX. **2020**,
- 104 Table_6.DOCX. **2020**,
- 103 TILA-TACE - an approach for effective local control of hepatocellular carcinoma. **2018**, 1, 58-63
- 102 Advanced hepatocellular carcinoma treated by transcatheter arterial chemoembolization with drug-eluting beads plus lenvatinib versus sorafenib, a propensity score matching retrospective study.. **2021**, 11, 6107-6118
- 101 Sevelamer arsenite nanoparticle as a Pi-responsive drug carrier and embolic agent for chemoembolization.. **2022**, 29, 1447-1456 1

- 100 Therapeutic Management of Advanced Hepatocellular Carcinoma: An Updated Review. **2022**, 14, 2357 3
- 99 Systematic Review and Pharmacokinetic Meta-analysis of Doxorubicin Exposure in Transcatheter Arterial Chemoembolization and Doxorubicin-Eluted Beads Chemoembolization for Treatment of Unresectable Hepatocellular Carcinoma.. **2022**,
- 98 Safety and efficacy of drug-eluting microspheres chemoembolization under cone beam computed tomography control in patients with early and intermediate stage hepatocellular carcinoma.. **2022**,
- 97 Stereotactic body radiation therapy for hepatocellular carcinoma: from infancy to ongoing maturity.. **2022**, 100498 1
- 96 Quaternary Nanoparticles Enable Sustained Release of Bortezomib for Hepatocellular Carcinoma. *Hepatology*, 11.2 0
- 95 Hepatobiliary Cancers. **2022**, 311-355
- 94 Intratumoral Pi deprivation benefits chemoembolization therapy via increased accumulation of intracellular doxorubicin. **2022**, 29, 1743-1753 0
- 93 Pi-induced in-situ Aggregation of Sevelamer Nanoparticles for Vascular Embolization. 0
- 92 Trial Designs for Integrating Novel Therapeutics into the Management of Intermediate-Stage Hepatocellular Carcinoma. Volume 9, 517-536
- 91 Decision-Making Scoring System for the Repetition of Conventional Transarterial Chemoembolization in Patients with Inoperable Hepatocellular Carcinoma. **2022**, Publish Ahead of Print,
- 90 I-125 seeds brachytherapy with transcatheter arterial chemoembolization for subcapsular hepatocellular carcinoma. **2022**, 22, 1
- 89 Hepatobiliary carcinomas. **2023**, 358-365
- 88 IR Liver-Directed Therapies for HCC. **2021**, 1-12
- 87 Tissue factor promotes HCC carcinogenesis by inhibiting BCL2-dependent autophagy. **2022**, 0
- 86 Conventional or drug-eluting beads? Randomized study of chemo-embolization for hepatocellular carcinoma: JIVROSG-1302. 0
- 85 Potential tumor marker for hepatocellular carcinoma identification: PI3K and pro-inflammatory cytokines (TGF- β 1, and IL-6). **2022**,
- 84 Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma. **2022**, 28, 2561-2568 0
- 83 Identification and Validation of a Novel Immune Infiltration-Based Diagnostic Score for Early Detection of Hepatocellular Carcinoma by Machine-Learning Strategies. **2022**, 2022, 1-16

- 82 Aggregation-induced Emission (AIE) and Magnetic Resonance Imaging Characteristics for Targeted and Image-guided siRNA Therapy of Hepatocellular Carcinoma. 2200579 0
- 81 Hepatocellular Carcinoma.
- 80 Intraarterial Therapies for the Management of Hepatocellular Carcinoma. **2022**, 14, 3351 1
- 79 Clinical values of Barcelona Clinic Liver Cancer subgroup and up-to-7 criteria in intermediate stage hepatocellular carcinoma with transcatheter arterial chemoembolization. **2022**, 10, 7275-7284
- 78 Interventional Imaging in the Oncologic Patient. **2023**, 670-680
- 77 Liver Cancer: Hepatocellular and Fibrolamellar Carcinoma. **2023**, 109-132
- 76 Benefits of step-by-step debulking microwave ablation for huge unresectable hepatocellular carcinoma patients after transcatheter arterial chemoembolization refractoriness. **2022**, 39, 935-945
- 75 Combination approaches in hepatocellular carcinoma: How systemic treatment can benefit candidates to locoregional modalities. **2022**, 28, 3573-3585
- 74 Hepatocellular Carcinoma: Aetiology and Mechanisms of Development. A Literature Review. **2022**, 12, 139-150
- 73 Effects of supplement therapy on HBV-related HCC: a case report of a significant tumour regression.
- 72 Proton therapy in the treatment of hepatocellular carcinoma. 12,
- 71 New concepts in the treatment of hepatocellular carcinoma. 1
- 70 Transarterial Chemoembolization in Hepatocellular Carcinoma: A Binational Japanese-German Study. Volume 9, 695-705
- 69 Oxaliplatin Eluting CalliSpheres Microspheres for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma. 13, 0
- 68 Stereotactic Body Radiation Therapy for the Management of Hepatocellular Carcinoma: Efficacy and Safety. **2022**, 14, 3892
- 67 Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma. **2022**, 2022, 1-9 0
- 66 RNA binding protein PUM2 promotes hepatocellular carcinoma proliferation and apoptosis via binding to the 3'UTR of BTG3. **2022**, 24,
- 65 Evaluating the best treatment for multifocal hepatocellular carcinoma: A propensity score-matched analysis. **2022**, 28, 3981-3993

- 64 Preclinical Therapeutic Evaluation of Lenvatinib-Eluting Microspheres for Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma. 1
- 63 Transarterial Chemoembolization and Unresectable Hepatocellular Carcinoma: A Narrative Review. **2022**, 0
- 62 Prospective of 31 P MR Spectroscopy in Hepatopancreatobiliary Cancer: A Systematic Review of the Literature. 0
- 61 A Nomogram Based on Preoperative Lipiodol Deposition after Sequential Retreatment with Transarterial Chemoembolization to Predict Prognoses for Intermediate-Stage Hepatocellular Carcinoma. **2022**, 12, 1375
- 60 An efficient method for detection of Epirubicin via Gelatin-CdTe/ZnS QDs as a nano-bioconjugated fluorescent sensor. **2022**, 645, 414283
- 59 Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A two-center retrospective study. 12, 0
- 58 Transarterial chemoembolization combined with metformin improves the prognosis of hepatocellular carcinoma patients with type 2 diabetes. 13, 0
- 57 IR Liver-Directed Therapies for HCC. **2022**, 147-158 0
- 56 Zytostatikabeschichtete Beads. **2022**, 1-8 0
- 55 Inflammasome-Mediated Cytokines: A Key Connection between Obesity-Associated NASH and Liver Cancer Progression. **2022**, 10, 2344 1
- 54 Individualized Approach in the Surgical Management of Hepatocellular Carcinoma: Results from a Greek Multicentre Study. **2022**, 14, 4387 0
- 53 PSMD12 promotes the activation of the MEK-ERK pathway by upregulating KIF15 to promote the malignant progression of liver cancer. **2022**, 23, 1-11 0
- 52 Impact of sarcopenia on tumor response and survival outcomes in patients with hepatocellular carcinoma treated by trans-arterial (chemo)-embolization. 28, 5324-5337 0
- 51 Hepatoprotective potential of a novel quinazoline derivative in thioacetamide-induced liver toxicity. 13, 0
- 50 The combination of sarcopenia and biochemical factors can predict the survival of hepatocellular carcinoma patients receiving transarterial chemoembolization. 12, 1
- 49 Hepatic Arterial Infusion Chemotherapy with Oxaliplatin Plus Raltitrexed as an Alternative Option in Advanced Hepatocellular Carcinoma Patients with Failure of, or Unsuitability for, Transarterial Chemoembolization. **2022**, 58, 1343 0
- 48 Clinical factors associated with early disease progression after radioembolization for hepatocellular carcinoma and feasibility of post-progression systemic therapy. 0
- 47 Addition of Camrelizumab to Transarterial Chemoembolization in Hepatocellular Carcinoma With Untreatable Progression. **2022**, 21, 153303382211313 0

46	Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy. Volume 9, 1109-1125	o
45	Sex differences in genomic features of hepatitis B associated hepatocellular carcinoma with distinct antitumor immunity. 2022 ,	o
44	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. 2022 , 28, 583-705	3
43	Transient Cytolysis after Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. 2022 , 12, 1663	1
42	Modified AlbuminBilirubin Model for Stratifying Survival in Patients with Hepatocellular Carcinoma Receiving Anticancer Therapy. 2022 , 14, 5083	o
41	Transarterial chemoembolisation for very early and early stage hepatocellular carcinoma: single-centre experience. 2022 ,	o
40	The radiological prognostic factors of transcatheter arterial chemoembolization to hepatocellular carcinoma. 2022 , 101, e30875	o
39	Diagnosis and Management of Hepatocellular Carcinoma. 2022 , 327-354	o
38	Pyogenic liver abscess in non-liver cancer patients and liver cancer patients treated with TACE : Etiological characteristics, treatment, and outcome analysis.	o
37	Stereotactic Radiotherapy after Incomplete Transarterial (Chemo-) Embolization (TAETACE) versus Exclusive TAE or TACE for Treatment of Inoperable HCC: A Phase III Trial (NCT02323360). 2022 , 29, 8802-8813	o
36	Construction and validation of an angiogenesis-related scoring model to predict prognosis, tumor immune microenvironment and therapeutic response in hepatocellular carcinoma. 13,	o
35	Simvastatin Induces Apoptosis And Suppresses Hepatocellular Carcinoma Induced In Rats.	o
34	Polymeric nanomedicines for the treatment of hepatic diseases. 2022 , 20,	o
33	Nonsurgical Treatment for Localised Hepatocellular Carcinoma. 69-75	o
32	2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. 2022 , 23, 1126	4
31	Interdisciplinary Approach in Hepatobiliary Cancers. 2022 ,	o
30	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.	o
29	Idarubicin-loaded biodegradable microspheres enhance sensitivity to anti-PD1 immunotherapy in transcatheter arterial chemoembolization of hepatocellular carcinoma. 2022 ,	o

- 28 Application of Intravoxel Incoherent Motion in the Evaluation of Hepatocellular Carcinoma after Transarterial Chemoembolization. **2022**, 29, 9855-9866 ○
- 27 Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma. **2022**, 10, 3202 1
- 26 Parthenolide induces rapid thiol oxidation that leads to ferroptosis in hepatocellular carcinoma cells. 4, 1
- 25 Yttrium-90 Radioembolization: Current Indications and Outcomes. ○
- 24 Drug-eluting Microspheres Compared to Conventional Transarterial Chemoembolization as First Line Treatment for Unresectable Hepatocellular Carcinoma: A Single-center Retrospective Cost-utility Analysis. ○
- 23 Increased expression of TBC1D10B as a potential prognostic and immunotherapy relevant biomarker in liver hepatocellular carcinoma. **2023**, 13, ○
- 22 Monodisperse CaCO₃-loaded gelatin microspheres for reversing lactic acid-induced chemotherapy resistance during TACE treatment. **2023**, 231, 123160 ○
- 21 Identification of Potential Predictors of Prognosis and Sorafenib-Associated Survival Benefits in Patients with Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization. **2023**, 30, 476-491 ○
- 20 Prognostic value of des-γ-carboxyprothrombin in patients with AFP-negative HCC treated with TACE. **2022**, 25, ○
- 19 Enumeration and Characterization of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. **2023**, 24, 2558 ○
- 18 Nanomaterial-Based Antivascular Therapy in the Multimodal Treatment of Cancer. **2023**, 15, 1207 ○
- 17 Comprehensive analysis of ESR1-related ceRNA axis as a novel prognostic biomarker in hepatocellular carcinoma. **2022**, 14, 1393-1409 ○
- 16 Immune checkpoint inhibition: a future guided by radiology. ○
- 15 Adjuvant effect of herbal medicine on transarterial chemoembolization in patients with hepatocellular carcinoma: A systematic review and meta-analysis. 13, ○
- 14 The Prognostic Role of VEGFR-2 Gene Amplification in Relation to Serum AFP Levels Among Liver-Transplanted Patients with Hepatocellular Carcinoma. **2022**, 5, 85-93 ○
- 13 Autophagy Modulation Attenuates Sorafenib Resistance In HCC Induced In Rats. ○
- 12 A Case of Target Immunotherapy Combined with Interventional Therapy for Massive Liver Cancer. **2023**, 11, 208-214 ○
- 11 Preliminary outcomes of DEB-TACE loaded with raltitrexed in the treatment of unresectable or recurrent hepatocellular carcinoma. **2023**, 23, ○

- 10 Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada. **2023**, 115, 102526
- 9 Vessels That Encapsulate Tumor Clusters (VETC) Predict cTACE Response in Hepatocellular Carcinoma. Volume 10, 383-397
- 8 Liver abscess formation after transarterial chemoembolization in patients with malignant hepatic tumors: a systematic review and meta-analysis.
- 7 Presence of an Arterial Feeding Vessel on Cross-Sectional Imaging Predicts Treatment Response and Survival after Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Retrospective Multivariable Analysis of 138 Patients.
- 6 In Vivo and in Vitro Biocompatibility Studies of Pt Based Nanoparticles: a New Agent for Chemoradiation Therapy.
- 5 Diagnosis and management of hepatocellular carcinoma. **2007**, 13, 1
- 4 Correlation and efficacy of TACE combined with lenvatinib plus PD -1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.
- 3 Prognostic value of systemic immune-inflammation index/ albumin for transcatheter arterial chemoembolization treatment. **2023**, 9, e15156
- 2 Pluronic modified PLA based hybrid block copolymeric nanoformulation enhanced anti-cancer therapeutic efficacy of Epirubicin. **2023**, 112084
- 1 Neutrophil extracellular traps-mediated molecular subtypes characterize the hallmarks of tumor microenvironment and guide precision medicine in hepatocellular carcinoma. **2023**, 16, 100577